


 Cite this: *RSC Adv.*, 2026, 16, 18495

# Exploring the synthesis of conduritol derivatives: strategies, challenges, and advances

 Soumyadip Malik<sup>a</sup> and Amrit Krishna Mitra <sup>\*b</sup>

Conduritol derivatives represent an important class of cyclitol-based molecules characterized by structural diversity, synthetic flexibility, and notable biological activity. Built on a cyclohexene core bearing multiple hydroxyl groups, conduritols have attracted sustained interest due to their potent glycosidase inhibitory properties and their occurrence in biologically active natural products such as pancratistatin and lycoricidine. The parent compound exists as six diastereomeric forms, and extensive methodological advances over recent decades have enabled access to all stereoisomers as well as a wide range of functionalized derivatives, including epoxidized, aminated, halogenated, and selectively protected analogues. Many of these compounds have shown promise as enzyme inhibitors and as leads for anticancer, antileukemic, and antimicrobial applications. Building on earlier work focused on the synthesis of conduritol stereoisomers, this review concentrates on strategies for the preparation of conduritol derivatives, emphasizing asymmetric synthesis, stereoselective functionalization, and recent developments in catalytic and green chemistry approaches. Key challenges related to regio- and stereocontrol are critically discussed, along with comparative assessments of established and emerging synthetic routes. The therapeutic relevance of conduritol derivatives, particularly in glycosidase-targeted interventions for metabolic and proliferative diseases, is also highlighted, providing an integrated perspective on current advances and future opportunities in this field. By consolidating and critically evaluating the diverse synthetic methodologies developed to date, this review aims to serve as a comprehensive resource for the research community, highlighting existing methodological gaps and guiding the design of more efficient, selective, and sustainable strategies for the synthesis and application of conduritol-based frameworks.

Received 2nd February 2026

Accepted 30th March 2026

DOI: 10.1039/d6ra00890a

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## 1. Introduction

Cyclitols, a structurally diverse class of cyclic polyols derived from a cyclohexane framework, are broadly categorized into three principal families: inositols, quercitols, and conduritols.<sup>1</sup> Among these, conduritols have emerged as a distinctive and highly impactful subgroup owing to their intricate stereochemical features and significant biological relevance.<sup>2,3</sup> Since Kübler's seminal 1908 report of a novel polyhydroxylated cyclohexene from *Marsdenia condurango*, later identified as conduritol A, these molecules have continued to inspire extensive research in organic synthesis, medicinal chemistry, and chemical biology.<sup>4</sup>

The six theoretically possible diastereomers of conduritol, designated A through F, encompass two meso forms (A and D) and four chiral enantiomeric pairs (B, C, E, and F). While conduritol F is relatively abundant in nature, conduritol A is isolated only in trace amounts. Despite their limited natural

availability, the conduritols have proven indispensable in synthetic organic chemistry, functioning as versatile intermediates and privileged scaffolds for the construction of structurally and biologically complex targets.<sup>5,6</sup>

Beyond their structural diversity, conduritols possess a remarkable breadth of biological activity. Numerous derivatives, including epoxides, aminoconduritols, cyclophellitols, and other functionalized analogues, display strong glycosidase inhibitory activity and have attracted considerable interest as potential therapeutic agents for metabolic and proliferative diseases, including diabetes, cancer, HIV/AIDS, and lysosomal storage disorders such as Gaucher's disease. Recent studies have further highlighted the importance of targeting glycosidase-related pathways and cyclitol-based inhibitors in therapeutic research.<sup>7</sup> Additional reported activities, including antifeedant, antibiotic, antileukemic, and plant growth-regulating effects, further underscore their pharmacological importance. The presence of conduritol A in traditional

<sup>a</sup>Department of Chemistry, Rani Rashmoni Green University Tarakeswar, Hooghly, West Bengal, Pin: 712410, India

<sup>b</sup>Department of Chemistry, Government General Degree College, Singur, Singur, Hooghly, West Bengal, Pin: 712409, India. E-mail: [amritseptles@gmail.com](mailto:amritseptles@gmail.com); Tel: +91-33-2630-0126; +91 9432164011



medicinal plants such as *Gymnema sylvestre* illustrates the longstanding connection between these molecules and natural therapeutic practices.<sup>3,8,9</sup>

From a synthetic perspective, conduritols also serve as strategic building blocks in the total synthesis of natural products, particularly members of the Amaryllidaceae alkaloid family. Notable examples include pancratistatin and lycoricidine, whose syntheses rely on conduramine or aminoconduritols cores. These natural products demonstrate a range of biological properties, including protein synthesis inhibition and cytotoxicity toward lymphocytic leukemia and ovarian sarcoma cell lines, positioning them as valuable leads in anticancer drug discovery and motivating continued investigation into cyclitol-based bioactive scaffolds.<sup>10–14</sup>

Progress in synthetic methodology over the past several decades has greatly expanded access to conduritols derivatives.<sup>1,2,6,15,16</sup> Classical transformations such as aromatic dihydroxylation have been complemented by advances in chemoenzymatic, enantioselective, and microbial oxidation strategies. Particularly noteworthy is the use of engineered microorganisms such as *Pseudomonas putida* for highly selective *cis*-dihydroxylation of aromatic substrates, enabling efficient construction of key intermediates for conduritols frameworks. These developments have facilitated the synthesis not only of the parent compounds but also of complex derivatives including glycomimetics, oligosaccharide analogues, and various unnatural sugars with therapeutic potential.

Our research group recently provided a comprehensive review of the synthetic approaches to all six stereoisomeric conduritols (A–F).<sup>6</sup> Building upon that foundation, the present review focuses specifically on conduritols derivatives, which constitute an equally important domain owing to their

biological functions and synthetic utility. The literature discussed in this review was selected through a comprehensive survey of the major scientific databases and journals to provide a representative overview of synthetic strategies reported for conduritols derivatives. In contrast to our previous review, which primarily addressed the preparation of the parent conduritols stereoisomers, the present article emphasizes the rapidly expanding chemistry of functionalized conduritols derivatives, including aminated, epoxidized, halogenated, phosphorylated, and structurally diversified analogues. By systematically compiling and critically comparing these synthetic approaches, this review aims to provide the broader research community with a consolidated platform for understanding the evolution of conduritols chemistry, identifying existing methodological limitations, and guiding the development of more efficient and sustainable strategies for the synthesis and application of these biologically significant cyclitol frameworks.

## 2. Synthetic landscape of conduritols derivatives

In recent years, continued advances in catalytic transformations, metathesis chemistry, and chemoenzymatic methodologies have further expanded the toolbox available for constructing highly functionalized conduritols derivatives.

The synthesis of conduritols derivatives has evolved through a wide variety of strategic approaches, ranging from chemoenzymatic arene dihydroxylation and carbohydrate-derived routes to modern catalytic and metathesis-based methodologies. These strategies differ not only in the origin of stereochemical information but also in the way the polyhydroxylated cyclohexene framework is constructed and functionalized. In



Soumyadip Malik

*Soumyadip Malik obtained his BSc degree from Rabindra Mahavidyalaya, under the University of Burdwan and his MSc from Rani Rashmoni Green University, India, where he carried out his MSc dissertation under the guidance of Dr Amrit Krishna Mitra. He is currently a research scholar at the Centre for Nano and Soft Matter Sciences (CeNS), Bengaluru, India.*



Amrit Krishna Mitra

*Amrit Krishna Mitra is a Group-A officer of the West Bengal Education Service and currently serves as an Assistant Professor of Chemistry at Government General Degree College, Singur, under the University of Burdwan, where he also served as the founder Head of the Department. He has additionally held the charge of Controller of Examinations at Rani Rashmoni Green University. He obtained his BSc degree from St. Xavier's*

*College, Kolkata, his MSc from the Indian Institute of Technology (IIT) Kharagpur, and his PhD in Organic Chemistry from the University of Calcutta. He has authored over 50 publications in reputed international journals and publishing houses, along with a book to his credit. His research interests encompass Synthetic Organic Chemistry, Photophysics, and Chemistry Education. He has also served as a Scientific Observer for the national delegation at the International Chemistry Olympiad in 2024 and 2025.*



the following sections, representative synthetic routes are discussed chronologically, highlighting key transformations, stereochemical considerations, and methodological innovations that have shaped the development of conduritol chemistry.

Over more than a century of investigation, conduritols and their nitrogen-containing congeners have evolved from rare natural curiosities into versatile molecular platforms central to modern synthetic, medicinal, and biological chemistry. Their densely functionalized cyclohexene core, rich stereochemical diversity, and close resemblance to carbohydrates have inspired an exceptional range of synthetic strategies. Across the literature, researchers have developed approaches that span classical oxidation–reduction sequences, stereocontrolled epoxidation and dihydroxylation protocols, ring-closing metathesis, Ramberg–Bäcklund transformations, and carbohydrate-derived routes. Equally transformative has been the emergence of chemoenzymatic methods, particularly selective microbial *cis*-dihydroxylation, which provides rapid access to key building blocks with high regio- and stereocontrol. Collectively, these methods illustrate the ingenuity and breadth of synthetic design applied to the construction of conduritols, conduramines, and inositol derivatives. The following section systematically reviews these advances, highlighting strategic innovations, stereochemical logic, and the evolving toolkit that continues to shape the synthesis of this important family of cyclitols.

### 2.1. Synthesis and advances in conduritol B epoxide

Conduritol B epoxide (CBE) is a well-established irreversible inhibitor of several D-glucosidases, displaying particularly high potency toward the mammalian  $\beta$ -glucosidase responsible for the hydrolysis of glucosylceramide. Impaired function of this enzyme underlies Gaucher disease, a major lysosomal storage disorder. Owing to its ease of synthetic access and reliable inhibitory profile, CBE has become an indispensable


biochemical probe for elucidating the molecular basis of this genetic condition using diverse animal models.

The first description of CBE was reported by Legler and co-workers in 1966, who demonstrated its capacity to inactivate both plant-derived glucosidases and mammalian  $\beta$ -glucosidases.<sup>17</sup> A decade later, in 1977, the same group proposed a synthetic route to CBE (**8**) from *myo*-inositol (**1**); however, this method suffered from modest yields and required large amounts of starting material, limiting its practical utility.<sup>18</sup>

To overcome these limitations, Lee *et al.* (1985) developed a significantly improved and operationally convenient protocol.<sup>19</sup> Their synthesis began with the reflux of *myo*-inositol (**1**) in cyclohexane–dimethyl sulfoxide (DMSO), catalyzed by *p*-toluenesulfonic acid monohydrate at 110 °C for 6 h, yielding 1,2-*O*-cyclohexylidene-*myo*-inositol (**2**) in ~85% yield. Subsequent acetylation with acetic anhydride and pyridine afforded 3,4,5,6-tetra-*O*-acetyl-1,2-*O*-cyclohexylidene-*myo*-inositol (**3**) in approximately 90% yield.


Removal of the cyclohexylidene protecting group was achieved by heating compound (**3**) in a 4 : 1 mixture of acetic acid and water in the presence of 0.1 M HCl at 100 °C, furnishing 1,4,5,6-tetra-*O*-acetyl-*myo*-inositol (**4**) in ~97% yield. Conversion of compound (**4**) to its corresponding thiocarbonate (**5**) was carried out using *N,N'*-thiocarbonyldiimidazole under nitrogen, also providing a ~97% yield.

Refluxing intermediate (**5**) with trimethyl phosphite for 5 h under nitrogen produced conduritol B tetraacetate (**6**) in ~75% yield. Mechanistically, this transformation proceeds through a phosphite-mediated elimination of the thiocarbonate functionality, enabling efficient generation of the cyclohexene framework that ultimately serves as the precursor for epoxide formation. Subsequent deacetylation of compound (**6**) with triethylamine in a 7 : 3 methanol–water mixture afforded conduritol B (**7**) in nearly quantitative yield. Final epoxidation of compound (**7**) with *meta*-chloroperbenzoic acid (*m*-CPBA) in methanol for 12 h, followed by crystallization from absolute ethanol, yielded conduritol B epoxide (CBE) (**8**) in ~90% overall



Scheme 1 Synthesis of conduritol B epoxide (**8**) from *myo*-inositol (**1**).





Scheme 2 Synthesis of radiolabelled  $^3\text{H}$ -conduritol B epoxide (**15**) from *p*-benzoquinone (**9**).

yield (Scheme 1). The use of *m*-CPBA as an oxidizing agent ensures efficient epoxide formation with high selectivity; however, the reliance on peracid oxidants and multiple protection–deprotection steps may limit the overall step economy and raise practical considerations related to reagent cost and waste generation when larger-scale synthesis is contemplated.

Conduritol B epoxide (CBE, **8**) is not only a potent irreversible inhibitor of  $\beta$ -glucosidase but also an indispensable molecular probe for elucidating the biochemical basis of Gaucher's disease. To study its biological activity, metabolic fate, and mechanism of enzyme inactivation, researchers frequently rely on radiolabelled analogues of CBE. In 1977, Legler *et al.* reported the first synthetic protocol for obtaining radiolabelled CBE using either [ $^{14}\text{C}$ ]– or [ $^3\text{H}$ ]–*myo*-inositol as the precursor.<sup>18</sup> However, the method suffered from low overall yields and the formation of isomeric mixtures, complicating purification and stereochemical characterization.

To address these shortcomings, Gal *et al.* (1987) developed a significantly improved route for the preparation of [ $^3\text{H}$ ]–labelled CBE, providing enhanced yields and superior stereochemical fidelity.<sup>20</sup> Their synthesis commenced with the bromination of *p*-benzoquinone (**9**), producing *trans*-5,6-dibromo-2-cyclohexene-1,4-dione (**10**) in ~65% yield. Reduction of compound (**10**) with sodium borotrifluoride hydride furnished the tritiated diol (1 $\alpha$ ,2 $\beta$ ,3 $\alpha$ ,4 $\beta$ )-(±)-2,3-dibromo-[1,4- $^3\text{H}$ ]-dihydroxy-5-cyclohexene (**11**) in approximately 60% yield.

Acetylation of intermediate (**11**) with acetic anhydride in the presence of 4-pyrrolidinopyridine afforded the corresponding diacetate (**12**) in ~74% yield. Oxidative debromination of compound (**12**) using either silver acetate or lead(II) acetate produced [ $^3\text{H}$ ]–labelled conduritol B tetraacetate (**13**) in yields of ~68% and ~54%, respectively. Subsequent deacetylation of compound (**13**) gave [ $^3\text{H}$ ]–conduritol B (**14**) in ~91% yield.

Final epoxidation of compound (**14**) with *p*-nitroperbenzoic acid afforded [ $^3\text{H}$ ]–conduritol B epoxide (**15**) in an overall yield of ~85% (Scheme 2). This improved synthetic protocol enabled the efficient and stereoselective preparation of radiolabelled CBE, greatly facilitating detailed mechanistic investigations into  $\beta$ -glucosidase inhibition and the pathophysiology of Gaucher's disease.

While conduritol B epoxide represents one of the earliest and most extensively studied functional derivatives of the conduritol framework, its chemistry also highlighted the broader synthetic potential of cyclitol scaffolds. In particular, the structural modification of conduritols through the introduction of nitrogen functionality led to the development of conduramine derivatives, which significantly expanded the biological and synthetic scope of this class of compounds.

## 2.2. Construction of conduramine frameworks: structural diversity and foundational synthetic methods

Aminocyclitols represent an important class of structurally diverse compounds that appear in numerous biologically active molecules. They form the core of aminoglycoside–aminocyclitol (AGAC) antibiotics, constitute key structural elements of several Amaryllidaceae alkaloids, and also function as ligands in cytostatic platinum-based complexes. Within this broader family, conduramines, which are aminated cyclohexenetriols, hold particular significance. Structurally, they are derived from the conduritol framework by replacing one hydroxyl group with an amino substituent.

Conduramines exhibit potent glycosidase inhibitory activity and have therefore attracted substantial interest as both pharmacologically active agents and versatile synthetic intermediates. Owing to their well-defined stereochemistry, these aminocyclitols serve as valuable chiral building blocks in the synthesis of several biologically important natural products, including (+)-narciclasine (**16**), (+)-valienamine (**17**), and (+)-lycoridine (**18**) (Fig. 1). Their synthetic utility extends further to the preparation of amino cyclitols that constitute the aglycone portion of numerous clinically relevant aminoglycoside antibiotics.

Beyond these applications, conduramines are integral to the construction of a wide range of therapeutically relevant molecular architectures such as aminosugars, sphingosines, azasugars, and various Narcissus alkaloids. Depending on the position of the amino functionality on the cyclohexene ring, conduramines may be categorized into several structural subclasses, each offering distinct reactivity patterns and synthetic potential.

In 1990, Werbitzky *et al.* reported a concise and efficient strategy for the synthesis of conduramine A tetraacetate based on a hetero-Diels–Alder reaction.<sup>21</sup> The Diels–Alder reaction and its hetero variants represent powerful cycloaddition methods for constructing six-membered frameworks and have also found applications in modern materials science through reversible Diels–Alder linkages.<sup>22</sup> The sequence began with the cycloaddition between diacetoxydiene (**19**) and protected 1-chloro-1-nitrosomannose (**20**) in a chloroform–ethanol solvent mixture. This [4 + 2] hetero-cycloaddition proceeded smoothly to afford the corresponding dihydrooxazine adduct (**21**) in ~89% yield. Subsequent reductive cleavage of the N–O bond in compound (**21**) using zinc in hydrochloric acid, followed by acetylation with acetic anhydride, provided conduramine A tetraacetate (**22**) in 82% yield (Scheme 3). This approach illustrates the effectiveness of hetero-Diels–Alder chemistry for constructing aminocyclitol frameworks with excellent regio- and stereocontrol.







Fig. 1 Representative structures of narciclasine (16), valienamine (17), and lycoricidine (18).



Scheme 3 Synthesis of conduramine A tetraacetate (22) employing hetero-Diels–Alder approach.

Mechanistically, the hetero-Diels–Alder cycloaddition enables simultaneous formation of the cyclohexene framework and installation of the nitrogen functionality, thereby streamlining the construction of the conduramine scaffold. Nevertheless, the requirement for specifically functionalized nitroso precursors and subsequent reductive N–O bond cleavage steps may limit the broader practicality of this strategy in comparison with more modular nitrogen-installation methods developed in later studies.

The development of efficient synthetic routes to conduramine derivatives also stimulated broader interest in structurally related cyclitol frameworks that display important biological and pharmacological properties. Among these, naturally occurring inositol derivatives such as pinitol have attracted considerable attention, prompting the exploration of enantioselective synthetic strategies capable of accessing these molecules with high stereochemical fidelity.

### 2.3. Enantiodivergent synthetic approaches to pinitol

D-Pinitol (3-O-methyl-D-chiro-inositol) (23) is a naturally occurring cyclitol widely distributed in plant species belonging to the Leguminosae and Pinaceae families. Functionally, it serves as an essential cellular osmoprotectant and defensive metabolite, enabling plants to tolerate abiotic stresses such as drought, salinity, and oxidative damage. Through its involvement in osmotic adjustment and stress-responsive metabolic pathways, D-pinitol plays a critical role in maintaining cellular homeostasis under adverse environmental conditions.

The name “D-pinitol” originates from its initial isolation from the heartwood of *Pinus monticola*. Later investigations established its presence in multiple plant tissues, including resin, wood, bark, and cambial sap, across many gymnosperms, particularly species of *Pinus* and *Abies*. Its distribution is not

confined to conifers; the compound has also been identified in several angiosperm families, including Fabaceae, Nyctaginaceae, Asteraceae, Zygophyllaceae, Caryophyllaceae, Aristolochiaceae, Sapindaceae, Santalaceae, and Aizoaceae.

Traditionally, plants enriched in D-pinitol have been employed in the treatment of diabetes, inflammation, cancer, and microbial infections, consistent with the broad biological activities attributed to this cyclitol. In recent years, interest in D-pinitol has grown markedly due to its abundance in nutritionally and pharmacologically important plant sources such as soybean (*Glycine max*), carob pod (*Ceratonia siliqua*), ice plant (*Mesembryanthemum crystallinum*), fenugreek seed (*Trigonella foenum-graecum*), and several *Retama* species.

Collectively, these findings underscore the significance of D-pinitol as a bioactive phytochemical with promising applications in nutraceuticals, phytopharmaceuticals, and agrobiotechnology (Fig. 2).

In 1990, Hudlicky *et al.* reported a seminal enantiodivergent synthetic strategy that enabled the preparation of both enantiomers of pinitol, (+)-pinitol (+)-23 and (–)-pinitol (–)-23 from a common chiral intermediate.<sup>23</sup> The sequence began with bromo-acetonide (24), which was subjected to osmium tetroxide/*N*-methylmorpholine *N*-oxide ( $\text{OsO}_4/\text{NMO}$ )-mediated dihydroxylation to furnish the conduritol E derivative (25) in approximately 85% yield.





Fig. 2 Representative structures of D-pinitol (23).





Scheme 4 Enantiospecific synthesis of both pinitol enantiomers (23) using the common bromo acetonide intermediate (24).

Reduction of compound (25) with lithium aluminium hydride ( $\text{LiAlH}_4$ ) afforded the corresponding olefin (ca. 85% yield), which underwent epoxidation with *m*-chloroperbenzoic acid (*m*-CPBA) to deliver epoxide (26) in 86% yield. Subsequent methanolysis followed by acetonide deprotection furnished (+)-pinitol (+)-23 in an overall yield of ~90%. The regio- and stereochemical outcome of these transformations is governed by the conformational preference of the conduritol intermediate, which directs nucleophilic attack and oxidative addition from the less sterically hindered face of the cyclohexene ring.

In the complementary sequence leading to the opposite enantiomer, bromo-acetonide (24) was first epoxidized directly with *m*-CPBA in dichloromethane to produce epoxide (27) in 80% yield. Methanolysis of epoxide (27) (89%) followed by dehalogenation (85%) yielded the conduritol F derivative (28). Dihydroxylation of compound (28) using  $\text{OsO}_4/\text{NMO}$  (63%) and subsequent deprotection provided (-)-pinitol (-)-23. Notably, substituting the bromo group in the acetonide precursor with chlorine markedly slowed the dehalogenation step, underscoring the importance of the bromine substituent in controlling reaction efficiency.

The  $\text{OsO}_4/\text{NMO}$  system plays a crucial role in establishing the *syn*-dihydroxylated stereochemical motif characteristic of many cyclitol frameworks. However, the use of osmium-based oxidants presents practical limitations due to their toxicity, high cost, and environmental concerns, which has motivated ongoing efforts to develop milder and more sustainable dihydroxylation methodologies.

This six-step route, originating from a diene diol generated *via* microbial oxidation of bromobenzene, enabled the enantiospecific synthesis of both pinitol enantiomers with excellent stereocontrol and regioselectivity. A key feature of this strategy was the use of a highly versatile chiral synthon that allowed complete diastereofacial control ( $\alpha$ - versus  $\beta$ -attack) and regioselective oxidative transformations in subsequent steps (Scheme 4).

The successful application of such stereocontrolled transformations in the synthesis of cyclitol derivatives also highlighted the broader synthetic versatility of conduritol-type intermediates. In particular, similar strategies involving selective protection, oxidation, and dihydroxylation reactions have

been employed in the construction of highly functionalized inositol derivatives, including biologically significant *myo*-inositol phosphates.

#### 2.4. Foundational synthetic routes to *myo*-inositol polyphosphates


Inositol phosphates constitute a structurally diverse family of naturally occurring organophosphorus compounds. Despite their widespread presence in terrestrial and aquatic environments, they remain among the least understood components of the global phosphorus cycle. These molecules, containing up to six phosphate groups esterified to an inositol scaffold, occur in several stereoisomeric forms, including *myo*, *D-chiro*, *scyllo*, and *neo* with *myo*-inositol hexakisphosphate (phytate) being the most abundant, particularly in plant-derived materials.

Inositol phosphates are primarily of plant origin and accumulate in soils as the dominant class of organic phosphorus species. They are also detected in notable concentrations in aquatic systems, where their partial bioavailability may influence eutrophication processes. Their environmental behavior, such as cycling, mobility, enzymatic turnover, and biological accessibility, is still poorly understood because isolating, separating, and detecting highly phosphorylated species from complex matrices remains analytically challenging.

Beyond their environmental significance, *myo*-inositol phosphates play pivotal roles in biological systems. Several members of this family act as indispensable secondary messengers, particularly in calcium signaling pathways, where they regulate intracellular calcium release and modulate key physiological processes.

A landmark synthetic contribution to this field was reported by Carless *et al.* in 1990, who developed a versatile route to biologically relevant *myo*-inositol phosphates.<sup>24</sup> The synthesis originated from MEM-protected *trans*-benzene diol (29), derived from benzene over seven steps in an overall yield of ~35%. Compound (29) underwent a [4 + 2] cycloaddition with singlet oxygen, followed by thiourea-mediated reduction to afford diol (30). Mechanistically, this pericyclic oxygenation step provides a rapid entry into oxygen-rich cyclohexane frameworks, demonstrating how pericyclic reactions can efficiently generate



Scheme 5 Synthesis of *myo*-inositol phosphates from MEM ether of *anti*-cyclohexa3,5-diene-1,2-diol.

the stereochemically dense intermediates required for complex cyclitol synthesis. Oxidation of the latter using 1.5 equivalents of PCC generated a mixture of hydroxyenones (**31**) and (**32**), isolated in 50% and 20% yield, respectively.

Lucho reduction of compound (**31**) provided the conduritol B derivative (**33**) in 90% yield. Alternatively, compound (**33**) could be accessed in ~70% yield by oxidation of diol (**30**) with 3 equivalents of PCC, followed by reduction of the resulting enedione. Dibenzilation of compound (**33**) with NaH and benzyl bromide furnished the corresponding protected intermediate in 95% yield. Subsequent dihydroxylation using osmium tetroxide/*N*-methylmorpholine *N*-oxide (OsO<sub>4</sub>/NMO) afforded cyclitol (**34**) in 96% yield, serving as a key branch point for the synthesis of multiple *myo*-inositol phosphate isomers. The OsO<sub>4</sub>/NMO-mediated dihydroxylation plays a decisive role in establishing the *syn*-vicinal diol configuration required for inositol phosphate synthesis; however, the reliance on osmium-based oxidants raises practical concerns related to reagent toxicity, cost, and environmental impact, factors that have motivated the search for greener oxidative methodologies in later studies.

From cyclitol (**34**), regioselective introduction of a third MEM protecting group yielded compounds (**35**) and (**36**) in 60% and 10% yield, respectively. Compound (**35**) underwent benzylation (86% yield), MEM deprotection with 6 N HCl in THF at 20 °C (59% yield), and phosphorylation using tetrabenzyl pyrophosphate (TBPP) and NaH (47% yield). Global hydrogenolysis furnished *myo*-inositol 1,4,5-triphosphate (**37**).

Similarly, *myo*-inositol 2,4,5-triphosphate (**38**) was obtained from compound (**36**) through benzylation (78%), MEM deprotection (82%), phosphorylation (53%), and final hydrogenolysis (85%).

Further elaboration of compound (**34**) *via* phosphorylation produced tetrol (**39**), which upon hydrogenolysis furnished racemic *myo*-inositol 1,2,4,5-tetrakisphosphate (**40**). In another sequence, benzylation of compound (**34**) followed by MEM deprotection generated compound (**41**), which upon phosphorylation with TBPP/BuLi in THF and subsequent debenylation afforded racemic *myo*-inositol 4,5-bisphosphate (**42**) (Scheme 5).

The development of such versatile cyclitol intermediates not only facilitated the synthesis of complex inositol phosphates but also underscored the broader synthetic potential of carbohydrate-derived precursors for constructing conduritol frameworks. Building on these concepts, subsequent studies explored stereocontrolled strategies that utilized naturally occurring sugars as chiral starting materials to access structurally diverse conduritol derivatives.

## 2.5. Stereodivergent synthesis of tetra-*O*-methylconduritol derivatives of conduritol A and C from *L*-arabinose

In 1991, McIntosh *et al.* reported a stereospecific and stereodivergent synthetic route to the tetra-*O*-methyl derivatives of conduritol A and conduritol C, starting from the naturally occurring pentose *L*-arabinose. The synthesis began with the



conversion of *L*-arabinose (**43**) into the corresponding di-thioacetal trimethyl ether (**44**) through a three-step sequence.<sup>25</sup>

Selective protection of the primary hydroxyl group in compound (**44**) was achieved using TBDMSCl, imidazole, and DAMP in DMF, affording the silyl ether (**45**) in 86% yield. Subsequent deprotection of the thioacetal moiety with HgO/HgCl<sub>2</sub> in an acetone–water mixture furnished aldehyde (**46**) in 98% yield.

Aldehyde (**46**) underwent Wittig olefination to yield dibromide (**47**) in 81% yield, which was then transformed into silylacetylene (**48**) in 73% yield following the Corey–Fuchs protocol. Hydrogenation of compound (**48**) using Pd/BaSO<sub>4</sub> under an atmosphere of H<sub>2</sub> in pyridine provided vinylsilane (**49**) in 91% yield. Hydrolytic removal of the silyl group with aqueous acetic acid afforded alcohol (**50**) in 80% yield, and oxidation of this primary alcohol produced vinylsilane aldehyde (**51**) with an excellent yield of 98%.

A key feature of this strategy was the stereochemical control achieved during intramolecular cyclization of aldehyde (**51**), governed by the choice of Lewis acid. In this context, the contrasting use of BF<sub>3</sub>·OEt<sub>2</sub> and SnCl<sub>4</sub> highlights the decisive role of Lewis acid coordination in controlling the transition-state geometry of the cyclization process, thereby directing the formation of either the anti or syn cyclohexenol framework. However, the requirement for strong Lewis acids and carefully controlled reaction temperatures may impose practical limitations when considering the scalability and operational simplicity of such transformations. Treatment with BF<sub>3</sub>·OEt<sub>2</sub> in dichloromethane at ambient temperature led to the formation of 1,2-*anti*-cyclohexenol (**52**) in 86% yield and with >30:1


isomeric purity. Conversely, treatment with SnCl<sub>4</sub> at –78 °C followed by gradual warming to room temperature afforded the 1,2-*syn*-cyclohexenol (**54**), also in 86% yield and >30:1 isomeric ratio.

Final methylation of the hydroxyl groups using Ag<sub>2</sub>O and methyl iodide completed the divergent sequence: the 1,2-*anti* intermediate (**52**) furnished tetra-*O*-methylconduritol A (**53**) in 71% yield, while the 1,2-*syn* intermediate (**54**) delivered tetra-*O*-methylconduritol C (**55**) in 91% yield (Scheme 6). This methodology elegantly demonstrates how Lewis acid-controlled cyclizations can direct stereochemical outcomes, enabling efficient access to distinct conduritol isomers from a common chiral precursor.

The ability to control stereochemical outcomes through strategic choice of reagents and reaction conditions also proved valuable in the synthesis of nitrogen-containing cyclitol derivatives. Building on the principles of stereoselective cyclization and functional group manipulation illustrated above, subsequent studies explored routes to aminocyclitol frameworks, which are of considerable importance in antibiotic development and medicinal chemistry.


## 2.6. Stereospecific synthesis of *cis*-1,3-diaminocyclitols

The selective synthesis of aminocyclitol isomers with retention of amino group configuration is of considerable interest, particularly due to their relevance in the mutasynthesis of new aminoglycoside antibiotics and their utility as ligands in cytosolic platinum(II) complexes. In 1991, Schürle *et al.* developed an elegant and stereospecific synthetic approach to *cis*-1,3-



Scheme 6 Synthesis of tetra-*O*-methylconduritol A (**53**) and tetra-*O*-methylconduritol C (**55**) from *L*-arabinose (**43**).



Scheme 7 Synthesis of 2,4-diamino-2,4-dideoxy-*chiro*-inositol (**67**) and 2,4-diamino-2,3,4-trideoxy-*allo*-inositol (**73**).

diamino-1,3-dideoxycyclitols, employing a conduramine A-1 derivative as the central intermediate.<sup>26</sup>

The key transformation in their strategy was a hetero-Diels-Alder reaction between compound (**56**), prepared from *cis*-cyclohexa-3,5-diene-1,2-diol, and (-)-2,3,5,6-di-*O*-isopropylidene-1-nitroso- $\alpha$ -D-manno-furanosyl chloride (-)-**57**. This cycloaddition furnished the oxazine (+)-**58** in 82% yield. Reductive cleavage of (+)-**58** with aluminum amalgam in aqueous THF then produced the conduramine A-1 derivative (-)-**59** in 94% yield.

Reaction of compound (-)-**59** with *N*-ethoxycarbonylphthalimide (**60**) and sodium carbonate afforded the protected amino derivative (-)-**61** in 90% yield. Hydrolysis of (-)-**61** subsequently delivered the triol (-)-**62** in 92% yield. Protection of the three hydroxyl groups as isopropylidimethylsilyl (IPDMS) ethers using chloro(isopropyl)dimethylsilane and imidazole afforded compound (-)-**63** in 98% yield.

Epoxidation of (-)-**63** with *p*-nitroperbenzoic acid, followed by desilylation with acetic acid, generated epoxy triol (-)-**64** in 87% yield. Subsequent treatment with trichloroacetonitrile and DBU furnished the trichloroacetimidate (-)-**65** in 94% yield. A crucial stereoselective intramolecular epoxide opening mediated by triethylaluminum led to exclusive formation of the 2-trichloromethyl-4,5-dihydro-1,3-oxazole (-)-**66** in 80% yield. The use of triethylaluminum as a Lewis acidic promoter is central to this transformation, facilitating controlled intramolecular epoxide opening through coordination to the oxygen atom and directing nucleophilic attack along a well-defined transition-state pathway. Nevertheless, the requirement for highly moisture-sensitive organoaluminum reagents and multistep protection-deprotection sequences may pose practical challenges when considering the operational robustness and scalability of this methodology.



Cleavage of the oxazole ring in (–)-66 using HCl followed by treatment with anhydrous hydrazine afforded (–)-1L-2,4-diamino-2,4-dideoxy-*chiro*-inositol (–)-67 in 79% yield. The opposite enantiomer, (+)-67, was obtained analogously starting from (+)-57.

In a complementary sequence, compound (–)-61 was converted into its trichloroacetamide derivative (–)-68 in 91% yield using trichloroacetonitrile in dichloromethane. Subsequent iodination with *N*-iodosuccinimide (NIS) afforded a 3 : 1 mixture of (–)-69 (66%, major) and (–)-70 (21%). Further iodination of (–)-69 with NIS produced the diiodide (–)-71 in 95% yield.

Radical dehalogenation of compound (–)-71 provided (+)-72 in 92% yield. Final global deprotection of (+)-72 with hydrazine in a chloroform–ethanol mixture delivered the target aminocyclitol, (–)-1L-2,4-diamino-2,3,4-trideoxy-*allo*-inositol (–)-73, in 73% yield. The enantiomeric form, (+)-73, was obtained similarly using the enantiomer (+)-57 (Scheme 7).


While the strategy described above highlights the power of hetero-Diels–Alder reactions and intramolecular epoxide openings for constructing aminocyclitol frameworks with precise stereochemical control, alternative approaches have also been explored to access conduritol and conduramine derivatives more directly from simple aromatic precursors. In particular, microbial arene oxidation has emerged as a highly effective strategy for generating *cis*-dihydroxylated intermediates that can serve as versatile building blocks for diverse cyclitol syntheses.

## 2.7. Synthesis of deoxyconduritol E and conduramine A-1 derivatives

In 1991, Hudlicky *et al.* reported a versatile and stereoselective synthetic strategy enabling access to a broad array of natural and synthetic conduritols.<sup>27</sup> The central feature of this unified approach was the microbial oxidation of chloro- or bromobenzene to generate the corresponding *cis*-cyclohexadienediols. These bio-oxidized intermediates, with their well-defined symmetry and inherent stereochemical bias, provided an ideal platform for introducing functional groups with excellent stereocontrol. The microbial arene dihydroxylation step is particularly valuable because it introduces vicinal *cis*-diol functionality with high enantioselectivity under mild conditions; however, practical implementation may depend on access to specialized microbial strains and biocatalytic facilities, which can limit the widespread application of this approach in laboratories lacking biotransformation infrastructure.

For the synthesis of deoxyconduritol E, bromocyclohexadienediol (74), obtained from bromobenzene oxidation, was first transformed into its acetonide-protected derivative. Epoxidation of this intermediate with *m*-CPBA in dichloromethane furnished epoxide (27). Similarly, chlorocyclohexadienediol (77) was converted into the corresponding epoxide (78) following acetonide protection and *m*-CPBA epoxidation.

Reduction of epoxides (27) and (78) with LiAlH<sub>4</sub> in ether afforded alcohols (75) and (79) in ~99% and 80% yields, respectively. Radical dehalogenation of these alcohols produced a common intermediate (76) in 80% yield. Subsequent acidic



Scheme 8 Synthesis of deoxyconduritol E (80), conduramine A-1 tetraacetate (22) tetraacetate along with dihydroconduramine A-1 (85).



deprotection of compound (76) delivered Deoxyconduritol E (80) in quantitative yield.

In a complementary sequence, Hudlicky and co-workers also developed an efficient route to conduramine A-1 tetraacetate, dihydroconduramine A-1, and its tetraacetate derivative.<sup>1,27</sup> The route began with a hetero-Diels–Alder reaction between bromocyclohexadienediol acetonide (24) and an *in situ*-generated nitrosyl dienophile derived from acetohydroxamic acid. This cycloaddition produced the oxazine (81) as a single enantiomer, installing four contiguous stereocenters in a single step.

Reductive cleavage of the N–O bond in oxazine (81) using aluminum amalgam furnished the amino alcohol (82) in 77% yield. Acidic deprotection of (82) then yielded triol (83) in ~99% yield. Acetylation of triol (83) afforded conduramine A-1 tetraacetate (22) in 63% yield. Moreover, palladium-catalyzed hydrogenation of triol (83) provided dihydroconduramine A-1 (84) in 99% yield, which upon acetylation in a THF–water mixture furnished dihydroconduramine A-1 tetraacetate (85) in 97% yield (Scheme 8).

The successful utilization of microbial arene dihydroxylation in these transformations highlighted the broader potential of biocatalytic oxidation for constructing highly functionalized cyclitol frameworks from simple aromatic precursors. Building upon this concept, subsequent studies expanded the scope of such chemoenzymatic strategies to access structurally modified inositol derivatives, including *C*-methyl-substituted cyclitols of biological significance.

## 2.8. Chemoenzymatic synthesis of *C*-methyl inositols: enantioselective access to (–)-laminitol and *C*-methyl muco-inositol

The identification of *D*-*myo*-inositol-1,4,5-trisphosphate (IP<sub>3</sub>) as a pivotal second messenger that mediates intracellular calcium ion release highlighted the need for efficient synthetic routes to


inositol phosphates and related analogues. These compounds became invaluable tools in probing signal transduction pathways. While several synthetic methods for *myo*-inositol phosphates had been developed, they often relied on naturally abundant *myo*-inositol as the starting material. Alternative strategies frequently employed benzene or cyclohexa-1,2-diene-1,2-diols (in *cis* or *trans* forms) to access the desired inositol phosphate analogues.

Although the biological functions of other inositol stereoisomers remained comparatively less explored, two naturally occurring *C*-methyl inositols, (–)-laminitol and mytilitol (a symmetrical derivative of *scyllo*-inositol) were isolated from marine algae. Of these, (–)-laminitol, featuring *myo*-inositol stereochemistry and a methyl group at C-4, demonstrated biological activity by inhibiting the growth of *Neurospora crassa*. While a racemic synthesis of laminitol from *myo*-inositol had been reported earlier, Carless *et al.* (1991) provided the first enantioselective total synthesis of (–)-laminitol (–)-93 and *C*-methyl muco-inositol (94), uniquely starting from toluene (86).<sup>28</sup>

Their synthetic route began with microbial oxidation of toluene using *Pseudomonas putida*, affording *cis*-cyclohexadienediol (87). Protection of the diol with 2,2-dimethoxypropane yielded the corresponding isopropylidene derivative (88) in ~65% yield. Epoxidation of compound (88) afforded epoxide (89), which was converted into the corresponding *trans*-diol (90) *via* acid-mediated ring opening. Subsequent deprotection of the isopropylidene group led to *C*-methyl conduritol F (91) in ~78% yield.

Hydroxyl-directed epoxidation of the remaining double bond in compound (91) yielded epoxide (92) in ~73% yield. The final step, an acid-catalyzed epoxide ring opening produced a 1 : 1 mixture of (–)-laminitol (–)-93 and *C*-methyl muco-inositol (94), with an excellent combined yield of ~95%.

Additionally, Carless *et al.* described an alternative synthetic route to *C*-methyl muco-inositol (94). This involved the reaction



Scheme 9 Chemoenzymatic synthesis of (–)-laminitol (–)-93 and *C*-methyl muco-inositol (94) from toluene (86).



of *cis*-cyclohexadienediol (**87**) with singlet oxygen to form endoperoxide (**95**). Reductive cleavage of the peroxide bond using thiourea yielded *C*-methyl conduritol A (**96**). Subsequent dihydroxylation of compound (**96**) with osmium tetroxide afforded *C*-methyl *muco*-inositol (**94**) in ~55% isolated yield (Scheme 9). The use of osmium tetroxide enables highly stereoselective *syn*-dihydroxylation of the cyclohexene framework; however, similar to other osmium-mediated oxidations discussed earlier, the toxicity and high cost of this reagent remain important considerations when evaluating the scalability and environmental sustainability of such methodologies.

The versatility of microbial arene dihydroxylation in generating highly functionalized cyclitol intermediates also inspired its application in the synthesis of structurally complex natural products. In particular, the stereochemically rich cyclohexadienediol intermediates obtained from aromatic biooxidation proved especially valuable for constructing the core frameworks of several Amaryllidaceae alkaloids, including lycoricidine and related compounds.

## 2.9. Chemoenzymatic synthesis of (+)-lycoricidine from chlorobenzene

The Narcissus alkaloids pancratistatin, narciclasine, and lycoricidine belong to a prominent class of bioactive natural products isolated from members of the Amaryllidaceae family. These compounds exhibit remarkable cytotoxic and antitumor activities, with pancratistatin emerging as the most promising therapeutic candidate since the initial structural elucidations reported in the late 1960s. However, the extremely low natural abundance of these alkaloids, coupled with the complexity of their extraction and purification from plant sources, severely limits their availability. These challenges highlight the need for synthetic approaches that are synthetically efficient, cost-effective, environmentally sustainable, and stereochemically well-controlled, ideally providing scalable access to all members of this alkaloid family.

In 1992, Hudlicky *et al.* disclosed an enantioselective total synthesis of (+)-lycoricidine that leveraged a biooxidative


strategy to establish the core stereochemical framework.<sup>29</sup> The synthesis began with microbial dihydroxylation of chlorobenzene (**97**) to afford *cis*-cyclohexadienediol (**98**), which was subsequently protected as its acetonide derivative (**77**). A hetero-Diels–Alder cycloaddition between acetonide (**77**) and dienophiles (**99**) or (**100**), promoted by Bu<sub>4</sub>NiO<sub>4</sub> in dichloromethane, furnished the corresponding oxazines (**101a**) and (**101b**) in 74% and 80% yield, respectively.

Reductive cleavage of the N–O bond in these oxazines using aluminum amalgam generated the protected conduramine D derivatives (**102a**) and (**102b**). Compound (**102a**) underwent silylation of the secondary hydroxyl group in 98% yield, followed by lithiation with *n*-BuLi in THF and subsequent acylation with 2-bromopiperonyl chloride (**103**) to deliver amide (**104**) in 77% yield. Alternatively, amide (**104**) could be obtained from compound (**102b**) *via* silylation followed by CBZ protection and analogous acylation.

The pivotal macrocyclization of amide (**104**) was accomplished through a modified Heck reaction employing Pd(OAc)<sub>2</sub>, Ti(OAc)<sub>4</sub>, and 1,2-bis(diphenylphosphino)ethane (DPPE) in anisole, furnishing the cyclized product (**105**) in 27% yield. Removal of the CBZ protecting group delivered amide (**106**) in nearly quantitative yield. Final acid-mediated removal of the acetonide and silyl protecting groups using trifluoroacetic acid (TFA) completed the synthesis, yielding (+)-lycoricidine (+)-**18** in 85% yield (Scheme 10).

Chemoenzymatic arene *cis*-dihydroxylation strategies provide a powerful entry into densely functionalized cyclitol frameworks because they introduce multiple stereocentres in a single step with excellent stereochemical control. Nevertheless, their broader application can sometimes be limited by substrate scope, the need for specialized microbial systems, and challenges associated with scaling up biotransformations for large-scale synthetic applications.

Beyond their application in the total synthesis of complex natural products such as lycoricidine, these chemoenzymatically generated cyclitol intermediates also provide versatile platforms for the preparation of structurally diverse



Scheme 10 Chemoenzymatic synthesis of (+)-lycoricidine (+)-**18** from chlorobenzene (**97**).



conduramine derivatives. Consequently, several studies have explored strategies that combine microbial oxidation with enzymatic resolution and stereospecific functionalization to access enantiomerically pure aminocyclitols with defined stereochemical configurations.

### 2.10. Stereoselective construction of conduramine C-1 and related conduramine A derivatives

Similar to the parent conduritols, conduramines display potent glycosidase inhibitory activity and therefore serve as valuable scaffolds for the design of enzyme inhibitors. In 1992, Johnson *et al.* reported an enantioselective synthesis of both enantiomers of conduramine C-1 (**114**), employing a strategy that combined microbial oxidation, enzymatic resolution, and Mitsunobu-type reactions.<sup>30</sup>

The synthesis commenced with *meso*-cyclohexa-3,5-dien-1,2-diol (**108**), generated from benzene (**107**) via microbial dihydroxylation. Protection of this diol afforded the corresponding conduritol A derivative (**109**). Selective enzymatic acetylation using *Pseudomonas cepacia* lipase and isopropenyl acetate provided monoacetate (**110**). After hydroxyl protection and subsequent deacetylation, compound (**111**) was isolated in ~98% yield.


Exposure of compound (**111**) to Mitsunobu conditions in the presence of phthalimide furnished protected conduramine C-1 (**112**) in 67% yield. The Mitsunobu reaction plays a crucial role in this transformation by enabling stereospecific inversion of configuration during nucleophilic substitution, thereby

allowing efficient introduction of the nitrogen functionality into the cyclitol framework. However, the use of stoichiometric quantities of azodicarboxylate reagents and triphenylphosphine generates significant by-product waste, which may limit the environmental sustainability of this approach when considered on larger scales. Global deprotection of (**112**) with *p*-toluenesulfonic acid (*p*-TSA) yielded intermediate (**113**), which upon treatment with 40% aqueous methylamine delivered (–)-conduramine C-1 (–)-**114** in quantitative yield.

In an alternative sequence, monoacetate (**110**) was subjected directly to a Mitsunobu reaction with phthalimide, affording protected intermediate (**115**) in 61% yield. Treatment of (**115**) with 40% aqueous methylamine produced compound (**116**) in ~81% yield, and a subsequent methylamine-induced deprotection step yielded (+)-conduramine C-1 (+)-**114** in ~99% yield.

Johnson *et al.* also described the preparation of partially protected conduramine A derivatives. The sequence began with a hetero-Diels–Alder reaction between diene (**56**) and an *in situ*-generated nitroso dienophile (formed by tetraethylammonium periodate oxidation of benzohydroxamic acid), producing racemic oxazine (**117**). Reductive cleavage of the N–O bond using aluminum amalgam in THF furnished racemic alcohol (**118**).

Resolution of racemic (**118**) was achieved using amano P-30 lipase in isopropenyl acetate, providing a mixture of acetate (**119**) and unreacted alcohol (–)-**118**. Deacetylation of (**119**) produced alcohol (**120**), which upon acidic deprotection with *p*-TSA yielded partially protected conduramine A (+)-**121**. The



Scheme 11 Synthesis of both enantiomers of conduramine C-1 (**114**) and partially protected conduramine A (**121**).

opposite enantiomer (–)-**121** was obtained by direct *p*-TSA-mediated deprotection of (–)-**118** (Scheme 11).

These studies demonstrate how combinations of microbial oxidation, enzymatic resolution, and stereospecific functionalization can provide efficient access to structurally diverse conduramine derivatives. In addition to such aminocyclitol frameworks, related synthetic efforts have also focused on the preparation of electrophilic conduritol epoxides, which serve as valuable mechanism-based inhibitors of glycosidases and important probes for studying carbohydrate-processing enzymes.

### 2.11. Unified route to conduritol E and F epoxides via carbocyclization of a mannose-derived intermediate

Epoxide derivatives of conduritols have attracted considerable attention owing to their function as mechanism-based inactivators of glycosidases. These electrophilic cyclitols act as potent biochemical probes for elucidating the mechanistic features of glycoside hydrolases. For example, epoxy-conduritol F has been shown to irreversibly inactivate a liver-specific isoform of  $\beta$ -mannosidase isolated from goat liver, underscoring the biological significance of such compounds.

In a seminal contribution published by Chretien *et al.* in 1993, a concise and efficient synthetic route to both conduritol E and F epoxides was developed starting from a *D*-mannose derivative.<sup>31</sup> The synthesis began with the transformation of methyl  $\alpha$ -*D*-mannopyranoside (**122**) into the crystalline 6-iodo peracetate (**123**) via a modified Garegg protocol followed by acetylation, affording the product in 91% yield.


Treatment of compound (**123**) with silver fluoride in pyridine induced an elimination reaction to furnish alkene (**124**) in 91% yield. Subsequent deacetylation of compound (**124**), followed by

benzylation, provided the dibenzylated intermediate (**125**), again in 91% yield. The key carbocyclization step was accomplished using catalytic  $\text{HgSO}_4$  in sulfuric acid, converting compound (**125**) into ketol (**126**) in 80% yield. This mercury-mediated carbocyclization efficiently constructs the cyclohexene framework characteristic of conduritols while preserving the stereochemical information derived from the carbohydrate precursor. However, the use of mercury salts raises environmental and safety concerns, and the development of alternative metal-catalyzed or organocatalytic cyclization strategies would be desirable for improving the sustainability of such transformations.

Elimination of the hydroxyl group in ketol (**126**) with tosyl chloride in pyridine generated enone (**127**) in 82% yield. Stereoselective Luche-type reduction of enone (**127**) with  $\text{NaBH}_4$  in the presence of  $\text{CeCl}_3$  produced a mixture of partially protected conduritol E (**128**) and conduritol F (**129**). Oxidation of these intermediates with *m*-chloroperbenzoic acid (*m*-CPBA) yielded the corresponding epoxides: partially protected conduritol E epoxide (**130**) in ~40% yield and conduritol F epoxide (**131**) in ~80% yield (Scheme 12).

This sequence provides an elegant carbohydrate-derived approach to conduritol epoxides, enabling the stereocontrolled preparation of two biologically important epoxide isomers from a readily available chiral pool precursor.

In addition to carbohydrate-derived strategies, complementary approaches have employed chemoenzymatic arene dihydroxylation to generate versatile cyclitol intermediates from simple aromatic substrates. Such biooxidative methods have proven particularly powerful for accessing diverse inositol stereoisomers through controlled transformations of conduritol epoxide intermediates.



Scheme 12 Synthesis of partially protected conduritol E epoxide (**130**) and conduritol F epoxide (**131**) from methyl  $\alpha$ -*D*-mannopyranoside (**122**).



## 2.12. Chemoenzymatic divergent synthesis of inositol stereoisomers from chlorobenzene

In 1993, Hudlicky *et al.* developed a versatile synthetic strategy for the preparation of various inositols starting from chlorobenzene, with a conduritol E epoxide derivative serving as a key intermediate.<sup>32</sup> The sequence commenced with the biotransformation of chlorobenzene (**97**) to chlorocyclohexadienediol (**98**) using *Pseudomonas putida* strain 39D. This microbial oxidation product was subsequently converted into the chloro epoxide (**132**), a pivotal branching point for constructing multiple inositol stereoisomers.

Hydrolysis of epoxide (**132**) over alumina furnished the corresponding ketone (**133**) in approximately 85% yield, and catalytic hydrogenation of (**133**) produced *allo*-inositol (**134**) in yields exceeding 90%. Under radical dehalogenation conditions, epoxide (**132**) was transformed into epoxide (**135**), which upon hydrolysis either using Amberlite IR-118 resin or under neutral aqueous conditions afforded a 7:3 mixture of (+)-*D*-*chiro*-inositol (+)-**137** and *neo*-inositol (**138**). The major isomer, (+)-**137**, was isolated in 60% yield and could be readily separated from *neo*-inositol *via* crystallization.

Further refinement of this route was achieved by treating epoxide (**135**) with a 1:1 mixture of amberlyst A-21 and Amberlite IRA-904, or alternatively with sodium benzoate, to promote highly selective formation of (+)-*D*-*chiro*-inositol *via* the acetone intermediate (**139**). This optimized method delivered (+)-**137** in 98% yield with >95% selectivity, accompanied by only trace amounts ( $\leq 5\%$ ) of *neo*-inositol (**138**).

Under acidic hydrolytic conditions, epoxide (**135**) underwent a Payne rearrangement, progressing through intermediates (**140**), (**141**), and (**142**) to ultimately furnish *muco*-inositol (**143**) (Scheme 13).


The Payne rearrangement plays a crucial role in this transformation by enabling intramolecular migration of the epoxide under basic or acidic conditions, thereby allowing controlled

redistribution of stereochemical information across the cyclitol framework. Such rearrangements provide an efficient means of accessing multiple inositol stereoisomers from a common intermediate, although careful control of reaction conditions is necessary to minimize competing side reactions.

The ability to generate diverse inositol stereoisomers from common cyclitol intermediates highlights the remarkable versatility of chemoenzymatic arene dihydroxylation strategies. Beyond the synthesis of inositol derivatives, similar intermediates have also been employed as chiral building blocks for constructing biologically significant aminocyclitol antibiotics and related natural products. One notable example is the stereocontrolled synthesis of the aminocyclitol antibiotic fortamine.


## 2.13. Efficient stereocontrolled route to (+)-fortamine dihydrochloride from *cis*-cyclohexadiene diol acetone

In 1994, Vandewalle *et al.* reported the total synthesis of (+)-fortamine dihydrochloride through a highly efficient and stereocontrolled sequence originating from the acetone-protected *cis*-cyclohexa-3,5-diene-1,2-diol derivative (**56**).<sup>33</sup> Following the protocol of Balci *et al.*, the starting material was transformed into diol (**109**) in an excellent 94% yield. Subsequent esterification of (**109**) with butanoyl chloride in the presence of triethylamine and 4-dimethylaminopyridine (DMAP) in dichloromethane afforded ester (**144**) in quantitative yield. Enzymatic hydrolysis of (**144**) using PGL (a recombinant *Fusarium solani pisi* cutinase) furnished the optically active alcohol (+)-**145** in approximately 83% yield. The use of an enzyme-catalysed hydrolysis step is particularly advantageous in this sequence, as it enables highly selective kinetic resolution under mild conditions while avoiding the need for harsh reagents typically required for chemical resolution methods. However, the efficiency of such biocatalytic processes can



Scheme 13 Enzyme-catalysed synthesis of various inositols from chlorobenzene (**97**).





Scheme 14 Synthesis of (+)-fortamine dihydrochloride (+)-156 employing an enzyme-catalysed ester hydrolysis.

depend strongly on enzyme availability, substrate compatibility, and reaction optimization.

Alcohol (+)-145 was then protected as its methoxyphenylmethyl (MPM) ether, and hydrolysis of the butanoate ester generated alcohol (146) in 98% yield. Under Mitsunobu conditions, compound (146) underwent regioselective inversion to give alcohol (147) in 97% yield. Subsequent silyl protection of the free hydroxyl group followed by acetone deprotection furnished diol (148) in 90% yield.

Treatment of diol (148) with sulfuryl chloride and triethylamine in dichloromethane led to formation of the cyclic sulfate (149) in 89% yield. Nucleophilic displacement of the sulfate moiety with lithium azide produced a 1 : 3 mixture of regioisomers (150) and (151), which were separated by column chromatography. The major regioisomer, (151), was desilylated and then subjected to olefin epoxidation with *m*-CPBA to yield epoxide (152) in 93% yield. Benzoylation of the hydroxyl groups followed by removal of the MPM protecting group afforded intermediate (153) in 98% yield.

Subsequent treatment of (153) with methyl isothiocyanate and triethylamine in dichloromethane produced the epoxyurethane (154), which upon sequential reaction with sodium hydride and methyl iodide provided compound (155) in quantitative yield. Finally, catalytic hydrogenolysis of the benzyl protecting groups in the presence of formic acid, followed by acid hydrolysis of (155) using 6 N HCl, delivered (+)-fortamine dihydrochloride (+)-156 in approximately 98% yield for the final transformation (Scheme 14).

The efficient construction of the aminocyclitol framework in this synthesis further illustrates the versatility of cyclohexadienediol-derived intermediates for accessing structurally diverse aminocyclitol natural products. In addition to antibiotic scaffolds such as fortamine, closely related synthetic strategies have also been applied to the preparation of

conduramine derivatives, which serve as valuable intermediates for the synthesis of glycosidase inhibitors and other biologically active cyclitols.

#### 2.14. Stereoselective construction of conduramine C-1: chemoenzymatic desymmetrization and carbohydrate-derived routes


Conduritol (cyclohex-5-ene-1,2,3,4-tetrols) and their amino analogues, conduramines in which one hydroxyl group is replaced by an amino functionality, have long attracted interest owing to their value as key intermediates in the synthesis of amino- and diaminocyclitols. These structural motifs constitute the aglycone cores of several aminoglycoside antibiotics, and numerous conduramine derivatives have demonstrated potent glycosidase inhibitory activity, underscoring their pharmacological relevance.

The first optically pure conduramines were reported in 1981 by Paulsen and co-workers, who prepared conduramine F from the naturally occurring cyclitol quebrachitol.<sup>34</sup> Subsequent advances in stereoselective synthesis further expanded access to this family of compounds. Notably, the groups of Ogawa and Knapp independently employed Ferrier-type cyclizations of *D*-glucose to furnish a variety of conduramine analogues, including the C1, C2, and F1 series.

Over the last few decades, numerous asymmetric methodologies have been developed for the construction of conduritol and conduramines. These include Diels–Alder cycloadditions of nitroso derivatives to cyclohexa-3,5-diene-1,2-diol systems as well as microbial oxidation of halogenated benzenes (*e.g.*, bromo- or chlorobenzene), which provides access to optically enriched cyclohexadienediol precursors.

In 1992, Johnson *et al.* reported the first enantioselective syntheses of both (–)-conduramine C1 and (+)-conduramine C1.<sup>34</sup> Their strategy began with the microbial oxidation of





Scheme 15 Stereoselective synthesis of (–)-conduramine C-1 (–)-114 via a carbohydrate-derived approach involving regioselective oxa-ring opening and intramolecular cyclization.

benzene to yield cyclohexa-3,5-diene-1,2-diol, which was subsequently converted into *meso*-2,3-*O*-isopropylideneconduritol A. The key desymmetrization step involved enzymatic monoacetylation using isopropenyl acetate in the presence of *Pseudomonas cepacia* lipase (Amano P-30), furnishing optically enriched intermediates suitable for divergence toward either enantiomer. Such chemoenzymatic desymmetrization strategies are particularly attractive because they enable efficient access to enantiomerically enriched intermediates from *meso* substrates under mild conditions. However, the outcome of enzymatic transformations may depend strongly on enzyme selectivity, substrate compatibility, and reaction optimization, which can influence their broader applicability in synthetic planning.

Further refinement came in 1994, when Vogel *et al.* developed an alternative synthesis of (–)-conduramine C1.<sup>35</sup> Beginning with the sugar derivative (+)-157, a six-step sequence delivered ketone (+)-158 in an overall yield of approximately 46%. Stereoselective reduction with sodium cyanoborohydride afforded the *endo*-alcohol (–)-159 in 97% yield, which was subsequently acetylated using acetic anhydride and pyridine to give acetate (–)-160 in 75% yield. Treatment of (–)-160 with hydrobromic acid in acetic acid induced a regio- and stereoselective oxa-ring opening to furnish (–)-161 in 56% yield. Cyclization mediated by DBU then produced the protected conduramine C1 derivative (–)-162 in 95% yield. Final acidic deprotection of (–)-162 furnished the target compound, (–)-conduramine C1 (–)-114, also in 95% yield (Scheme 15).

The synthetic routes described above highlight the effectiveness of chemoenzymatic desymmetrization and carbohydrate-derived strategies for accessing stereochemically defined conduramine frameworks. Complementary approaches have also explored oxidative transformations of cyclohexadiene derivatives, where photooxygenation and subsequent rearrangements provide alternative entry points to aminocyclitol architectures.

## 2.15. Stereoselective synthesis of conduramine F-4 via photooxygenation-derived *endo*-peroxides


Aminocyclitols have garnered considerable attention owing to their potent glycosidase inhibitory activity and their value as key intermediates in the synthesis of aminoinositols and other biologically active cyclitol derivatives. Hasegawa *et al.* demonstrated the successful preparation of several aminocyclitols starting from *cis*- and *trans*-benzene diol isomers, highlighting the versatility of these precursors.<sup>36</sup>

In 1994, Seçen *et al.* reported an efficient synthetic approach to conduramine F-4 (166), employing a concise sequence involving photooxygenation, reductive rearrangement, and nucleophilic epoxide opening.<sup>36</sup> The route began with the photooxygenation of cyclohexadiene acetone (56) using a 150-W projection lamp and tetraphenylporphyrin as a singlet oxygen sensitizer, affording the corresponding *endo*-peroxide (163) in an excellent 95% yield after silica gel purification. The singlet oxygen-mediated photooxygenation step is particularly valuable because it rapidly installs the peroxide functionality with high regio- and stereoselectivity, thereby generating a versatile intermediate that can be transformed into epoxides and aminocyclitols through subsequent reductive and nucleophilic processes. However, such photochemical transformations often require specialized irradiation equipment and careful control of reaction conditions.

Reductive cleavage of the *endo*-peroxide (163) with triethyl phosphite in chloroform furnished a single epoxide product (164) in 55% yield. This epoxide was then subjected to nucleophilic ring opening with ammonia in methanol, delivering the conduramine F-4 precursor (165) in approximately 95% yield. Final deprotection of the acetonide functionality under acidic hydrolytic conditions afforded conduramine F-4 (166) in near-quantitative yield (Scheme 16).

This concise and stereoselective sequence illustrates the synthetic utility of photooxygenation-derived *endo*-peroxides and epoxide intermediates in accessing biologically relevant aminocyclitols.





Scheme 16 Synthesis of conduramine F-4 (**166**) via a photooxygenation-derived *endo*-peroxide intermediate.

While photooxygenation-based strategies provide an efficient route to aminocyclitol frameworks, alternative synthetic approaches have also been explored to access structurally diverse conduramine derivatives. In particular, cycloaddition-based methodologies have proven valuable for constructing highly functionalized intermediates that can be transformed into multiple conduramine isomers through divergent synthetic sequences.

### 2.16. Divergent synthesis of conduramine A-1, F-1, and C-1 from an *N*-Boc pyrrole Diels–Alder adduct

In 1994, Muchowski and co-workers reported a series of comprehensive synthetic routes to various conduramine derivatives using an *N*-substituted pyrrole framework as the key starting scaffold.<sup>37</sup> One of their significant achievements was the synthesis of ( $\pm$ )-conduramine A-1 ( $\pm$ )-**177**. The sequence commenced with a Diels–Alder cycloaddition between *N*-Boc-pyrrole (**167**) and tosylacetylene (**168**) in a 2 : 1 molar ratio at 85 °C for 24 hours, furnishing cycloadduct (**169**) in 80–85% yield. The use of an *N*-substituted pyrrole as the diene component in this cycloaddition provides a versatile platform for constructing densely functionalized intermediates that can be diversified into multiple conduramine frameworks. However, the requirement for elevated temperatures and multistep downstream functionalization highlights the synthetic complexity associated with such cycloaddition-based approaches.

Reduction of (**169**) with sodium borohydride in methanol produced an 8 : 1 mixture of *endo/exo* isomers of alcohol (**170**) in 94% yield. Subsequent treatment of this mixture with lithium bis(trimethylsilyl)amide (LiHMDS) in THF generated the conjugated diene (**171**) in 70–75% yield. Protection of the amino group in (**171**) with (Boc)<sub>2</sub>O in the presence of catalytic 4-DMAP afforded diene (**172**) in 85% yield.

*Cis*-dihydroxylation of (**172**) using osmium tetroxide/NMO provided diol (**173**) in 91% yield. Reductive desulfonation of (**173**) with sodium amalgam in buffered methanol furnished compound (**174**) in 42–50% yield. Protection of the resulting diol as an acetonide followed by epoxidation with *m*-CPBA delivered epoxide (**175**) in 90% yield. Regioselective epoxide opening with phenylselenide, followed by oxidative elimination with hydrogen peroxide, produced the protected conduramine A-1 intermediate (**176**) in 76% yield. Global deprotection furnished ( $\pm$ )-conduramine A-1 ( $\pm$ )-**177** in 92% final yield.

The authors also developed a route to conduramine F-1 (**183**). Starting from diene (**171**), epoxidation with *m*-CPBA in dichloromethane gave epoxide (**178**) in approximately 90%

yield. Acid-catalyzed hydrolysis afforded *trans*-diol (**179**) in 73% yield. Reductive desulfonation using sodium amalgam yielded compound (**180**) in 76% yield. Acetylation followed by epoxidation produced epoxide (**181**) in 68% yield, which was subsequently transformed into the protected conduramine F-1 derivative (**182**) in 51% yield. Final deprotection provided conduramine F-1 (**183**) in 95% yield.


Muchowski *et al.*<sup>37</sup> also described the synthesis of ( $\pm$ )-conduramine C-1 ( $\pm$ )-**114**. The sequence began with *syn*-dihydroxylation of cycloadduct (**169**), followed by acetonide protection to afford compound (**184**) in 55–65% overall yield. Reduction with sodium borohydride delivered intermediate (**185**) in 97% yield. Treatment with LiHMDS afforded diene (**186**) in 72–75% yield, which underwent reductive desulfonylation to produce alkene (**187**) in 28–52% yield. Epoxidation of (**187**) furnished epoxide (**188**) in 99% yield. Subsequent epoxide opening followed by oxidation gave the protected conduramine C-1 intermediate (**189**) in 83% yield. Global deprotection ultimately delivered ( $\pm$ )-conduramine C-1 ( $\pm$ )-**114** in 65% yield (Scheme 17).

While the Diels–Alder-based approach provides an effective strategy for constructing conduramine frameworks from heterocyclic precursors, alternative synthetic routes have also been explored to access structurally modified cyclitol derivatives. In particular, photochemical oxygenation reactions have proven valuable for generating oxygen-rich intermediates that can be transformed into higher homologues of conduritols through controlled ring functionalization.

### 2.17. Synthesis of bis-homo-conduritrol-D and -F via photooxygenation of cyclooctatetraene

In 1994, Balci and co-workers reported an efficient and stereo-controlled synthetic route to bis-homo-conduritols starting from cyclooctatetraene (**190**).<sup>38</sup> The sequence began with the transformation of cyclooctatetraene into dibromobicyclo[4.2.0]octa-2,4-diene (**191**), which was subsequently subjected to photooxygenation using tetraphenylporphyrin as a singlet oxygen sensitizer. This reaction afforded the corresponding *endo*-peroxide (**192**) in approximately 80% yield. The singlet-oxygen mediated photooxygenation of cyclooctatetraene provides an efficient entry into highly oxygenated bicyclic intermediates, enabling rapid construction of the functionalized frameworks required for bis-homo-conduritols. However, the requirement for photochemical irradiation and the inherent reactivity of peroxide intermediates may present practical challenges in terms of reaction control and scalability.





Scheme 17 Synthesis of (±)-conduramine A-1 (±)-177, conduramine F-1 (183) and (±)-conduramine C-1 (±)-114 from a single *N*-Boc pyrrole (167).

Reductive cleavage of the *endo*-peroxide functionality in (192) with thiourea in methanol, followed by acetylation with acetic anhydride in pyridine, furnished diacetate (193) in 75% yield. Epoxidation of (193) using *m*-CPBA in chloroform produced epoxide (194), which upon debromination with zinc in DMSO yielded compound (195) in 84% yield. Regioselective epoxide ring opening under acidic conditions in the presence of acetic anhydride, followed by deacetylation, provided bis-homo-conduritol-F (196).

In a complementary sequence, *syn*-dihydroxylation of diacetate (193) with ethanolic KMnO<sub>4</sub> generated diol (197), which was subsequently acetylated to furnish tetraacetate (198) with an overall yield of approximately 68%. Debromination of (198) using zinc in DMSO, followed by methanolysis to remove the acetyl groups, afforded bis-homo-conduritol-D (199) in quantitative yield (Scheme 18).


While the photooxygenation strategy described above provides efficient access to structurally expanded cyclitol frameworks such as bis-homo-conduritols, conduritol

derivatives have also played a crucial role as chiral building blocks in the synthesis of complex biologically active natural products. In particular, the inherent stereochemical richness of conduritol scaffolds has enabled their application in the asymmetric synthesis of pharmacologically important alkaloids, including pancratistatin.

## 2.18. Stereocontrolled construction of (+)-pancratistatin from a conduritol-based chiral building block

One of the major limitations of contemporary cancer chemotherapy is the lack of selectivity, wherein cytotoxic agents frequently damage healthy cells alongside malignant ones. This persistent challenge has motivated the search for natural products exhibiting inherent selectivity toward cancer cells. Among these, pancratistatin, a natural alkaloid isolated from *Pancreaticum littorale* (spider lily), has attracted significant attention due to its remarkable and highly selective anticancer properties.





Scheme 18 Synthesis of bis-homo-conduritols (199) and bis-homo-conduritols (196) utilizing a photooxygenation procedure.

In 1995, Trost *et al.* reported a stereoselective and efficient asymmetric total synthesis of (+)-pancratistatin based on a conduritols-derived chiral building block.<sup>39</sup> Their synthetic sequence began with the protected conduritols A derivative (109), which was treated with two equivalents of *n*-butyllithium in THF at 0 °C. Quenching this dianion with methyl chloroformate afforded the decarbonate intermediate (200) in approximately 87% yield.

Azidation of (200) using trimethylsilyl azide, the chiral ligand (201), and  $\pi$ -allylpalladium chloride furnished azide (202) in 82% yield. The palladium-catalyzed azidation step represents a key stereochemical control element in this synthesis, enabling efficient installation of the nitrogen functionality while preserving the stereochemical integrity of the conduritols-derived framework. Nevertheless, the use of transition-metal catalysts and organometallic reagents may introduce considerations related to cost, reagent handling, and large-scale applicability. Subsequent reaction of azide (202) with Grignard reagent (203) in the presence of CuCN produced the corresponding 1,4-addition product (204). *Syn*-dihydroxylation of (204) with osmium tetroxide then delivered diol (205) in 62% yield. Protection of the resulting diol as its triethylsilyl (TES) ethers gave compound (206) quantitatively, which upon NBS bromination provided bromide (207) in 75% yield.

Compound (207) was further transformed through a sequence involving treatment with trimethylphosphine in THF/water, followed by reaction with phosgene in THF and triethylamine, affording intermediate (208). Exposure of (208) to *tert*-butyllithium induced metal-halogen exchange and intramolecular nucleophilic cyclization, yielding lactone (209) in 60–65% yield.

Removal of the TES protecting groups from (209) using TBAF in THF generated diol (210). Subsequent treatment with thionyl chloride and triethylamine, followed by RuCl<sub>3</sub>-catalyzed oxidation with NaO<sub>4</sub>, furnished cyclic sulfate (211) in 72% yield. Regioselective ring opening of (211) with phenylsulfonyl cesium (PhSO<sub>2</sub>Cs), followed by acidic hydrolysis, afforded alcohol (212) in 85% yield.

Final global deprotection of (212) furnished (+)-pancratistatin (+)-213 in approximately 85% yield, completing an elegant and highly stereocontrolled total synthesis (Scheme 19).


While conduritols derivatives have proven highly effective as chiral building blocks for the asymmetric synthesis of complex natural products such as pancratistatin, they have also been widely employed for the construction of aminocyclitol motifs present in biologically active antibiotics. In particular, conduritols-based intermediates provide convenient access to amino-deoxy-*neo*-inositol frameworks, which constitute essential structural elements in several antibacterial natural products.

### 2.19. Construction of the amino-deoxy-*neo*-inositol framework of hygromycin A


Hygromycin A, an antibiotic produced by several *Streptomyces* species, demonstrates potent activity against both Gram-positive and Gram-negative bacteria. A defining structural feature of this molecule is the presence of a distinctive aminocyclitol moiety, an amino-deoxy-*neo*-inositol derivative. Recent structure-activity relationship studies on Hygromycin A analogues have emphasized the indispensable role of this aminocyclitol core in sustaining antibacterial potency.

In 1995, Arjona *et al.* reported a synthetic route to this key aminocyclitol unit starting from a conduritols B derivative.<sup>40</sup>





Scheme 19 Enantioselective synthesis of (+)-pancratistatin (+)-213 from partially protected conduritol A.



Scheme 20 Synthesis of the aminocyclitol unit (218) of hygromycin A.


Their sequence began with compound (**214**), which underwent sequential ring opening, Luche reduction, and acidic work-up to afford diol (**215**) in approximately 35% yield. Protection of the resulting diol with *tert*-butyldimethylsilyl triflate (TBSOTf) in the presence of triethylamine furnished the corresponding TBS ether (**216**) in 66% yield.

Mesylation of compound (**216**) using methanesulfonyl chloride in pyridine afforded the mesylate in about 90% yield. Subsequent nucleophilic substitution with tetra-butylammonium azide ( $n\text{-Bu}_4\text{NN}_3$ ) produced azide (**217**) in 82% yield with clean inversion of configuration, an essential


transformation for establishing the desired stereochemical framework. The azide displacement step is particularly valuable in this sequence because it enables stereospecific introduction of the nitrogen functionality through an  $\text{S}_{\text{N}}2$ -type mechanism, thereby allowing precise control over the configuration of the aminocyclitol scaffold. However, the use of azide reagents requires careful handling due to their potential toxicity and safety considerations in large-scale operations.

The azide (**217**) was then subjected to *syn*-dihydroxylation using osmium tetroxide and trimethylamine *N*-oxide as the co-oxidant, delivering diol (**218**) in 75% yield with a diastereomeric





Scheme 21 Synthesis of conduramine E (221) and conduramine E tetraacetate (222) via Staudinger reduction of an azide followed by deprotection and acetylation.



Scheme 22 Synthesis of (-)-conduritol F tetraacetate (-)-230 from D-sorbitol (223).


ratio of 86:14 (*neo*:*epi*). The  $\text{OsO}_4/\text{TMAO}$  system provides efficient *syn*-dihydroxylation of the cyclohexene framework, enabling stereoselective installation of vicinal diol functionality required for the aminocyclitol architecture; nevertheless, the toxicity and cost of osmium reagents remain important considerations for large-scale applications. This diol (218) represents a versatile intermediate for assembling aminocyclitol architectures, thereby enabling the synthesis of hygromycin A analogues with potential antibacterial applications (Scheme 20).

In 1995, Trost *et al.* described a concise and highly efficient synthetic route to conduramine E.<sup>41</sup> The sequence began with azide (219), which underwent a Staudinger reduction upon treatment with trimethylphosphine, affording amine (220) in an excellent 94% yield. Subsequent acidic hydrolysis of the

acetone protecting group in (220) furnished conduramine E (221) in approximately 88% yield. Final acetylation of conduramine E (221) with acetic anhydride in the presence of pyridine provided conduramine E tetraacetate (222) in about 70% yield (Scheme 21).

While the preceding strategies highlight the use of conduritol derivatives as versatile intermediates for constructing aminocyclitol frameworks, alternative approaches have focused on the direct stereoselective synthesis of conduritol derivatives from readily available polyols. In this context, chiral pool precursors such as sorbitol have proven particularly valuable, providing an efficient and scalable platform for accessing stereochemically defined conduritol derivatives.





Scheme 23 Stepwise synthesis of pseudosugars via a conduritol E intermediate derived from iodocyclohexadienediol.

## 2.20. Enantioselective synthesis of (–)-conduritol F tetraacetate from D-sorbitol

In 1995, Chiara *et al.* reported an enantioselective synthesis of (–)-conduritol F tetraacetate (–)-230 starting from D-sorbitol (223).<sup>42</sup> The sequence began with protection of D-sorbitol using acetone in the presence of sulfuric acid, followed by treatment with 70% aqueous acetic acid and subsequent benzoylation with benzoyl chloride in pyridine/dichloromethane, affording the protected intermediate (224). This compound then underwent disilylation with TBDPSCl and imidazole, and selective deprotection of the benzoate ether using DIBAL-H in toluene furnished alcohol (225).

Oxidation of (225) under Swern conditions, followed by Pinacol coupling mediated by samarium(II) iodide, generated a diastereomeric mixture of *myo*-inositol (226) and *L-chiro*-inositol (227), strongly favoring the latter in a 6 : 94 ratio. The SmI<sub>2</sub>-mediated Pinacol coupling represents a powerful reductive carbon–carbon bond-forming transformation that enables rapid construction of the cyclitol framework from acyclic precursors. However, the requirement for low-valent samarium reagents and strictly controlled reaction conditions may limit the practicality of this approach for large-scale applications. The major isomer, *L-chiro*-inositol (227), was isolated and converted to thiocarbonate (228) via reaction with *N,N'*-thiocarbonyl diimidazole in toluene. Formation of the thiocarbonate intermediate is crucial for enabling subsequent elimination reactions that generate the cyclohexene framework characteristic of conduritol derivatives. Thermal treatment of (228) with trimethyl phosphite yielded the (–)-conduritol F derivative (229).

Final deprotection was accomplished through a sequential protocol involving pyridinium *p*-toluenesulfonate in dichloromethane/methanol, followed by desilylation with TBAF in THF, and concluding with acetylation using acetic anhydride in pyridine. This sequence furnished (–)-conduritol F tetraacetate (–)-230 (Scheme 22).

While the chiral pool strategy described above enables efficient access to conduritol derivatives from readily available polyols, alternative synthetic approaches have employed functionalized cyclohexadienediols as versatile intermediates for constructing structurally diverse cyclitol and pseudo-sugar frameworks. In particular, halogenated cyclohexadienediol

derivatives have proven valuable for introducing additional functional groups through metal–halogen exchange and related transformations.

## 2.21. Construction of pseudo-β-D-altropyranose derivatives from iodocyclohexadienediol

In 1995, Hudlicky and co-workers reported an efficient synthetic route to pseudo-sugars featuring a conduritol E intermediate as the key scaffold.<sup>43</sup> The sequence began with the acetonide protection of the hydroxyl groups in iodocyclohexadienediol (231), affording compound (232). Subsequent dihydroxylation with osmium tetroxide and *N*-methylmorpholine *N*-oxide (NMO) provided the partially protected iodoconduritol E derivative (233). The OsO<sub>4</sub>/NMO-mediated dihydroxylation step plays a central role in establishing the vicinal diol motif required for the conduritol E scaffold, providing high stereochemical control. However, as noted for several related transformations discussed earlier, the toxicity and cost of osmium reagents represent important considerations when evaluating the practicality and environmental sustainability of this methodology. The remaining free hydroxyl groups in (233) were then masked using 2,2-dimethoxypropane (DMP) under acid catalysis to furnish the corresponding diacetone (234) in an overall yield of approximately 75% from starting material (231).

A metal–halogen exchange followed by carboxylation with CO<sub>2</sub> and methylation with methyl iodide delivered ester (235) in ~90% yield. This metal–halogen exchange strategy provides a convenient means of introducing carboxyl functionality at the iodinated position, thereby enabling further functionalization of the cyclitol framework toward pseudo-sugar architectures. Stereoselective hydrogenation over palladium generated ester (236) in 92% yield. Subsequent reduction of ester (236) with DIBAL-H in toluene afforded alcohol (237) in 74% yield. Finally, deprotection of the acetone groups in (237) using amberlyst-15 resin in wet methanol, followed by acetylation with acetic anhydride in pyridine, furnished the target pentaacetate (238), a pseudo-β-D-altropyranose derivative in 89% overall yield (Scheme 23).

While the above strategy illustrates how conduritol intermediates can be elaborated into structurally diverse pseudo-sugar frameworks, alternative methodologies have focused on



exploiting enzymatic transformations to achieve stereoselective functionalization of conduritol derivatives. In particular, lipase-mediated kinetic resolution has emerged as an effective approach for accessing enantiomerically enriched conduritols and conduramines under mild conditions.


## 2.22. Synthesis of (+)-conduritol C and (+)-conduramine C-4 via enzymatic resolution

In 1996, Nicolosi *et al.* described a stereoselective approach for converting conduritol D tetraacetate (**239**) into (+)-conduritol C and (+)-conduramine C-4.<sup>44</sup> The synthetic sequence commenced with the enzymatic resolution of compound (**239**) using various lipases in the presence of *n*-butanol, leading to the formation of alcohol (**241**). Among the enzymes screened, porcine pancreatic lipase (PPL) demonstrated the highest stereoselectivity, furnishing exclusively alcohol (+)-**241**, whereas the other lipases afforded mixtures of diol (+)-**240** and alcohol (+)-**241**. The lipase-mediated kinetic resolution represents a particularly attractive strategy for generating enantiomerically enriched conduritol derivatives, as it proceeds under mild conditions and avoids the need for stoichiometric chiral auxiliaries or metal catalysts.


Nevertheless, such enzymatic processes may be sensitive to substrate structure and reaction parameters, which can influence their broader synthetic applicability.

The enantiomerically enriched alcohol (+)-**241** was subsequently subjected to a Mitsunobu esterification with benzoic acid to yield (–)-benzoate (–)-**242**. The Mitsunobu reaction enables stereospecific inversion of configuration during nucleophilic substitution, providing an efficient means of introducing functional groups while maintaining control over the stereochemical outcome. Methanolysis of (–)-**242** then provided (+)-conduritol C (+)-**243**. In a parallel transformation, (+)-conduramine C-4 (+)-**244** was synthesized from alcohol (+)-**241** via a Mitsunobu reaction employing diethyl azodicarboxylate (DEAD), triphenylphosphine, and phthalimide, followed by nucleophilic cleavage with methylamine (Scheme 24).

While enzymatic resolution provides an effective strategy for obtaining enantiomerically enriched conduritol and conduramine derivatives, complementary synthetic approaches have also focused on constructing aminocyclitol frameworks through direct functionalization of unsaturated precursors. In



Scheme 24 Synthesis of (+)-conduritol C (+)-**243** and (+)-conduramine C-4 (+)-**244** using enzyme-catalysed selective ester hydrolysis.



Scheme 25 Synthesis of a partially protected conduramine E derivative via aminohydroxylation, epoxidation, and base-induced cyclization.



particular, aminohydroxylation reactions of dienyl systems have emerged as valuable transformations for introducing nitrogen and oxygen functionalities simultaneously, thereby enabling rapid assembly of conduramine scaffolds.

### 2.23. Synthesis of a partially protected conduramine E derivative

In 1997, Angelaud *et al.* developed a concise synthetic route to a partially protected conduramine E derivative starting from dienylsilane (**245**).<sup>45</sup> The sequence began with an aminohydroxylation reaction, which afforded compound (**246**) in approximately 75% yield. The aminohydroxylation transformation is particularly valuable in this context because it enables simultaneous introduction of both nitrogen and oxygen functionalities across the unsaturated framework, thereby rapidly generating the key aminocyclitol architecture. However, the success of such reactions often depends strongly on substrate geometry and reagent compatibility, which can influence regio- and stereochemical outcomes. Oxidative cleavage of the C–Si bond using hydrogen peroxide, followed by acetone protection of the resulting hydroxy-carbamate, furnished allylic alcohol (**247**) in about 70% yield. Subsequent epoxidation of (**247**) with *m*-CPBA generated epoxide (**248**) in 84% yield. Finally, treatment of epoxide (**248**) with 3.5 equivalents of lithium diisopropylamide (LDA) afforded the partially protected conduramine E derivative (**249**) in approximately 89% yield (Scheme 25).

The use of the strong, non-nucleophilic base LDA facilitates regioselective ring opening of the epoxide intermediate, enabling controlled formation of the aminocyclitol framework while preserving the established stereochemical relationships.


While the above strategy highlights the use of aminohydroxylation and epoxide ring-opening reactions for constructing conduramine frameworks, complementary approaches have explored chemoenzymatic transformations to achieve selective functionalization of conduritol derivatives. In

particular, lipase-catalysed acylation reactions have proven highly effective for introducing protecting groups in a stereo-selective manner, thereby enabling access to enantiomerically enriched conduritol intermediates.


### 2.24. Chemoenzymatic preparation of partial esters of conduritol E via lipase-catalysed selective acylation

In 1997, Sanfilippo and co-workers reported a chemoenzymatic strategy for the preparation of partial esters of conduritol E.<sup>46</sup> The synthesis began with the dihydroxylation of *syn*-cyclohexadienediacetate (**19**) using osmium tetroxide, furnishing conduritol E diacetate ( $\pm$ )-**250** in nearly quantitative yield. Subsequent enzymatic acylation of ( $\pm$ )-**250** with lipozyme IM (lipase from *Mucor miehei*) and vinyl acetate in *tert*-butyl methyl ether (*t*-BME) afforded a diastereomeric mixture consisting of unreacted (+)-conduritol E diacetate (+)-**250** and (–)-conduritol E triacetate (–)-**251**. Lipase-catalysed acylation represents a powerful tool for achieving selective esterification of polyhydroxylated substrates, offering high regio- and stereo-selectivity under mild reaction conditions. However, the efficiency of such enzymatic transformations can depend strongly on solvent choice, enzyme activity, and substrate structure. The two components were separated by column chromatography. These partially esterified derivatives serve as useful intermediates for the enantioselective synthesis of both enantiomers of conduritol E and related analogues, including conduramines (Scheme 26).

While chemoenzymatic strategies such as lipase-mediated acylation provide efficient routes to selectively functionalized conduritol derivatives, purely chemical transformations have also been exploited to construct the cyclohexene framework characteristic of conduritols. Among these, rearrangement reactions capable of converting sulfone precursors into olefinic cyclitol derivatives have emerged as particularly valuable tools for generating conduritol scaffolds with high efficiency.



Scheme 26 Synthesis of partial esters of conduritol E utilizing enzyme-catalysed selective ester hydrolysis.



Scheme 27 Synthesis of 1,4-dimethoxy conduritol E (**255**) employing a Ramberg–Bäcklund reaction.



### 2.25. Synthesis of 1,4-dimethoxy conduritol E via Ramberg–Bäcklund rearrangement of a D-mannitol-derived sulfone


In 1997, Cerè *et al.* developed an efficient route to 1,4-dimethoxy conduritol E starting from D-mannitol.<sup>47</sup> The sequence began with the oxidation of the D-mannitol-derived intermediate (1*S*,2*S*,6*S*,7*S*)-(–)-2,6-dimethoxy-9,9-dimethyl-8,10-dioxo-4-thiabicyclo[5.3.0]decane (252), which furnished the corresponding sulfone (253) in 98% yield. Treatment of sulfone (253) with KOH in *tert*-butanol and tetrachloromethane induced a Ramberg–Bäcklund rearrangement, providing the conduritol E derivative (254) in 94% yield. The Ramberg–Bäcklund rearrangement represents a powerful method for converting sulfone precursors into olefinic systems, enabling efficient construction of the cyclohexene framework characteristic of conduritol derivatives. Nevertheless, the reaction typically requires strong base and halogenating conditions, which may impose limitations when sensitive functional groups are present. Hydrolysis of the acetonide protecting group in (254) subsequently afforded 1,4-dimethoxy conduritol E (255), also in 94% yield. Importantly, this intermediate can be converted to (–)-conduritol E in excellent yield without the need for further purification, underscoring the efficiency of the overall sequence (Scheme 27).

While rearrangement reactions such as the Ramberg–Bäcklund transformation provide efficient access to olefinic conduritol frameworks, alternative strategies have focused on the construction of structurally modified conduritols through nucleophilic transformations of epoxide intermediates. In particular, epoxide ring-opening reactions offer a versatile approach for introducing nitrogen-containing bridges and generating conformationally constrained aminocyclitol architectures.


### 2.26. Synthesis of an amino-bridged conduritol via nucleophilic epoxide opening and acetonide deprotection

In 1997, Lallemand *et al.* reported a synthetic strategy for the construction of an amino-bridged conduritol.<sup>48</sup> The sequence began with the bicyclic conduramine derivative (256), which was heated in a sealed tube with *tert*-butanol and epoxide (257), yielding the bridged amine (258) in approximately 50%. The nucleophilic opening of the epoxide ring plays a crucial role in this transformation by enabling formation of the nitrogen-bridged cyclitol framework while simultaneously establishing the required connectivity between the two ring systems. However, such intramolecular or intermolecular epoxide-opening reactions can sometimes suffer from moderate yields and competing side reactions, depending on the reaction conditions and nucleophile employed. Subsequent hydrolysis of the acetonide protecting group in (258) using TFA in aqueous THF afforded the desired amino-bridged conduritol (259) in about 90% yield (Scheme 28). Acid-mediated deprotection of the acetonide group provides a straightforward route to liberate the polyhydroxylated cyclitol framework while maintaining the stereochemical integrity of the bridged system.

While epoxide-opening reactions provide an effective route for constructing bridged aminocyclitol architectures, alternative strategies have explored the use of rearrangement reactions to generate functionalized conduritol derivatives bearing multiple nitrogen substituents. In particular, the Ramberg–Bäcklund rearrangement has proven valuable for converting sulfone precursors into cyclohexene frameworks that can subsequently be transformed into diamino-conduritol derivatives.




Scheme 28 Synthesis of amino-bridged conduritol (259) via nucleophilic epoxide opening followed by acetonide deprotection.



Scheme 29 Synthesis of diamino conduritol B derivative (264) via a Ramberg–Bäcklund rearrangement and subsequent reduction.





Scheme 30 Synthesis of L-ascorbic acid (272) synthesis of L-ascorbic acid from a conduritol F derivative.

### 2.27. Synthesis of a diamino conduritol B derivative via Ramberg–Bäcklund rearrangement

In 1998, Cerè *et al.* described an efficient synthetic route to a diamino conduritol B derivative.<sup>49</sup> The sequence began with the nucleophilic substitution of (–)-(3*S*,4*R*,5*R*,6*S*)-4,5-dimesyl-3,6-dimethoxythiepane (260) with sodium azide in DMSO, affording diazide (261) in approximately 94% yield. Oxidation of (261) with *m*-CPBA in dichloromethane then provided the corresponding sulfone (262) in 98% yield. The sulfone underwent a Ramberg–Bäcklund transformation to give the cyclohexene derivative (263) with ~78% efficiency. In this transformation, the Ramberg–Bäcklund rearrangement enables efficient conversion of the sulfone intermediate into the unsaturated cyclohexene framework characteristic of conduritol derivatives. However, the reaction typically requires strong base and halogenating conditions, which may restrict its compatibility with sensitive functional groups. Finally, simultaneous reduction of both the double bond and the azide groups in (263) was accomplished by refluxing with LiAlH<sub>4</sub>, delivering the target diamino conduritol B derivative (264) in 91% yield (Scheme 29).

While rearrangement-based strategies such as the Ramberg–Bäcklund transformation provide efficient access to nitrogen-functionalized conduritol derivatives, conduritol frameworks have also served as versatile intermediates in the synthesis of biologically important natural products. In particular, the well-defined stereochemical arrangement of hydroxyl groups within conduritol derivatives has enabled their application in the synthesis of structurally related polyhydroxylated molecules such as L-ascorbic acid.

### 2.28. Conduritol F-based synthetic route to L-ascorbic acid

In 1998, Banwell and co-workers reported a synthetic strategy for the preparation of L-ascorbic acid (272) that employed

a conduritol F derivative as a key intermediate.<sup>50</sup> The sequence began with the protection of the hydroxyl groups of diol (98) using 2,2-dimethoxypropane, affording compound (77). Epoxidation of (77) with *m*-CPBA furnished epoxide (78), which was subsequently opened by benzyl alcohol in the presence of trifluoromethanesulfonic acid to provide the protected conduritol F derivative (265) in approximately 50% yield.

Ozonolysis of compound (265) in methanol, followed by *in situ* reduction with sodium cyanoborohydride under acidic conditions, afforded compound (266) in 74% yield. Palladium-catalyzed hydrogenolysis of (266) in the presence of cyclohexa-1,4-diene (267) generated alcohol (268) in 53% yield. Reaction of (268) with benzaldehyde under acidic conditions then furnished acetal (269) in 47% yield.

Transformation of the primary hydroxyl group of (269) into its TBDMS ether gave compound (270) in 74% yield. Oxidation of (270) with Dess–Martin periodinane in dichloromethane afforded compound (271), which upon hydrolysis in acetic acid delivered the target molecule, L-ascorbic acid (272), in 66% yield (Scheme 30).

### 2.29. Synthesis of conduramine D-1 and its tetraacetate

In 1998, Leung-Toung *et al.* reported a multistep synthetic strategy for the preparation of conduramine D-1 starting from *N*-tert-butoxycarbonylpyrrole.<sup>51</sup> A Diels–Alder reaction between *N*-Boc-pyrrole (167) and tosyl acetylene (168) furnished cycloadduct (169) in 84% yield. The Diels–Alder cycloaddition between the *N*-protected pyrrole and tosyl acetylene provides an efficient entry into a densely functionalized bicyclic framework that can be strategically manipulated toward conduramine architectures. Such cycloaddition-based approaches enable rapid construction of molecular complexity; however, subsequent functional group interconversions are often required to convert the bicyclic intermediate into the desired cyclitol



skeleton. *Syn*-dihydroxylation of (**169**) with osmium tetroxide followed by treatment with PhB(OH)<sub>2</sub> in *tert*-butanol produced borate (**273**) in 92% yield, which upon oxidation with hydrogen peroxide gave diol (**274**) in 88% yield. Alternatively, (**274**) could be obtained directly from (**169**) in 73% yield *via syn*-dihydroxylation with OsO<sub>4</sub>/NMO in *tert*-butanol.


The osmium tetroxide-mediated *syn*-dihydroxylation is crucial for establishing the vicinal diol functionality with high stereochemical control, which subsequently enables efficient protection and downstream transformations leading to the conduramine framework. Nevertheless, the toxicity and cost associated with osmium reagents remain important considerations when evaluating the scalability of such methodologies.

Protection of the vicinal diol (**274**) as its acetonide using 2,2-dimethoxypropane and *p*-toluenesulfonic acid afforded compound (**275**) in 85% yield. Reduction of (**275**) with sodium borohydride generated a mixture of *endo*- and *exo*-isomers of (**276**), which underwent bicyclic fragmentation upon treatment


with Li(NTMS)<sub>2</sub> to furnish (**277**) in 79% yield. Deprotection of the acetonide group in (**277**) yielded diol (**278**) in 89% yield, and subsequent reductive desulfonation of (**278**) afforded diol (**279**).

Stereoselective epoxidation of (**279**) with *m*-CPBA provided epoxide (**280**) in 79% yield. Regioselective ring opening of (**280**) with (PhSe)<sub>2</sub> in the presence of *n*-BuLi, followed by acetylation with acetic anhydride, afforded triacetate (**281**) in 70% yield. Oxidative elimination of (**281**) then furnished the protected conduramine D-1 derivative (**282**) in 90% yield. Global deprotection of (**282**) by refluxing in 5 N HCl produced conduramine D-1 (**283**), which upon acetylation gave conduramine D-1 tetraacetate (**284**) in 95% combined yield over the final two steps (Scheme 31).

Beyond the synthesis of conduramines, cyclohexadienediol-derived conduritol frameworks have also proven valuable intermediates for the preparation of structurally diverse natural products. In this context, Donohoe and co-workers reported



Scheme 31 Synthesis of conduramine D-1 (**283**) and conduramine D-1 tetraacetate (**284**) *via* a Diels–Alder–based strategy.



Scheme 32 Synthesis of (+)-pericosine B (+)-**291** from bromocyclohexadienediol.



a stereoselective route to the bioactive cyclitol natural product (+)-pericosine B using a bromocyclohexadienediol precursor.<sup>52</sup>

### 2.30. Synthesis of (+)-pericosine B from bromocyclohexadienediol

In 1998, Donohoe *et al.* reported a stereoselective synthesis of (+)-pericosine B (+)-**291**, beginning from bromocyclohexadienediol (**74**).<sup>52</sup> Protection of one hydroxyl group with TIPSOTf in the presence of triethylamine afforded compound (**285**) in 95% yield. The remaining free hydroxyl group was methylated using sodium hydride and methyl iodide, and subsequent removal of the TIPS group with TBAF furnished alcohol (**286**) in 61% yield.

Dihydroxylation of the diene (**286**) with osmium tetroxide yielded a mixture of *anti*-diol (**287**) and *syn*-diol (**288**), corresponding to conduritol E and D derivatives, respectively. The ratio of products was strongly influenced by the reaction medium and co-catalysts; notably, use of osmium tetroxide in dichloromethane with quinuclidine favored the *syn*-diol, giving an *anti*:*syn* ratio of 1:2.2 and a combined yield of approximately 71%.

The diastereoselectivity of osmium-mediated dihydroxylation is known to be sensitive to solvent effects and coordinating additives. In this case, the presence of quinuclidine likely modulates the approach of the osmium species to the diene framework, thereby influencing the facial selectivity of the oxidation and favoring formation of the *syn*-diol derivative.

Protection of the hydroxyl groups of the conduritol D derivative (**288**) as triethylsilyl ethers afforded compound (**289**) in 95% yield. Subsequent metal-halogen exchange using *t*-BuLi followed by trapping with methyl chloroformate produced ester (**290**) in ~95% yield. The metal-halogen exchange step provides an efficient method for introducing a carbonyl functionality at the halogen-bearing position of the cyclohexene framework, enabling rapid functionalization of the conduritol-derived intermediate and facilitating conversion into the ester precursor required for completion of the natural product synthesis. Final desilylation with trifluoroacetic acid in dichloromethane furnished the target natural product, (+)-pericosine B (+)-**291**, in 90% yield (Scheme 32).

In addition to natural product synthesis, the development of new catalytic strategies has significantly expanded the synthetic toolbox for constructing conduritol frameworks. In this context, Chang and co-workers reported an elegant approach to 3,6-di-*O*-methyl conduritol E employing a ruthenium-catalysed ring-closing metathesis reaction.<sup>53</sup>

### 2.31. Synthesis of 3,6-di-*O*-methyl conduritol E via Ru-catalysed RCM


In 1999, Chang *et al.* reported an efficient synthetic route to 3,6-di-*O*-methyl conduritol E (**255**).<sup>53</sup> The synthesis began with the partial reduction of (2*R*,3*R*)-2,3-*O*-isopropylidene tartrate (**292**), followed by nucleophilic addition of vinylmagnesium bromide, furnishing bis-allyl alcohol (**293**) in approximately 54% yield. Subsequent methylation of the resulting diol with sodium hydride and methyl iodide afforded the dimethoxy ether (**294**) in ~94% yield.

Cleavage of the acetonide protecting group with 10% HCl in methanol produced diol (**295**) in nearly quantitative yield (~99%). Acetylation of (**295**) with acetic anhydride in the presence of triethylamine provided diacetate (**296**) in 92% yield. The key step involved a ring-closing metathesis (RCM) of (**296**) catalyzed by Grubbs' first-generation Ru-benzylidene complex [Cl<sub>2</sub>(PCy<sub>3</sub>)<sub>2</sub>Ru=CHPh], giving the conduritol E derivative (**297**) in ~73% yield. Final deacetylation of (**297**) furnished the target 3,6-di-*O*-methyl conduritol E (**255**) in ~99% yield (Scheme 33).

Beyond the development of new catalytic approaches for conduritol synthesis, cyclohexadienediol-derived intermediates have also played an important role in the preparation of complex bioactive natural products. A notable example is the chemoenzymatic synthesis of the anticancer alkaloid narciclasine reported by Gonzalez and co-workers.<sup>11</sup>

### 2.32. Chemoenzymatic route to narciclasine involving microbial *cis*-dihydroxylation, Suzuki coupling, and intramolecular lactamization

Narciclasine, a biologically active alkaloid renowned for its potent anticancer and anti-inflammatory properties, was synthesized by Gonzalez *et al.* in 1999 *via* a chemoenzymatic route beginning with the biotransformation of *m*-di-bromobenzene (**298**) using *E. coli* JM109 (pDTG601G).<sup>11</sup> This



Scheme 33 Synthesis of 3,6-di-*O*-methyl conduritol E (**255**) *via* Ru-catalysed RCM.



process afforded *syn*-diol (**299**), which was converted into oxime (**300**) in approximately 70% yield through sequential acetonide protection of the hydroxyl groups followed by reaction with methyl carbamate (NHCO<sub>2</sub>Me) in the presence of sodium periodate (NaIO<sub>4</sub>).


A Suzuki cross-coupling between oxime (**300**) and borate (**301**), catalyzed by Pd(PPh<sub>3</sub>)<sub>4</sub>, yielded compound (**302**) in ~30% yield. Radical-mediated deoxygenation of (**302**) using TTMSS (*tris*(trimethylsilyl)silane) and AIBN furnished the key  $\alpha,\beta$ -unsaturated ketone (**303**) in approximately 80% yield. Alternatively, a one-pot sequence involving Suzuki coupling of (**300**) with (**301**) followed by Mo(CO)<sub>6</sub>-mediated reduction in refluxing acetonitrile provided enone (**303**) in ~45% yield.

Lucho reduction of enone (**303**) gave allylic alcohol (**304**) in ~80% yield, which underwent a Mitsunobu reaction with tributylphosphine, DEAD, and benzoic acid to furnish benzoate


(**305**) in ~65% yield. Acetonide deprotection of (**305**) using Dowex 50X8 resin in methanol, followed by acetylation of the resulting hydroxyl groups with acetic anhydride in pyridine, afforded diacetate (**306**) in ~70% yield.

Subsequent treatment of (**306**) with trifluoromethanesulfonic anhydride and DMAP induced lactam formation, yielding compound (**307**) in ~40% yield. Finally, global deprotection of the ester and methyl ester functionalities provided narciclasine (**16**) in ~20% overall yield from the lactam stage (Scheme 34).

In addition to enabling the synthesis of complex natural products, microbial *cis*-dihydroxylation of aromatic substrates has also been widely applied in the preparation of cyclitol frameworks. An illustrative example is the chemoenzymatic synthesis of *neo*-inositol reported by Hudlicky and co-workers.<sup>54</sup>



Scheme 34 Synthesis of narciclasine (**16**) utilizing enzyme-catalysed regio- and stereoselective dihydroxylation.



Scheme 35 Synthesis of *neo*-inositol (**138**) utilizing enzyme-catalysed regio- and stereoselective dihydroxylation.



### 2.33. Chemoenzymatic preparation of *neo*-inositol

In 1999, Hudlicky *et al.* described a chemoenzymatic route to *neo*-inositol (**138**) beginning from bromobenzene (**308**).<sup>54</sup> The synthesis commenced with a regio- and stereoselective enzymatic *cis*-dihydroxylation of bromobenzene using *E. coli* JM109 (pDTG601), furnishing the bromo-cyclohexadiene-*cis*-diol (**74**). Protection of the resulting diol as its acetonide was achieved using 2,2-dimethoxypropane and *p*-toluenesulfonic acid in acetone. The protected intermediate was then brominated with 1,3-dibromo-5,5-dimethylhydantoin (DBH) in aqueous acetone to yield bromohydrin (**309**).

Treatment of bromohydrin (**309**) with aqueous KOH induced intramolecular cyclization to generate an unisolated epoxide (**310**), which rearranged upon reflux to yield the *trans*-diol (**311**). Radical debromination of (**311**) with tributyltin hydride (Bu<sub>3</sub>SnH) and AIBN in benzene afforded the corresponding conduritol C derivative (**312**).

Dihydroxylation of the alkene moiety in (**312**) with osmium tetroxide and NMO in a *tert*-butanol–acetone–water mixture produced the tetrol (**313**). Final acidic removal of the acetonide protecting group using methanolic HCl furnished *neo*-inositol (**138**) in approximately 77% yield from tetrol (**313**) (Scheme 35).

In addition to chemoenzymatic strategies, synthetic approaches based on classical functional group transformations and modern catalytic reactions have also been developed for constructing conduritol frameworks. In this context, Gallos and co-workers reported an efficient route to tetrabenzylated conduritol derivatives employing a ring-closing metathesis strategy.<sup>55</sup>

### 2.34. Synthesis of tetrabenzylated conduritols A, E, and F

In 1999, Gallos *et al.* reported an efficient synthetic strategy for the preparation of tetrabenzylated derivatives of conduritols A, E, and F, starting from the readily available alditols galactitol (**314**), *D*-mannitol (**319**), and *D*-glucitol (**323**), respectively.<sup>55</sup> The


synthetic sequence began with selective protection and benzylation steps: each alditol was sequentially treated with triphenylmethyl chloride, 4-dimethylaminopyridine (DMAP), and triethylamine in DMF, followed by benzylation with sodium hydride and benzyl chloride in DMF, and final acidic detriptylation with sulfuric acid in a methanol–dichloromethane mixture. These transformations furnished the partially protected alcohol intermediates (**315**), (**320**), and (**324**) in 34%, 50%, and 39% yields, respectively.

Swern oxidation of the primary alcohols afforded the corresponding dialdehydes, which underwent Wittig olefination with methyltriphenylphosphonium bromide in the presence of 12-crown-4 to give the dienes (**316**), (**321**), and (**325**) in 50%, 52%, and 53% yields, respectively. The final ring-closing metathesis (RCM) of these dienes, catalyzed by Grubbs' first-generation catalyst (**317**) in refluxing dichloromethane, produced the tetrabenzylated conduritol derivatives: conduritol A (**318**) in 99% yield, conduritol E (**322**) in 58% yield, and conduritol F (**326**) in 77% yield (Scheme 36).

In addition to alditol-based approaches, carbohydrate-derived intermediates have also been widely employed for the stereoselective construction of conduramine frameworks. An illustrative example is the synthesis of a protected conduramine E derivative reported by Ovaa and co-workers.<sup>56</sup>


### 2.35. Carbohydrate-mediated synthesis of protected conduramine E

In 1999, Ovaa *et al.* reported a concise synthetic route to a protected conduramine E derivative starting from the readily available *p*-methoxyphenyl-β-*D*-galactopyranoside (**327**).<sup>56</sup> The synthesis began with protection of the primary hydroxyl group as its *tert*-butyldiphenylsilyl (TBDPS) ether using TBDPSCl and pyridine. The *syn*-diol unit was then converted into an acetonide using dimethoxypropane under acidic conditions, followed by benzylation of the remaining free hydroxyl group with benzyl



Scheme 36 Synthesis of tetra-*O*-benzyl derivatives of conduritol A (**318**), conduritol E (**322**) and conduritol F (**326**).





Scheme 37 Synthesis of protected conduramine E from a sugar derivative.

bromide and sodium hydride. Subsequent desilylation with TBAF furnished alcohol (**328**) in 88% yield.

Alcohol (**328**) was transformed into iodide (**329**) in 95% yield, and chemoselective reduction of (**329**) with zinc in methanol afforded the open-chain aldehyde (**330**) in ~99% yield. Wittig olefination of the aldehyde with methyl triphenylphosphoranylidene in acetonitrile provided the *E*-alkene (**331**) in 95% yield, which was reduced with lithium aluminium hydride in THF to furnish the allylic alcohol (**332**) in 72% yield.

Treatment of (**332**) with trichloroacetonitrile and DBU produced intermediate (**333**) in 95% yield. An Overman rearrangement of (**333**), catalyzed by  $\text{PdCl}_2(\text{MeCN})_2$  in toluene, delivered amide (**334**) in 73% yield. Hydrolysis of the amide followed by Boc-protection of the liberated amine using  $(\text{Boc})_2\text{O}$  and triethylamine afforded compound (**335**) in 75% yield. Finally, ring-closing metathesis (RCM) mediated by Grubbs' catalyst generated the target protected conduramine E (**336**) in 65% yield (Scheme 37).

In addition to conduramine derivatives, conduritol frameworks have also served as valuable intermediates in the synthesis of biologically active cyclitol natural products. A notable example is the stereocontrolled synthesis of (+)-cyclophellitol reported by Trost and co-workers.<sup>57</sup>

### 2.36. Stereocontrolled construction of (+)-cyclophellitol from conduritol B tetraacetate

In 1999, Trost *et al.* reported an elegant asymmetric synthesis of (+)-cyclophellitol, a potent  $\beta$ -glucosidase and HIV inhibitor, starting from racemic conduritol B tetraacetate ( $\pm$ )-**6**.<sup>57</sup> The strategy commenced with a kinetic resolution mediated by  $[\eta^3\text{-C}_3\text{H}_5\text{PdCl}]_2$  in combination with the chiral ligand (**337**), which, at 50% conversion, afforded a mixture consisting of unreacted (+)-conduritol B tetraacetate (+)-**6** in near-quantitative yield, the desired monopivalate (–)-**338** in ~88% yield, and only ~1% of dipivalate (**339**).

The monopivalate (–)-**338** was subjected to ammonium hydroxide in methanol, effecting global deacetylation and furnishing triol (**340**) in ~95% yield. Benzoylation of (**340**) with benzyl bromide in the presence of tetrabutylammonium iodide (TBAI) delivered the tribenzyl ether (**341**) in ~79% yield. Reduction of the pivalate ester in (**341**) using DIBAL-H in dichloromethane afforded alcohol (**342**) in ~90% yield.


Alkylation of (**342**) with  $(\text{C}_4\text{H}_9)_3\text{SnCH}_2\text{I}$  and potassium iodide provided compound (**343**) in ~90% yield. A tin–lithium exchange followed by a 2,3-sigmatropic rearrangement established the requisite regio- and stereochemistry, giving compound (**344**) in ~72% yield. Subsequent epoxidation of (**344**) with *m*-CPBA in dichloromethane produced epoxide (**345**) in ~90% yield. A final palladium-catalyzed hydrogenolysis furnished (+)-cyclophellitol (+)-**346** in an excellent ~91% yield (Scheme 38).

In addition to serving as intermediates in the synthesis of biologically active cyclitols, conduritol frameworks have also been accessed through divergent strategies starting from carbohydrate precursors. An illustrative example is the diastereodivergent conversion of *D*-xylopyranose into conduritol and inositol derivatives reported by Kornienko and co-workers.<sup>58</sup>


### 2.37. Diastereodivergent conversion of *D*-xylopyranose into conduritol and inositol derivatives

In 1999, Kornienko *et al.* described a versatile approach for synthesizing partially protected derivatives of conduritols, *l*-*chiro*-inositol, and *myo*-inositol *via* protected conduritol intermediates.<sup>58</sup> The sequence began with 2,3,4-tri-*O*-benzyl-*D*-xylopyranose (**347**), which was oxidatively transformed into aldehyde (**348**). Nucleophilic addition of vinylmagnesium bromide to aldehyde (**348**) afforded a mixture of diastereomeric dienes (**349**) and (**350**), with the ratio of these diastereomers tunable through modifications of the reaction conditions, as illustrated in Scheme 39.





Scheme 38 Synthesis of (+)-cyclophellitol (+)-346 from conduritol B tetraacetate (±)-6.


Scheme 39 Synthesis of partially protected *L-chiro* and *myo*-inositols from a single sugar derivative.

Both dienes (**349**) and (**350**) underwent efficient ring-closing olefin metathesis (RCM) in the presence of Grubbs' catalyst, yielding the partially protected conduritol derivatives conduritol F (**351**) in ~99% yield and conduritol B (**353**) in ~95% yield, respectively. Subsequent benzylation of these intermediates using benzyl bromide, sodium hydride, and DMF, followed by dihydroxylation with OsO<sub>4</sub> and NMO in an acetone–water mixture, furnished the corresponding partially protected

inositol derivatives: *L-chiro*-inositol (**352**) from compound (**351**) and *myo*-inositol (**354**) from compound (**353**) (Scheme 39).

In addition to carbohydrate-derived strategies, alternative synthetic approaches employing bicyclic precursors have also been developed for constructing conduritol and inositol frameworks. An illustrative example is the synthesis of *allo*-inositol and related derivatives reported by Mehta and co-workers.<sup>59</sup>





Scheme 40 Divergent synthesis of *allo*-inositol (**134**) and MK 7607 (**367**) from norbornyl-derived precursors via a conduritol E intermediate.

### 2.38. Synthesis of *allo*-inositol and MK 7607 from norbornyl-derived precursors

In 2000, Mehta *et al.* reported a synthetic route to *allo*-inositol (**134**) via a protected conduritol E intermediate.<sup>59</sup> The sequence began with norbornyl derivative (**355**), which was treated with sodium methoxide in methanol to afford compound (**356**). Compound (**356**) was subsequently converted into the bis-acetonide tosylate (**357**). Heating compound (**357**) with sodium iodide in acetone for 30 hours furnished the corresponding iodide in ~92% yield. Treatment of this iodide with potassium *tert*-butoxide in *tert*-butyl alcohol effected an elimination to give olefin (**358**) in 70% yield.

Ozonolysis of olefin (**358**) provided cyclohexanone (**359**) in ~90% yield. Reduction of (**359**) with sodium borohydride in methanol afforded the corresponding alcohol in 89% yield, which was then mesylated using methanesulfonyl chloride and triethylamine in dichloromethane to yield mesylate (**360**) in 90% yield. Elimination of (**360**) with potassium *tert*-butoxide in DMSO furnished the conduritol E derivative (**361**) in ~75% yield. Subsequent dihydroxylation of (**361**) with osmium tetroxide in the presence of NMMO provided diol (**362**) in 70% yield. Deprotection of the acetonide groups using 5% HCl afforded *allo*-inositol (**134**).

Olefin (**358**) also served as a precursor for the synthesis of MK 7607 (**367**). Dihydroxylation of (**358**) with osmium tetroxide and NMMO generated a 70 : 30 mixture of diols (**363**) and (**364**) in an overall 95% yield. Acetylation of diol (**363**) with acetic anhydride produced the corresponding diacetate in nearly quantitative yield. Treatment of this diacetate with thionyl chloride and pyridine gave a 1 : 2 mixture of acetates (**365**) and (**366**) in ~45% yield. Finally, MK 7607 (**367**) was obtained in

>95% yield through one-pot acetonide deprotection and hydrolysis of acetate (**365**) using 5% HCl (Scheme 40).


Beyond the synthesis of simple cyclitol derivatives, conduritol intermediates have also been employed in the preparation of biologically significant inositol phosphates. A representative example is the synthesis of *myo*-inositol polyphosphates reported by Plettenburg and co-workers using a conduritol B intermediate.

### 2.39. Synthesis of *myo*-inositol polyphosphates via a conduritol B intermediate

In 2000, Plettenburg *et al.* reported a synthesis of *myo*-Ins(1,2,3,4)P<sub>4</sub> (**376**) starting from *p*-benzoquinone (**9**) via an intermediate conduritol B derivative.<sup>60</sup> The racemic diacetate ( $\pm$ )-**368**, prepared in three steps from *p*-benzoquinone, was subjected to enzymatic resolution using pig pancreas lipase, affording diol (**369**) and the unreacted diacetate (**368**), both in high yields and separable by recrystallization. Hydrolysis of the diacetate with KOH in anhydrous THF followed by intramolecular nucleophilic substitution furnished the diepoxide (**370**) in approximately 80% yield. Subsequent reaction of (**370**) with dibenzyl benzoate resulted in double allylic epoxide opening to generate diphosphoconduritol B (**371**) in ~80% yield.

Acetylation of diphosphoconduritol B (**371**) with acetic anhydride in pyridine provided the corresponding diacetate (**372**) in nearly quantitative yield. Oxidation of (**372**) using RuCl<sub>3</sub> and NaIO<sub>4</sub> furnished diol (**373**) in ~86% yield. Phosphorylation of diol (**373**) with 3-diethylamino-2,4,3-benzodioxaphosphhepane (**374**) in the presence of 1*H*-tetrazole, followed by oxidation with *m*-CPBA, afforded compound (**375**)




Scheme 41 Synthesis of *myo*-inositol phosphate (*myo*-Ins(1,2,3,4)P<sub>4</sub>) (376) from *p*-benzoquinone (9).

in ~80% yield. Finally, hydrogenolysis of (375) over Pd/C, followed by hydrolysis of the acetate groups, delivered *myo*-Ins(1,2,3,4)P<sub>4</sub> (376) in nearly quantitative yield (Scheme 41).

In addition to their application in the synthesis of inositol phosphates, conduritol derivatives have also served as valuable precursors for the preparation of aminocyclitols such as conduramines. An illustrative example is the chemoenzymatic synthesis of (–)-conduramine E reported by Prinzbach and co-workers.<sup>61</sup>


#### 2.40. Chemoenzymatic synthesis of (–)-conduramine E via enzymatic resolution and Mitsunobu functionalization

In 2000, Prinzbach *et al.* reported a synthesis of (–)-conduramine E (–)-221.<sup>61</sup> The sequence began with diacetate (377), which was subjected to enzymatic resolution using SP 523 in *n*-hexane and a 0.2 N phosphate buffer (pH ≈ 7), affording alcohol (+)-378 in 80–90% yield with 94% enantiomeric excess. Alcohol (+)-378 was then converted into compound (379) via a Mitsunobu reaction employing NHZ<sub>2</sub> as the nucleophile, along with triphenylphosphine and DEAD, giving the product in 80–92% yield.



Scheme 42 Synthesis of (–)-conduramine E (–)-221 employing enzymatic hydrolysis.





Scheme 43 Synthesis of both enantiomers of conduritol B epoxide (1L-8) and (1D-8) from 1L-quebrachitol (382).

Deprotection of (379) with ammonia in methanol furnished primary amine (380) in nearly quantitative yield. Treatment of (380) with aqueous acetic acid generated urethane (381) in ~92% yield. Hydrolysis of urethane (381) with barium hydroxide then delivered (–)-conduramine E (–)-221 in approximately 86% yield (Scheme 42).

While chemoenzymatic approaches provide an efficient strategy for accessing enantiomerically enriched conduramines, alternative routes to related cyclitol derivatives have been developed using naturally occurring chiral pool precursors. In this context, Falshaw and co-workers demonstrated enantio-divergent syntheses of conduritol B epoxides starting from naturally occurring inositol derivatives such as quebrachitol and pinitol.<sup>62</sup>

#### 2.41. Enantiodivergent syntheses of 1L- and 1D-conduritol B epoxides from quebrachitol and pinitol

In 2000, Falshaw *et al.* reported the synthesis of both enantiomers of conduritol B epoxide.<sup>62</sup> For the preparation of 1L-conduritol B epoxide (1L-8), the synthesis commenced from the natural product 1L-quebrachitol (382), which was demethylated with hydroiodic acid to afford 1L-chiro-inositol (1L-137). Subsequent treatment with 2,3-butanedione and trimethyl orthoformate in the presence of an acid catalyst furnished the corresponding diacetal (383). The free hydroxyl groups of (383) were then converted into allyl ethers using allyl bromide and sodium hydride, providing compound (384). Acidic hydrolysis of the acetal moiety with trifluoroacetic acid in water yielded the tetraol (385), which upon benzylation with benzyl bromide and sodium hydride gave benzyl ether (386). Cleavage of the allyl protecting groups in (386) using *p*-toluenesulfonic acid produced diol (387), which was subsequently transformed into

epoxide (388) *via* a Mitsunobu reaction employing triphenylphosphine and DEAD. Final palladium-catalyzed hydrogenolysis of (388) afforded 1L-conduritol B epoxide (1L-8) in an overall yield of approximately 9%.


The synthesis of 1D-conduritol B epoxide (1D-8) began from 1D-pinitol (23), which underwent demethylation with hydroiodic acid to produce 1D-chiro-inositol (1D-137). Protection of the vicinal diols with 2,2-dimethoxypropane in the presence of catalytic TsOH furnished the diacetonide (389). Benzylolation of the remaining free hydroxyl groups with benzyl bromide, tetrabutylammonium iodide, and sodium hydride provided di-benzyl ether (390). Subsequent removal of the acetone groups using trifluoroacetic acid generated tetraol (391). Regioselective stannylene-mediated benzylation of the 2,5-equatorial hydroxyl groups delivered the tetrabenzyl intermediate (392), which was converted into epoxide (393) through a Mitsunobu reaction. Final palladium-catalyzed hydrogenolysis of (393) furnished 1D-conduritol B epoxide (1D-8) in an overall yield of approximately 29% (Scheme 43).

While chiral pool strategies based on naturally occurring inositols provide efficient routes to stereochemically defined conduritol derivatives, alternative approaches have explored the construction of more complex architectures incorporating multiple cyclitol units. In this context, Mehta and co-workers reported the synthesis of unusual fused-ring systems in which two conduritol frameworks share a common bond.<sup>63</sup>

#### 2.42. Construction of conduritol D-E and A-E fused ring systems

In 2000, Mehta *et al.* described the synthesis of a unique class of molecules incorporating two fused conduritol rings sharing a common bond.<sup>63</sup> The sequence began with the Diels–Alder





Scheme 44 Synthesis of fused conduritol D–E and A–E bicyclic systems from a Diels–Alder-derived precursor.

adduct (**394**), which was transformed into the corresponding diene (**395**) following a strategically modified literature protocol based on the procedures of Forman and Dailey. The diene (**395**) was then subjected to dihydroxylation using catalytic osmium tetroxide in the presence of *N*-methylmorpholine *N*-oxide (NMMO), delivering the tetraol (**396**) in approximately 66% yield.

Sequential treatment of (**396**) with amberlyst-15 resin and 4 Å molecular sieves afforded a dehydrated intermediate in 75% yield, which underwent reductive dechlorination to give compound (**397**) in 49% yield. Deketalisation of (**397**) with amberlyst-15 in acetone produced the ketone (**398**) in 98% yield. Subsequent decarbonylation of (**398**) with nitrobenzene furnished the cyclohexadiene derivative (**399**) in 62% yield. Dihydroxylation of (**399**) using OsO<sub>4</sub>/NMMO afforded diol (**400**) in 85% yield. Final acetonide deprotection with trifluoroacetic acid delivered compound (**401**)—a fused system comprising conduritol D and conduritol E in ~95% yield.

In a complementary pathway, the Diels–Alder adduct (**394**) was converted to diol (**402**) following a previously reported method. Deketalisation of (**402**) using amberlyst-15 in acetone yielded the ketone (**403**) in 95% yield. Decarbonylation of (**403**) with nitrobenzene provided the cyclohexadiene (**404**) in 34% yield, which upon dihydroxylation with OsO<sub>4</sub>/NMMO afforded

diol (**405**) in 73% yield. Final acetonide deprotection using trifluoroacetic acid furnished compound (**406**), featuring a fused conduritol A–conduritol E framework, in 90% yield (Scheme 44).


While the construction of fused conduritol frameworks illustrates the structural diversity accessible from cyclitol intermediates, alternative strategies have focused on functional group transformations of conduritol epoxides to access aminocyclitol derivatives. In this regard, Lee and co-workers reported a regioselective aminolysis of conduritol epoxides for the preparation of protected conduramine F derivatives.<sup>64</sup>

#### 2.43. Regioselective aminolysis of conduritol epoxides for constructing conduramine F frameworks


In 2000, Lee *et al.* described an efficient approach for the synthesis of protected derivatives of conduramine F.<sup>64</sup> The strategy began with the *cis*-diols (**98**) and (**74**), obtained through the microbial oxidation of chlorobenzene and bromobenzene, respectively, using *Pseudomonas putida*. These diols were converted into their corresponding acetonides (**77**) and (**24**) *via* treatment with 2,2-dimethoxypropane, providing the protected derivatives in 86% and 90% yields, respectively.

Epoxidation of acetonides (**77**) and (**24**) using *m*-chloroperbenzoic acid (*m*-CPBA) in dichloromethane furnished the





Scheme 45 Regioselective aminolysis of conduritol epoxides for the synthesis of protected conduramine F derivatives.



Scheme 46 Conduritol E-based chiral pool synthesis of (-)-gabosine A (-)-415.

epoxides (**78**) and (**27**) in 85% and 84% yields, respectively. Subsequent reaction of epoxides (**78**) and (**27**) with aniline in the presence of neutral alumina resulted in regioselective epoxide ring opening, affording the protected conduramine F derivatives (**407**) and (**408**) in 72% and 70% yields, respectively. Likewise, treatment of epoxide (**27**) with benzylamine under analogous conditions provided the corresponding protected amine (**409**) in approximately 70% yield.

The derivatives (**407**), (**408**), and (**409**) serve as versatile intermediates for the synthesis of conduramine F, dihydroconduramine F, and a range of structurally related analogues (Scheme 45).

While regioselective aminolysis of conduritol epoxides provides an efficient route to aminocyclitol derivatives such as conduramines, conduritol intermediates have also been exploited as versatile chiral building blocks for the synthesis of other biologically active carba-sugars. A notable example is the enantioselective synthesis of gabosine derivatives reported by Banwell and co-workers.<sup>65</sup>

#### 2.44. Conduritol E-based chiral pool approach to (-)-gabosine A

Gabosines constitute a distinctive class of carba-sugars noted for their enzyme-inhibitory activity, plant growth-regulating properties, and DNA-binding capabilities. In 2001, Banwell *et al.* developed an enantioselective synthetic route to


(-)-gabosine A (-)-**415**, employing a conduritol E-derived intermediate as a central building block.<sup>65</sup>

The synthesis began with the regioselective protection of the less hindered hydroxyl group of iodocyclohexadienediol (**231**) using *tert*-butyldiphenylsilyl chloride (TBDPSCl), affording the silyl ether (**410**). Subsequent dihydroxylation of (**410**) with osmium tetroxide in the presence of *N*-methylmorpholine *N*-oxide (NMMO) delivered the partially protected conduritol E derivative (**411**).

The newly formed *syn*-diol in (**411**) was then protected as an acetonide using 2,2-dimethoxypropane and catalytic *p*-toluenesulfonic acid, providing compound (**412**) in an overall yield of ~78% from starting material (**231**). Swern oxidation of (**412**) afforded the corresponding ketone (**413**) in 85% yield. Nucleophilic addition of MeMgCl to (**413**), promoted by FeCl<sub>3</sub> and 2-methyl-2-nitropropane (MNP), produced compound (**414**) in 94% yield. Finally, acidic removal of the acetonide protecting group furnished (-)-gabosine A (-)-**415** in ~85% yield (Scheme 46).

While conduritol E-derived intermediates have been successfully utilized as chiral building blocks for the synthesis of biologically active carba-sugars such as gabosines, conduritol derivatives have also served as valuable precursors in asymmetric catalytic approaches toward aminocyclitol-based natural products. An illustrative example is the enantioselective palladium-catalyzed synthesis of cyclophellitol reported by Trost and co-workers.<sup>66</sup>





Scheme 47 Synthesis of (–)-cyclophellitol (–)-346 from a conduritol B derivative (+)-416.

#### 2.45. Synthesis of (–)-cyclophellitol *via* enantioselective Pd catalysis

In 2001, Trost *et al.* reported an enantioselective synthesis of (–)-cyclophellitol (–)-346.<sup>66</sup> The route began with the coupling of the protected conduritol B derivative (+)-416 with the sodium salt of (phenylsulfonyl)nitromethane (417), catalyzed by 2.5% [Pd<sub>2</sub>(dba)<sub>3</sub>]·CHCl<sub>3</sub> in the presence of the chiral ligand (R,R)-337. This transformation afforded compound (418) in 81% yield and 88% enantiomeric excess.

Treatment of (418) with *N,N,N',N'*-tetramethylguanidine (TMG) in dichloromethane, followed by oxidation with dimethyldioxirane (DMDO), furnished the carboxylic acid (419) in 78% yield. Subsequent reduction of (419) provided the alcohol (420) in 70% yield, which upon epoxidation generated a mixture of epoxides (421) and (422). Among the methods evaluated, the MTO/H<sub>2</sub>O<sub>2</sub> system proved optimal, delivering epoxide (421) in 15% yield and epoxide (422) in 65% yield.

Finally, global deprotection of the major epoxide (422) furnished (–)-cyclophellitol (–)-346 in 95% yield (Scheme 47).

While enantioselective palladium-catalyzed methodologies have enabled efficient access to biologically important cyclitol derivatives such as cyclophellitol, similar asymmetric catalytic strategies have also been applied to the synthesis of aminocyclitol fragments present in clinically relevant antibiotics. A notable example is the synthesis of the aminocyclitol core of hygromycin A reported by Trost and co-workers.<sup>67</sup>

#### 2.46. Synthesis of the hygromycin A aminocyclitol scaffold *via* asymmetric Pd catalysis

In 2001, Trost *et al.* reported an efficient synthetic route toward the aminocyclitol core of the antibiotic hygromycin A.<sup>67</sup> The sequence commenced with the bromination of *p*-benzoquinone (9) in dichloromethane using elemental bromine, affording the corresponding *anti*-dibromo adduct in 76% yield. Subsequent reduction with sodium borohydride furnished diol (369) in 82% yield. Acetylation of the resulting hydroxyl groups with acetic anhydride in the presence of potassium carbonate, followed by refluxing in acetic acid, delivered conduritol B tetraacetate (6) in

71% overall yield. This intermediate was further converted into the tetra(2,2,2-trichloroethyl carbonate) derivative (416).

The tetra(2,2,2-trichloroethyl carbonate) derivative was then subjected to an asymmetric palladium-catalyzed process employing [η<sup>3</sup>-C<sub>3</sub>H<sub>5</sub>PdCl]<sub>2</sub>, the chiral ligand (S,S)-337, benzoic acid, and tetrahexylammonium benzoate (THAB), affording dibenzoate (423) in an excellent 90% yield. Subsequent reduction of (423) with zinc in acetic acid provided the *anti*-diol (424) in 77% yield. Treatment of (424) with benzyl isocyanate in the presence of triethylamine generated the corresponding monocarbamate (425), which upon exposure to triflic anhydride furnished triflate (426).



Displacement of the triflate (426) with potassium bis(trimethylsilyl)amide afforded the oxazolidinone (427) in 70% yield over two steps. Dihydroxylation of (427) using osmium tetroxide with *N*-methylmorpholine *N*-oxide (NMO) as the stoichiometric reoxidant delivered diol (428) in 80% yield. Conversion of the two free hydroxyl groups of (428) to the corresponding methylene acetal (429) was achieved almost quantitatively using dimethoxymethane in the presence of trimethylsilyl triflate and 2,6-lutidine. Finally, reductive deprotection of the benzylic amine and benzoate ester functionalities in (429) with lithium in liquid ammonia furnished the partially protected aminocyclitol fragment of hygromycin A, compound (430), in 77% yield (Scheme 48).

While asymmetric catalytic strategies provide powerful approaches for constructing complex aminocyclitol frameworks, alternative methodologies have focused on the stereoselective functionalization of simpler cyclohexene derivatives to access conduritol analogues. In this context, Sousa and co-workers reported an efficient synthesis of conduritol F tetraacetate *via* α-hydroxylation of an allylic alcohol intermediate.<sup>68</sup>

#### 2.47. Synthesis of conduritol F tetraacetate *via* α-hydroxylation of an allylic alcohol

In 2001, Sousa *et al.* reported an efficient synthesis of conduritol F tetraacetate (230).<sup>68</sup> The sequence began with the epoxidation of cyclohexene (431) using *m*-CPBA in cyclohexane, affording the *anti*-epoxide (432) in 81% yield. Ring opening of (432) with



Scheme 48 Synthesis of aminocyclitol unit of hygromycin A (430) from *p*-benzoquinone (9).Scheme 49 Synthesis of conduritol F tetraacetate (230) via  $\alpha$ -hydroxylation of an allylic alcohol.


the chiral base **(1S,2R)-433** provided the corresponding allylic alcohol (**434**) in >90% yield. Subsequent oxidation of (**434**) with PCC in dichloromethane furnished enone (**435**) in 88% yield.

Deprotonation of enone (**435**) with NaHMDS in THF generated the corresponding enolate, which was directly trapped with Davis' oxaziridine (**436**) to give  $\alpha$ -hydroxylated product (**437**) in 91% yield. Sequential acetylation of (**437**) using acetic

anhydride/pyridine, followed by Luche reduction, afforded alcohol (**438**) in nearly quantitative yield. Final desilylation of (**438**) with TBAF in THF, followed by global acetylation using acetic anhydride/pyridine, delivered conduritol F tetraacetate (**230**) in an overall yield of 87% over the last four steps (Scheme 49).







Scheme 51 Synthesis of 2,3-diamino-1,4-dimethoxy conduritol F (**463**) and 2,3-diamino conduritol B (**472**) employing a Ramberg–Bäcklund reaction.

53% yield, respectively. Subsequent hydrolysis of the amide and ester functionalities, reductive treatment with sodium in liquid ammonia, and removal of the acetonide groups delivered the *N*-linked inositol dimers (**444**) and (**449**) in 77% and 87% yield, respectively.

The synthesis of *O*-linked inositol oligomers began with epoxide ring opening using KOH to afford diol (**450**) in 63% yield. Reaction of (**450**) with vinylaziridine (**439**) in the presence of BF<sub>3</sub>·OEt<sub>2</sub> produced a mixture of *O*-linked conduritol F derivatives (**451**) and (**452**) in 52% combined yield. Radical debromination of (**451**) and (**452**) afforded (**453**) and (**454**), respectively, in 68% yield. These intermediates underwent *syn*-dihydroxylation followed by acetonide protection to yield compound (**455**) in 60% overall yield (two steps). Finally, global deprotection of (**455**) furnished the *O*-linked inositol dimer (**456**) in 52% yield (Scheme 50).

While the construction of *N*-linked and *O*-linked inositol dimers highlights the potential of conduramine and conduritol derivatives for assembling higher-order cyclitol architectures, further synthetic developments have explored strategies for introducing multiple amino functionalities into the cyclitol framework. In this regard, Arcelli and co-workers reported the synthesis of diamino-substituted conduritol derivatives *via* sulfone–olefin rearrangement pathways.<sup>70</sup>

#### 2.49. Synthesis of 2,3-diamino conduritol F and B analogues *via* sulfone–olefin rearrangement pathways

In 2001, Arcelli and co-workers reported the synthesis of both 2,3-diamino-1,4-dimethoxyconduritol F and 2,3-diamino


conduritol B.<sup>70</sup> The synthesis of 2,3-diamino-1,4-dimethoxyconduritol F began with the protection of the hydroxyl groups of diol (**457**) using methanesulfonyl chloride in pyridine, affording dimesylate (**458**). Subsequent oxidation of (**458**) with *m*-CPBA in dichloromethane furnished sulfone (**459**) in 93% yield.

Sulfone (**459**) was treated with sodium azide in DMSO to give a mixture of the expected azide (**460**) and byproduct (**461**) in 62% and 24% yield, respectively. Purification of (**460**) by flash chromatography followed by a Ramberg–Bäcklund olefination furnished cyclohexene (**462**) in 90% yield. Reduction of (**462**) with triethylamine and 1,3-propanedithiol in methanol then afforded 2,3-diamino-1,4-dimethoxyconduritol F (**463**) in 70% yield.

The synthesis of 2,3-diamino conduritol B (**472**) commenced from *D*-mannitol (**319**), which was transformed into 3,6-dihydroxy-4,5-di-*O*-isopropylidene- $\alpha$ -D-glucopyranose (**464**). Treatment of (**464**) with sodium hydride and benzoyl bromide in THF afforded dibenzyl ether (**465**) in 96% yield. Acidic cleavage of the acetonide group in (**465**) furnished diol (**466**) in 95% yield, which upon treatment with methanesulfonyl chloride in pyridine gave dimesylate (**467**) in 92% yield. Reaction of (**467**) with sodium azide in DMSO produced diazide (**468**) in 85% yield, and subsequent oxidation with *m*-CPBA provided sulfone (**469**) in 98% yield.

Application of Ramberg–Bäcklund conditions to (**469**) delivered cyclohexene (**470**) in 61% yield. Reduction of (**470**) using triethylamine and 1,3-propanedithiol in methanol afforded diamine (**471**) in 68% yield. Final deprotection of the benzyl



Scheme 52 Conduritol A-derived total synthesis of narciclasine (**16**) via a Diels–Alder-based strategy.

ethers in (**471**) with boron trichloride in dichloromethane furnished 2,3-diamino conduritol B (**472**) in 72% yield (Scheme 51).

While sulfone–olefin rearrangement strategies provide efficient access to diamino-substituted conduritol derivatives, conduritol-based intermediates have also been widely utilized in the synthesis of complex natural products. In this context, Elango and co-workers reported a concise conduritol A-derived pathway toward the total synthesis of the biologically significant alkaloid narciclasine.<sup>12</sup>

### 2.50. Conduritol A-derived pathway to the total synthesis of narciclasine

In 2002, Elango and co-workers reported a concise synthetic route to narciclasine (**16**).<sup>12</sup> The sequence began with a Diels–Alder cycloaddition between the chiral chloronitroso compound (**473**) and diene (**56**), furnishing cycloadduct (**58**). Reduction of (**58**) with aluminum amalgam provided the partially protected conduritol A derivative (**59**) in ~85% yield. Subsequent treatment of (**59**) with *p*-nitrobenzenesulfonyl chloride, followed by silylation of the unprotected hydroxyl group with TBSCl, afforded derivative (**474**) in ~78% yield. Bromination of (**474**) with NBS in acetone produced a 1 : 1 mixture of bromohydrins (**475**) and (**476**) in ~98% combined yield.

Alkylation of this mixture with benzyl bromide (**477**) in acetonitrile in the presence of potassium carbonate furnished epoxide (**478**) in ~88% yield. Exposure of (**478**) to SnCl<sub>4</sub> in dry dichloromethane promoted regioselective opening of the epoxide, and acetylation of the resulting hydroxyl group furnished acetate (**479**) in ~98% yield. Treatment of acetate (**479**) with two equivalents of mercaptoacetic acid in the presence of LiOH (5 equiv.) in DMF at room temperature delivered amine (**480**) in ~78% yield. Conversion of (**480**) to imide (**481**) was

achieved by sequential Boc protection and oxidative cleavage using RuCl<sub>3</sub>/NaIO<sub>4</sub>, affording (**481**) in ~67% yield.

Heating imide (**481**) with DBU in benzene induced a *syn*-elimination to provide compound (**482**) in ~97% yield. Finally, global deprotection of (**482**) furnished Narciclasine (**16**) in ~65% yield (Scheme 52).


While conduritol-derived intermediates have proven valuable in the synthesis of biologically significant alkaloids such as narciclasine, related cyclitol-based frameworks have also been employed for the preparation of other Amaryllidaceae alkaloid analogues. In this regard, Rinner and co-workers reported an epoxyconduramine-driven strategy for constructing *epi*-7-deoxypancrastatin.<sup>71</sup>

### 2.51. Epoxyconduramine-driven construction of *epi*-7-deoxypancrastatin

In 2002, Rinner and co-workers reported the synthesis of *epi*-7-deoxypancrastatin (**493**).<sup>71</sup> The sequence began with the conversion of bromobenzene (**308**) into aziridine (**483**), which was subsequently subjected to RuCl<sub>3</sub>/NaIO<sub>4</sub>-mediated *syn*-dihydroxylation to afford diol (**484**) in ~85% yield. Treatment of (**484**) with sulfuryl chloride and triethylamine generated the corresponding cyclic sulfate (**485**) in ~93% yield. Sequential reaction of (**485**) with BzONH<sub>4</sub> in DMF, followed by hydrolysis, delivered benzoate (**486**) in ~90% yield.

Protection of the free hydroxyl group in (**486**) with TBSCl/imidazole, followed by methanolysis of the benzoate using sodium methoxide in THF, furnished compound (**487**) in ~63% combined yield (two steps). Treatment of (**487**) with *t*-BuLi in THF, followed by coupling with piperonyl bromide in the presence of tetrabutylammonium iodide, afforded the epoxyconduramine derivative (**488**) in ~68% yield.





Scheme 53 Epoxyconduramine-based synthesis of *epi*-7-deoxypancrastatin (**493**).

Lewis acid-mediated cyclization of (**488**) with  $\text{Me}_2\text{AlCl}$  in dichloromethane furnished bicyclic intermediate (**489**) in ~68% yield. Protection of the resulting free hydroxyl group as its MOM ether afforded compound (**490**) in ~97% yield. Oxidation of (**490**) with  $\text{RuCl}_3/\text{NaIO}_4$  delivered lactam (**491**) in ~50% yield. Subsequent reduction of (**491**) using sodium/naphthalene furnished compound (**492**) in ~75% yield. Finally, global deprotection of (**492**) yielded *epi*-7-deoxypancrastatin (**493**) in ~68% yield (Scheme 53).

While epoxyconduramine intermediates have proven useful for the synthesis of Amaryllidaceae alkaloid analogues such as *epi*-7-deoxypancrastatin, conduritol derivatives have also found application as versatile chiral building blocks for the construction of complex marine natural products. In this context, Lambert and co-workers employed a conduritol E-derived scaffold for the synthesis of the C1–C14 fragment of the potent anticancer agent Halichondrin B.<sup>72</sup>

### 2.52. Construction of the C<sub>1</sub>–C<sub>14</sub> halichondrin B subunit via a conduritol E-derived scaffold

In 2003, Lambert and co-workers reported the synthesis of the C<sub>1</sub>–C<sub>14</sub> subunit of halichondrin B, beginning from (+)-conduritol E (+)-**494**.<sup>72</sup> Protection of (+)-**494** with TBDPSCl in pyridine/DMF afforded diol (**495**) in ~83% yield. Ozonolysis of (**495**) furnished the bicyclic intermediate (**496**), which underwent rapid dehydration upon treatment with acetic anhydride/ $\text{Et}_3\text{N}$  to afford hemiacetal (**497**). Conversion of (**497**) into a single diastereomeric lactone (**498**) was accomplished using TESCl/imidazole in ~80% yield. Methylation of (**498**) with dimethyltitanocene furnished compound (**499**) in ~93% yield.

Hydroboration–oxidation of (**499**) with  $\text{BH}_3 \cdot \text{Me}_2\text{S}$ , followed by oxidative workup with  $\text{H}_2\text{O}_2/\text{NaOH}$ , provided alcohol (**500**) in ~70% yield. Protection of (**500**) as the corresponding pivalate, followed by acidic methanolysis, furnished hemiacetal (**501**) in ~99% yield. A one-carbon Wittig homologation converted (**501**)

into enol ether (**502**) in ~87% yield. Subsequent dihydroxylation of (**502**) using  $\text{OsO}_4/\text{NMO}$  delivered diol (**503**) in ~73% yield.

Acetylation of diol (**503**) with  $\text{Ac}_2\text{O}/\text{DMAP}/\text{pyridine}$  generated diacetate (**504**) in ~68% yield. Lewis acid–promoted coupling of (**504**) with allylic silane (**505**) in the presence of  $\text{BF}_3 \cdot \text{OEt}_2$  afforded coupling product (**506**) in ~71% yield. Desilylation of (**506**) with TBAF/ $\text{AcOH}$ , followed by amberlyst IRA-400 treatment in methanol, provided triol (**507**) in ~62% yield. Refluxing (**507**) with DBU in toluene delivered stereodefined diol (**508**) in ~78% yield.

Further treatment of (**508**) with amberlyst IRA-400 in methanol furnished triol (**509**) in ~93% yield. Sequential silylation with TESCl/imidazole and Swern oxidation afforded aldehyde (**510**) in ~74% yield. Wittig olefination of (**510**) with phosphonium salt (**511**) and *n*-BuLi in THF produced enol ethers **512(Z)** and **512(E)** in ~37% and ~42% yields, respectively; the isomers were separated by Florisil chromatography.


Finally, acidic hydrolysis of the enol ether mixture with *p*-TsOH in  $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}/\text{MeOH}$  furnished the C1–C14 subunit of Halichondrin B (**513**) in ~67% overall yield from triol (**509**) (Scheme 54).

While conduritol derivatives have proven valuable as chiral building blocks in the synthesis of complex natural product fragments such as halichondrin B, their structural versatility has also inspired the development of annulated conduritol systems. These conformationally constrained derivatives provide useful platforms for accessing novel inositol analogues and exploring new stereochemical architectures.

### 2.53. Strategies for the construction of cyclohexa- and cyclopenta-annulated conduritols

In 2003, Mehta and co-workers reported versatile synthetic strategies for the preparation of annulated conduritols and conformationally constrained inositols.<sup>73</sup> Their studies commenced with 1,2,3,4,5,8-hexahydronaphthalene (**514**),



Scheme 44 Synthesis of C1–C14 subunit of halichondrin B (**513**) from (+)-conduritol E (+)-**494**.

which underwent regioselective epoxidation with *m*-CPBA in dichloromethane to furnish epoxide (**515**) in ~85% yield. Acid-catalyzed ring opening of (**515**), followed by acetylation, afforded the *trans*-diacetate (**516**) in ~90% overall yield. Allylic bromination of (**516**), followed by DBU-mediated dehydrobromination, produced diene (**517**) in ~52% overall yield. Stereoselective mono-epoxidation of (**517**) yielded a 1 : 9 mixture of diastereomeric epoxides (**518**) and (**519**) in ~73% combined yield.

Ring opening of the major epoxide (**519**) with 10% aqueous acetic acid in THF afforded a mixture of annulated conduritol F (**520**) and annulated conduritol B (**521**) in a 3 : 1 ratio (~80% yield). Catalytic dihydroxylation of (**520**) with OsO<sub>4</sub>/NMMO in acetone–water provided triol (**522**) in ~88% yield, which upon basic hydrolysis furnished 2,3-cyclohexa-annulated *chiro*-


inositol (**523**) in ~96% yield. Similarly, hydrolysis of (**521**) generated annulated conduritol B derivative (**524**) in ~95% yield; subsequent dihydroxylation of (**524**) afforded 3,4-cyclohexa-annulated *myo*-inositol (**525**) in ~80% yield.

Catalytic hydroxylation of diene (**517**) produced a 2 : 1 mixture of diols (**526**) and (**527**) in ~70% yield, which upon basic hydrolysis delivered 3,4-cyclohexa-annulated *chiro*-inositol (**528**) in ~90% yield.

For cyclopenta-annulated derivatives, 2,3,4,7-tetrahydro-1*H*-indene (**529**) was treated with MMPP in THF/water to provide the *trans*-diol (**530**) in ~85% yield, followed by ring opening in 10% aqueous acetic acid (~90% yield). Bromination and subsequent acetylation of (**530**) afforded dibromide (**531**) in ~66% and ~89% yields, respectively. Double dehydrobromination of (**531**) using DBU/DMSO yielded diene (**532**) in







Scheme 56 Synthesis of cyclohexa-annulated derivatives of conduritol C and *neo*-inositol.

(546). The major diol (546) was converted to the corresponding diacetate (547), which upon epoxidation with *m*-CPBA in dichloromethane afforded a 1 : 10 mixture of epoxides (548) and (549) in ~86% overall yield.

Ring opening of the major epoxide (549) with 10% aqueous acetic acid yielded diol (550) in ~85% yield. Bromination of (550) furnished dibromide (551) in ~77% yield. Treatment of (551) with potassium *tert*-butoxide induced regio- and stereo-selective transesterification coupled with dehydrobromination, affording bicyclic ether (552) in ~45% yield. Subsequent dihydroxylation followed by acetylation provided diacetate (553) in ~75% yield over two steps.

Refluxing diacetate (553) with tetrabutylammonium iodide generated iodide (554) in ~73% yield. Treatment of (554) with potassium *tert*-butoxide afforded the partially protected, cyclohexa-annulated, conformationally locked conduritol C derivative (555) in ~63% yield. Dihydroxylation of (555) with OsO<sub>4</sub> furnished triol (556) in ~60% yield, and final hydrolysis of the acetate groups delivered the cyclohexa-annulated, conformationally constrained *neo*-inositol derivative (557) in ~67% yield (Scheme 56).

While the construction of annulated conduritol derivatives provides access to conformationally constrained cyclitol architectures, alternative synthetic strategies have focused on introducing halogen substituents and polyacetylated functionalities into conduritol frameworks. Such modifications expand the structural diversity of conduritols and provide valuable intermediates for further synthetic transformations.

### 2.55. Advances in the synthesis of halogenated and polyacetylated conduritol frameworks

In 2003, Baran and co-workers reported the synthesis of a series of haloconduritols and conduritol tetraacetates.<sup>75</sup> The study commenced with a Diels–Alder cycloaddition between furan (558) and vinylene carbonate (559), generating a mixture of the

*exo*-adduct (560) and *endo*-adduct (561) in ~34% and ~8% yields, respectively. Sequential hydrolysis and acetylation of these adducts afforded the corresponding diacetates (562) and (563), in ~8% and ~64% yields, respectively.

Treatment of *endo*-diacetate (563) with BCl<sub>3</sub> at –78 °C furnished chloroconduritol A diacetate (565) in ~96% yield, while reaction with BBr<sub>3</sub> under analogous conditions produced bromoconduritol A diacetate (566) in ~94% yield. Subsequent acetylation of the free hydroxyl group in compounds (565) and (566) using acetyl chloride in dichloromethane provided the corresponding triacetates (567) and (568) in nearly quantitative yields. Global deprotection of these triacetates then yielded chloroconduritol A (569) and bromoconduritol A (570), each obtained in almost quantitative yield.


In addition, treatment of *endo*-diacetate (563) with acetic anhydride and sulfuric acid generated a 2 : 1 mixture of conduritol A tetraacetate (564) and conduritol F tetraacetate (230) in nearly quantitative yield. Conduritol A tetraacetate (564) could also be obtained *via* halide displacement in compounds (565) and (566) using acetate, affording the tetraacetate in ~78% and ~73% yields, respectively (Scheme 57).

Beyond halogenated and polyacetylated conduritol derivatives, further synthetic developments have explored oxidative transformations of conduritol frameworks for accessing various inositol stereoisomers and their biologically significant phosphate derivatives. Such strategies highlight the versatility of conduritols as intermediates in the synthesis of polyhydroxylated cyclitols and their phosphorylated analogues.

### 2.56. Oxidative transformations of conduritol derivatives toward inositols and their polyphosphate analogues

In 2003, Podeschwa and co-workers reported a series of synthetic methods leading to conduritol tetraacetates, inositols, and their corresponding hexakis(phosphate) derivatives.<sup>76</sup> The synthesis began with *anti*-dibromide (+)-368, which was





Scheme 57 Synthesis of halogenated conduritols and conduritol tetraacetates via a Diels–Alder-based strategy.

sequentially treated with sodium acetate in acetic acid and subsequently with an anhydride to furnish conduritol E tetraacetate (+)-571 in ~70% yield (67% after recrystallization). Oxidative ring opening of (+)-571 with trifluoroacetic anhydride, hydrogen peroxide, dichloromethane, and sodium bicarbonate generated epoxide (+)-572 (24% yield), which underwent further oxidation to give 2,3,4,5-tetra-*O*-acetyl-*neo*-inositol (+)-573 in 71% yield. Acetylation of (+)-573 in pyridine produced *neo*-inositol hexaacetate (574) in 83% yield, and subsequent deprotection afforded *neo*-inositol (138) in ~99% yield. Phosphorylation of *neo*-inositol (138) with 3-diethylamino-2,4,3-benzodioxaphosphepane (374) and 1*H*-tetrazole, followed by palladium-catalyzed hydrogenolysis, provided *neo*-inositol hexakis(phosphate) (575) in ~99% yield.

Similarly, dihydroxylation of conduritol E tetraacetate (+)-571 using  $\text{RuCl}_3/\text{NaIO}_4$  afforded 3,4,5,6-tetra-*O*-acetyl-*allo*-inositol (+)-576 in ~90% yield. Deacetylation produced *allo*-inositol (134) in ~83% yield, which upon phosphorylation via the same sequence gave *allo*-inositol hexakis(phosphate) (577) in ~99% yield.

For the synthesis of *epi*-inositol, dihydroxylation of (+)-368 with  $\text{RuCl}_3/\text{NaIO}_4$  furnished *syn*-diol (–)-578 in ~81% yield. Acetylation afforded tetraacetate (–)-579 (~99%), which underwent zinc-mediated elimination to provide (–)-conduritol C tetraacetate (–)-580 in ~68% yield. Subsequent dihydroxylation and acetylation yielded hexa-*O*-acetyl-*epi*-inositol (581) in ~74% yield, and deprotection furnished *epi*-inositol (582) in ~99% yield.

Diol (–)-578 was also converted into orthoester (–)-583 (~93%) using triethyl orthoformate and *p*-toluenesulfonic acid, followed by acidic workup. Zinc-mediated elimination afforded partially protected conduritol C (–)-584 (~82%), which, after phosphorylation and oxidation, generated triphosphate (+)-586 (~50%). Hydrogenolysis and deacetylation then furnished *D*-*epi*-inositol-1,4,5-triphosphate (+)-587 in ~99% yield.

The dibromide (+)-368 was further transformed into partially protected conduritol B (–)-588 (~80%), which upon treatment

with trifluoroacetic anhydride and hydrogen peroxide afforded epoxide (–)-589 (~71%). Acidic ring opening of (–)-589 with  $\text{H}_2\text{SO}_4$  in dioxane–water yielded anti-diol (–)-590 (~80%), which underwent hydrogenolysis to provide *L*-*chiro*-inositol (–)-137 in ~99% yield. Phosphorylation of *L*-*chiro*-inositol (–)-137 furnished *L*-*chiro*-inositol hexakis(phosphate) (–)-591 in ~60% yield.


Dihydroxylation of (–)-588 afforded 1,4-di-*O*-benzyl-*myo*-inositol (–)-592 in ~82% yield. Protection of the free hydroxyl groups of epoxide (–)-589 using 2,2-dimethoxypropane and PPTS gave the corresponding acetonide (593) in ~96% yield. Epoxide opening with an allylic alcohol, followed by acetonide removal, produced partially protected *scyllo*-inositol (594) in ~60% yield. Complete deprotection yielded *scyllo*-inositol (595) in ~60% yield, which upon phosphorylation afforded *L*-*scyllo*-inositol hexakis(phosphate) (596) in ~60% yield (Scheme 58).

In addition to oxidative transformations that convert conduritol frameworks into inositol derivatives, further synthetic efforts have focused on the introduction of nitrogen-containing functionalities. Such modifications enable access to azido- and amino-substituted conduritols and inositol derivatives, which are valuable intermediates for the synthesis of biologically relevant aminocyclitols and phosphorylated inositol analogues.

### 2.57. Stereocontrolled synthesis of azido- and amino-functionalized conduritols and inositol derivatives

In 2003, Podeschwa and co-workers reported the synthesis of both enantiomers of 1-azidoconduritols and a series of amino-inositol phosphates.<sup>77</sup> The study began with the treatment of diacetate (+)-368 and diol (+)-369 with lithium hydroxide in diethyl ether/methanol, generating the corresponding epoxides (+)-597 and (–)-597 in ~99% yield. Nucleophilic ring opening of these epoxides with sodium azide afforded azides (–)-598 and (+)-598 in ~90% yield. Subsequent treatment with lithium hydroxide followed by *p*-toluenesulfonic acid provided the 1-azidoconduritols B derivatives (–)-600 and (+)-600 in ~47% yield.






Scheme 58 Synthesis of inositols and inositol phosphates.

Acetylation of the triols (–)-600 and (+)-600 with acetic anhydride/pyridine furnished the 2,3,4-tri-*O*-acetyl derivatives (–)-601 and (+)-601 in ~96% yield. Dihydroxylation of (+)-601 with RuCl<sub>3</sub>/NaIO<sub>4</sub> delivered a 4 : 6 mixture of 3,4,5-tri-*O*-acetyl-6-azido-*myo*-inositol (–)-602 and 4,5,6-tri-*O*-acetyl-3-azido-*myo*-inositol (+)-603 in ~91% overall yield. Acetylation of (–)-602 afforded pentaacetate (+)-604 (~98%), and deprotection furnished 1-deoxy-1-azido-*myo*-inositol (–)-605 in ~99% yield.

Hydrogenation of (–)-605 produced 6-deoxy-6-amino-*myo*-inositol (+)-606 in ~99% yield. Sequential hydrogenation (80%), acetylation (99%), acetate deprotection (80%), phosphorylation (43%), and hydrogenolysis (80%) of (+)-604 yielded 6-deoxy-6-acetamido-*myo*-inositol-1,2,3,4,5-pentakisphosphate (–)-607. Similarly, phosphorylation (51%) and hydrogenolysis (90%) of (–)-605 afforded 6-deoxy-6-amino-*myo*-inositol-1,2,3,4,5-pentakisphosphate (–)-608.





Scheme 60 Divergent synthesis of *scyllo*-inositol polyphosphates from a conduritol B-derived precursor.

(+)-615 with RuCl<sub>3</sub>/NaIO<sub>4</sub> afforded 4,5-di-*O*-acetyl-3,6-diazido-*myo*-inositol (–)-616 (~99%), and deacetylation furnished 3,6-dideoxy-3,6-diazido-*myo*-inositol (–)-617 (~99%). Phosphitylation using 3-diethylamino-2,4,3-benzodioxaphosphane (374) and 1*H*-tetrazole gave (–)-618 (~45%), which upon treatment with TMSBr in CH<sub>2</sub>Cl<sub>2</sub> produced 3,6-dideoxy-3,6-diazido-1,2,4,5-*myo*-inositol tetrakisphosphate (–)-619 in ~90% yield (Scheme 59).

Beyond azido- and amino-functionalized conduritol derivatives, further synthetic developments have explored the preparation of higher-order inositol polyphosphates from conduritol precursors. These strategies highlight the versatility of conduritol frameworks as intermediates for accessing structurally diverse phosphorylated cyclitols with important biological functions.

### 2.58. Diversified synthesis of higher-order *scyllo*-inositol polyphosphates from a conduritol B precursor

In 2003, Know and co-workers reported the synthesis of several *scyllo*-inositol polyphosphates using conduritol B acetonide as the key starting material.<sup>78</sup> The sequence began with conduritol B acetonide (+)-620, which was treated with benzyl bromide and sodium hydride to convert the free hydroxyl groups into benzyl ethers, affording compound (+)-621 in ~96% yield. Dihydroxylation of (+)-621 with osmium tetroxide and NMO furnished the partially protected *myo*-inositol derivative (–)-622 in ~94.4% yield.

The partially protected inositol (–)-622 was subjected to a Mitsunobu inversion using benzoic acid, triphenylphosphine, and DEAD to give benzoate (–)-623 in ~79% yield. Deprotection of the benzoate ester with sodium methoxide in methanol provided the partially protected *scyllo*-inositol derivative (–)-624 in ~96% yield. Phosphorylation of (–)-624 with

a phosphoramidite reagent followed by oxidation with *m*-CPBA afforded phosphate ester (–)-625 in ~75% yield. Global deprotection *via* palladium-catalyzed hydrogenolysis and alkaline hydrolysis delivered *D*-*scyllo*-inositol-(1,2)-diphosphate (–)-626 in ~94% yield.

Heating benzoate (–)-623 in 80% aqueous acetic acid produced partially protected *scyllo*-inositol (–)-627 in nearly quantitative yield. Phosphorylation with a phosphoramidite reagent and oxidation with *m*-CPBA furnished compound (–)-628 in ~96% yield. Subsequent palladium-catalyzed hydrogenolysis followed by complete deprotection afforded *scyllo*-inositol-(1,2,4)-triphosphate (629) in ~91% yield.


Further derivatization of (–)-623 by benzylation of the remaining hydroxyl group provided (–)-630 in ~99% yield. Palladium-catalyzed hydrogenolysis of benzyl ethers followed by acidic cleavage of the acetonide group yielded tetraol (+)-631 in ~96% yield. Phosphorylation and oxidation of (+)-631 produced phosphate ester (+)-632 in ~77% yield. Final palladium-catalyzed hydrogenolysis and benzoate deprotection delivered *scyllo*-inositol-(1,2,3,4)-tetrakisphosphate (633) in ~89% yield (Scheme 60).

While conduritol derivatives have proven valuable intermediates for accessing inositol polyphosphates, their synthetic versatility has also enabled the preparation of structurally modified conduritol analogues. In particular, aryl-substituted deoxyconduritol derivatives have attracted considerable attention due to their role as key intermediates in the synthesis of biologically active natural products such as pancratistatins.

### 2.59. *D*-xylose-derived routes to aryl-substituted deoxyconduritol F analogues

In 2004, Nadein and co-workers reported an efficient synthetic route to 1-aryl-1-deoxyconduritol F derivatives, which serve as





Scheme 61 D-Xylose-derived synthesis of 1-aryl-1-deoxyconduritol F derivatives via a ring-closing metathesis strategy.

key precursors in the synthesis of pancratistatins.<sup>79</sup> The sequence commenced with D-xylose (**634**), which was converted into its tribenzyl ether (**347**) in ~71% yield.

Tribenzyl ether (**347**) was then subjected to a sequence of olefination steps, beginning with a Wittig reaction using  $\text{H}_2\text{C}=\text{PPh}_3$  in THF, followed by Swern oxidation, and a second Wittig reaction employing  $\text{PPh}_3=\text{CHCO}_2\text{Me}$ . This sequence afforded diene (**635**) in ~84% overall yield. The diene (**635**) underwent 1,4-conjugate addition with various Gilman reagents to furnish the corresponding substituted intermediates (**636a-d**) in 95–97% yield.

Reduction of compounds (**636a-d**) with lithium aluminum hydride, followed by selenoxide elimination, provided allylic alcohols (**637a-d**). Finally, ring-closing metathesis (RCM) using Grubbs' catalyst converted these intermediates into the desired 1-aryl-1-deoxyconduritol F derivatives (**638a-d**) (Scheme 61).

While carbohydrate-derived strategies provide versatile access to aryl-substituted conduritol derivatives, alternative approaches have also employed chemoenzymatic transformations for constructing cyclitol frameworks. In particular, enzymatic dihydroxylation combined with chemical functionalization offers an efficient route to various inositol stereoisomers.

## 2.60. Synthesis of *epi*-inositol through chemoenzymatic dihydroxylation and radical debromination

In 2004, Vitelio and co-workers reported an efficient method for the synthesis of *epi*-inositol.<sup>80</sup> The sequence began with the dihydroxylation of bromobenzene (**308**) using toluene dioxygenase to afford diol (**74**). This diol was subjected to a second dihydroxylation with osmium tetroxide/NMO, and the resulting tetraol was protected as its diacetonide using 2,2-dimethoxypropane and *p*-toluenesulfonic acid, yielding compound (**639**) in ~75% yield.

Epoxidation of diacetonide (**639**) with *m*-CPBA furnished epoxide (**640**) in ~70% yield. Radical debromination of (**640**) provided the dehalogenated epoxide (**641**) in ~85% yield. Finally, global deprotection of the acetonide groups followed by epoxide ring opening delivered *epi*-inositol (**582**) in ~90% yield (Scheme 62).

While chemoenzymatic dihydroxylation strategies have proven effective for constructing inositol stereoisomers, further developments have explored structural modifications of the conduritol framework through aromatic ring substitution. Such approaches enable access to polyhydroxylated tetrahydronaphthalene derivatives with expanded structural diversity and potential biological relevance.



## 2.61. Aromatic extensions of the conduritol scaffold: synthesis of 7-substituted polyhydroxylated tetrahydronaphthalenes

In 2004, Orsini and co-workers developed a method for synthesizing aromatic ring-substituted conduritol derivatives.<sup>81</sup> The sequence began with 7-substituted naphthalene derivatives (**642a-f**), which were converted into the corresponding 7-substituted (1*R*,2*S*)-1,2-dihydroxy-1,2-dihydronaphthalenes (**643a-f**) via biotransformation using *E. coli* JM109 engineered to express naphthalene dioxygenase from *Pseudomonas fluorescens* N3. Protection of these diols with dimethoxypropane (DMP) in the presence of *p*-toluenesulfonic acid furnished the isopropylidene derivatives (**644a-f**). Epoxidation of (**644a-f**) with *m*-CPBA afforded the corresponding epoxides (**645a-f**).

Heating epoxides (**645a-d**) with sodium azide in DMF provided azides (**646a-d**). Catalytic hydrogenation of azides (**646a**) and (**646d**) over Pd/C gave the amines (**647a**) and (**647d**), and subsequent acidic deprotection of their isopropylidene groups with methanolic HCl furnished the 7-substituted 1,2,3-trihydroxy-4-amino-tetrahydronaphthalenes (**648a**) and (**648d**).

To access 7-substituted 1,2,3,4-tetrahydroxy-tetrahydronaphthalenes and additional 1,2,3-trihydroxy-4-amino derivatives, the isopropylidene diols (**644a,b,d,e**) were subjected to dihydroxylation using  $\beta$ -AD-mix in *t*-butanol, affording diols (**649a,b,d,e**). Reaction of diols (**649a,b,e**) with triphosgene in pyridine/ $\text{CH}_2\text{Cl}_2$  generated chloroformate intermediates (**650a,b,e**), which were converted into azides and subsequently reduced over Pd/C to give amines (**647a**) and (**647e**). Deprotection of these amines with methanolic HCl provided the corresponding 7-substituted 1,2,3-trihydroxy-4-amino-tetrahydronaphthalenes (**648a**) and (**648e**). Similarly, acidic removal of the isopropylidene group from diols (**649a,d,e**)



Scheme 62 Chemoenzymatic synthesis of *epi*-inositol (**582**) via dihydroxylation and radical debromination.

Scheme 63 Synthesis of 7-substituted 1,2,3-trihydroxy-4-amino-tetrahydronaphthalenes and 7-substituted 1,2,3,4-tetrahydroxy-tetrahydronaphthalenes.

furnished the 7-substituted 1,2,3,4-tetrahydroxy-tetrahydronaphthalenes (**651a,d,e**) (Scheme 63).


While aromatic substitutions provide access to structurally diverse conduritol-derived scaffolds, another major direction in cyclitol chemistry involves the synthesis of highly phosphorylated inositol derivatives. Such compounds play important roles in cellular signaling pathways, motivating the development of efficient synthetic routes to various inositol polyphosphates.

### 2.62. Divergent construction of *D*- and *L*-*myo*-inositol polyphosphates via conduritol B intermediates

In 2004, Saito and co-workers reported a synthetic route for *D*-*myo*-inositol-3,4,5,6-tetrakisphosphate (*D*-**664**) and *L*-*myo*-

inositol-3,4,5,6-tetrakisphosphate (*L*-**674**) starting from a *D*-glucose derivative.<sup>82</sup> *D*-Glucose was first converted into compound (**652**), which was then transformed into aldehyde (**653**) in approximately 67% yield. A 1,2-addition of vinylcopper to aldehyde (**653**) afforded allyl alcohol (**654**) with around 75% yield. Protection of the allylic hydroxyl group as 4-methoxybenzoyl (PMB) or 2-methoxybenzoyl (OMB) ethers yielded compounds (**655a**) and (**655b**) in about 98% yield each. Hydrolysis of the isopropylidene acetal with sulfuric acid in THF produced hemiacetals (**656a**) (50% yield) and (**656b**) (78% yield). Wittig methylenation of these hemiacetals furnished 1,7-dienes (**657a**) (70% yield) and (**657b**) (75% yield), which underwent ring-closing metathesis (RCM) using Grubbs' catalyst to give





Scheme 64 Synthesis of D-myo-inositol-3,4,5,6-tetrakisphosphate (D-664) and L-myo-inositol-3,4,5,6-tetrakisphosphate (L-674).


partially protected conduritol B derivatives (**658a**) (87% yield) and (**658b**) (84% yield).

For the D-myo-inositol pathway, the free hydroxyl groups of (**658a**) were converted into PMB ethers using PMBCl and sodium hydride, yielding compound (**659**) almost quantitatively. Dihydroxylation of (**659**) with osmium tetroxide, NMO, and quinuclidine afforded partially protected myo-inositol (**660**) in 80% yield. Benzoylation of the free hydroxyls gave compound (**661**) (93% yield), and PMB deprotection with DDQ yielded tetraol (–)-**662** in 68% yield. Sequential phosphorylation using

(BnO)<sub>2</sub>PNET<sub>2</sub> and oxidation with *m*-CPBA produced (+)-**663** (78% yield), which upon palladium-catalyzed hydrogenolysis gave D-myo-inositol-3,4,5,6-tetrakisphosphate (D-**664**) in nearly quantitative yield.

For the L-myo-inositol pathway, diol (**658b**) was converted to benzoate (**665**) (72% yield) and reacted with Cl<sub>3</sub>CC(=NH)O-PMB to yield compound (**666**) (57% yield). Dihydroxylation of (**666**) produced diol (**667**) in 86% yield, which was protected as a THP ether (**668**) (72% yield). Hydrolysis of the benzoate gave diol (**669**) (75% yield), followed by benzoylation of the free



Scheme 65 Synthesis of conduritol F dimers (**677**, **680**) and muco-di-inositol (**684**).

hydroxyls to give (**670**) (71% yield). THP deprotection produced compound (**671**) quantitatively, and removal of PMB/OMB groups with DDQ yielded 1,2-*O*-dibenzyl-*D*-myo-inositol (+)-**672** in 72% yield. Sequential phosphorylation and oxidation afforded (–)-**673** in 92% yield, and final palladium-catalyzed hydrogenolysis yielded *L*-myo-inositol-3,4,5,6-tetrakisphosphate (**674**) in 94% yield (Scheme 64).

In 2004, Freeman *et al.* reported a synthetic route for conduritol F oligomers and muco-inositol oligomers.<sup>83</sup> The synthesis began with diol (**74**), which was converted into epoxide (**27**) via protection with 2,2-dimethoxypropane and acetone in the presence of *p*-TsOH, followed by epoxidation using *m*-CPBA in dichloromethane.

Treatment of epoxide (**27**) with a Lewis acid and either cinnamyl alcohol or benzyl alcohol produced compounds (**675a**) and (**675b**) in 73% and 75% yields, respectively. Coupling these intermediates with epoxide (**27**) under Lewis acid catalysis afforded ethers (**676a**) and (**676b**) in about 55% yield.

The conduritol F dimer (**677**) was obtained through sequential dehalogenation, deprotection of the cinnamyl group, and hydrolysis of ether (**676a**). In a related approach, epoxide (**27**) was hydrolyzed to diol (**678**), which coupled with epoxide (**27**) in the presence of a Lewis acid to form ether (**679**). Subsequent dehalogenation, deprotection, and hydrolysis yielded a second conduritol F dimer, (**680**).

Ether (**676b**) underwent electrochemical reduction to give compound (**681**) in approximately 77% yield. Treatment of (**681**) with oxone and trifluoroacetone in the presence of sodium bicarbonate in acetonitrile afforded epoxide (**682**) in about 40% yield. Hydrolysis of epoxide (**682**) using amberlyst A-27 resin

produced compound (**683**) in 61% yield. Finally, complete deprotection of all protecting groups furnished muco-di-inositol (**684**) with an excellent yield of 97% (Scheme 65).

In addition to oligomeric cyclitols, conduritol intermediates have also been employed as versatile precursors for the synthesis of diverse inositol phosphate derivatives with potential biological activity.


### 2.63. Synthesis of inositol phosphate derivatives from sugar-derived conduritol B

In 2004, Andresen *et al.* reported a synthetic approach for phosphatidylinositol derivatives with potential anti-tumor activity, starting from partially protected conduritol B.<sup>84</sup> The synthesis began with 6-iodo-6-deoxy- $\alpha$ -*D*-glucopyranoside (**685**), which underwent sequential benzylation of its hydroxyl groups. Sonication with zinc followed by reaction with vinyl magnesium bromide yielded a 1:5 mixture of dienes (**349**) and (**350**) in about 59% overall yield. Ring-closing metathesis (RCM) then afforded tribenzyl conduritol F (**351**) (14%) and tribenzyl conduritol B (**353**) (69%), with a combined yield of approximately 83%.

Oxidation of compound (**351**) with Dess-Martin periodinane followed by reduction with sodium borohydride and CeCl<sub>3</sub>·7H<sub>2</sub>O produced compound (**353**) in about 70% yield. Palladium-catalyzed hydrogenation of (**353**) yielded 1*D*-4,5,6-tri-*O*-benzyl-2,3-dideoxy-*myo*-inositol (**686**) nearly quantitatively. Epoxidation of (**353**) using *m*-CPBA generated partially protected conduritol B epoxide (**687**) in ~91% yield, which, upon







Scheme 67 Synthesis of 3,6-dimethoxy derivatives of conduritol A, conduritol C and conduritol D and solid phase preparation of 3,6-dimethoxy conduritol derivatives.

Beyond structural modification of the conduritol scaffold, considerable attention has also been devoted to the development of nitrogen-containing cyclitol derivatives, particularly aminoinositols, owing to their significant biological relevance.

### 2.65. Divergent syntheses of aminoinositol derivatives from conduritol B epoxide

In 2005, Serrano *et al.* developed a comprehensive strategy for accessing a diverse array of aminoinositol derivatives from tetra-*O*-benzylconduritol B epoxide (**388**).<sup>86</sup> Nucleophilic opening of epoxide (**388**) with sodium azide in the presence of LiClO<sub>4</sub> in acetonitrile afforded azido alcohol (**723**) in 91% yield. Subsequent benzylation of the free hydroxyl group furnished derivative (**724**) in 95% yield. Reduction of the azides in (**723**) and (**724**) with LiAlH<sub>4</sub> provided the tetrabenzyl and pentabenzyl *scyllo*-aminoinositol derivatives (**726**) and (**725**) in excellent yields (92–99%).

Mesylation of the free hydroxyl group in (**723**) with mesyl chloride and triethylamine generated mesylate (**727**) in 88–92% yield. Heating (**727**) in DMF promoted stereochemical inversion to give alcohol (**728**) in 82% yield, and reduction of its azide group with LiAlH<sub>4</sub> furnished the tetrabenzyl *myo*-aminoinositol derivative (**729**) in 87% yield. An alternative azidation route involved treating epoxide (**388**) with sodium azide and ammonium chloride in aqueous methanol, producing azide (**730**) in 91% yield; its mesylation provided mesylate (**731**) in 88–92% yield.

Mesyates (**727**) and (**731**) underwent intramolecular cyclization upon treatment with LiAlH<sub>4</sub> to generate tetra-*O*-

benzylconduritol B aziridine (**732**) in 90% yield. Nucleophilic ring opening of aziridine (**732**) with a mixture of sodium azide and ammonium azide (9 : 1 MeOH/H<sub>2</sub>O) afforded a 1 : 1 mixture of tetrabenzyl *chiro*-2-azido-1-aminoinositol (**733**) and *scyllo*-2-azido-1-aminoinositol (**734**) in 82% overall yield. Reduction of the azide group in (**730**) also gave amino alcohol (**735**) in 92–99% yield. Boc protection of (**735**) afforded (**736**) in 78% yield; mesylation produced (**737**) (84%), and heating in DMF led to a transient oxazolidine intermediate (**738**). Hydrolysis of this intermediate delivered the tetrabenzyl *myo*-inositol derivative (**739**) in 65% yield.


Overall, this unified sequence from epoxide (**388**) enabled efficient and stereochemically controlled access to *scyllo*-, *myo*-, and *chiro*-configured aminoinositol derivatives through judicious selection of nucleophiles, protecting groups, and azide/mesyate manipulations (Scheme 68a).

In continuation of their 2005 study, Serrano *et al.* expanded the synthetic utility of conduritol B epoxide-derived intermediates by accessing a diverse library of *N*-acylated and diamino inositol derivatives.<sup>86</sup>

**2.65.1. *N*-Octanoyl aminoinositols.** The free amine functionalities in compounds (**725**), (**729**), (**735**), and (**739**) were acylated using octanoyl chloride (C<sub>7</sub>H<sub>15</sub>COCl) in the presence of triethylamine, furnishing the corresponding *N*-octanoylamides (**740**), (**742**), (**744**), and (**746**) in 78–90% yield. Subsequent hydrogenolysis of the benzyl protecting groups delivered the 1-*N*-octanoylamino derivatives of *scyllo*-inositol (**741**), *myo*-inositol (**743**), *chiro*-inositol (**745**), and *myo*-inositol (**747**) in good yields (65–83%).







Scheme 69 Synthesis of (-)-conduramine B-1 (-)-772 using reductive and Mitsunobu transformations.

### 2.67. Synthesis of a conduramine D-2 based bicyclic framework

In 2006, Kelebekli *et al.* reported a synthetic route to a bicyclic aminocyclitol derivative with a conduramine D-2 configuration.<sup>88</sup> The synthesis began with cyclooctatetraene (**190**), which was treated with  $\text{Hg}(\text{OAc})_2$  to give diene (**773**) in approximately 84% yield. This diene underwent photooxygenation with singlet oxygen in the presence of tetraphenylporphyrin, producing *endo*-peroxide (**774**) in around 70% yield. Such photooxygenation reactions provide an efficient strategy for introducing oxygen functionality into cyclic polyene systems.

Reductive cleavage of the *endo*-peroxide using thiourea in methanol furnished diol (**775**) with nearly quantitative yield (~99%). The diol was then converted into bis-carbamate (**776**) *via* reaction with two equivalents of toluenesulfonyl isocyanate. Cyclization using triisopropylphosphine in the presence of  $(\text{dba})\text{Pd}_2\text{CHCl}_3$  yielded oxazolidinone (**777**) in about 48% yield.

Subsequent dihydroxylation of (**777**) with  $\text{KMnO}_4$  in acetone/THF afforded *syn*-diol (**778**) in roughly 84% yield. Acetylation of the free hydroxyls using sodium acetate and acetic anhydride


produced compound (**779**) in approximately 30% yield. Finally, acidic hydrolysis of (**779**) yielded the target aminocyclitol (**780**) with close to 84% yield (Scheme 70).

Alongside efforts directed toward bicyclic aminocyclitol frameworks, related studies have also focused on the stereocontrolled synthesis of conduramine derivatives from bicyclic precursors.

### 2.68. Stereocontrolled synthesis of ( $\pm$ )-conduramine F-1 from a bicyclic enone precursor


In 2006, Lysek *et al.* reported an efficient route to ( $\pm$ )-conduramine F-1.<sup>89</sup> The synthesis commenced with ( $\pm$ )-7-oxabicyclo[2.2.1]hept-5-en-2-one ( $\pm$ )-**781**, which was converted to enone ( $\pm$ )-**766**. Reduction of this enone with diisobutylaluminium hydride furnished a 1:5.1 mixture of alcohols ( $\pm$ )-**767** and ( $\pm$ )-**768** in an excellent combined yield of approximately 98%. DIBAL-H enables selective reduction of the conjugated carbonyl functionality while preserving the bicyclic framework.

A Mitsunobu reaction on this mixture using phthalimide, triphenylphosphine, and DEAD generated a 1:2.5 mixture of *N*-



Scheme 70 Synthesis of bicyclic aminocyclitol derivative.





Scheme 71 Synthesis of (±)-conduramine F-1 (±)-183 from a bicyclic enone precursor.

phthalimido derivatives (±)-769 and (±)-770 in 53% overall yield, and these were separated by chromatographic purification.

Hydrazinolysis of compound (±)-770 produced amine (±)-782 in 56% yield; however, direct desilylation at this stage resulted in impure (±)-conduramine F-1. In contrast, mild acid-mediated deprotection of (±)-770 using 1% *p*-toluenesulfonic acid in methanol afforded triol (±)-783 in 93% yield. Subsequent aminolysis with 40% aqueous methylamine efficiently delivered (±)-conduramine F-1 (±)-183 in 91% yield, corresponding to an overall yield of 85% from (±)-770 (Scheme 71).

In addition to purely synthetic strategies from bicyclic intermediates, chemoenzymatic approaches have also been developed for the preparation of conduramine derivatives.


### 2.69. Chemoenzymatic route to (–)-conduramine C-4 from bromobenzene

In 2007, Bellomo *et al.* reported an enantioselective synthesis of (–)-conduramine C-4 (–)-244 starting from bromobenzene

(308).<sup>90</sup> Enzymatic dihydroxylation of bromobenzene using *Pseudomonas putida* F39/D furnished bromo-cyclohexadienediol (74), which was subsequently protected as its acetonide (24) using 2,2-dimethoxypropane and *p*-toluenesulfonic acid in ~85% yield.


Oxidation of acetonide 24 with *N*-bromosuccinimide in aqueous THF generated a mixture of bromohydrins (309) and (784). Cyclization of this mixture under basic conditions (NH<sub>4</sub>-BuHSO<sub>4</sub>) provided epoxides (310) and (27) in a 7 : 1 ratio and an overall yield of ~50%; the two epoxides were separated chromatographically.

The major epoxide (310) underwent nucleophilic ring opening with sodium azide to give azido alcohol (785) in nearly quantitative yield (~98%). Staudinger reduction of the azide furnished the corresponding amine (786) in 74% yield. Radical debromination of (786) using Bu<sub>3</sub>SnH and ABCC afforded compound (787) in ~75% yield. An alternative approach from



Scheme 72 Synthesis of (–)-conduramine C-4 (–)-244 from bromobenzene.





Scheme 73 Synthesis of (±)-conduramine B-1 (±)-772 and (±)-conduramine F-1 epoxides (±)-793 and (±)-794.

azido alcohol (785) *via* LiAlH<sub>4</sub> reduction also yielded (787), though with significantly lower efficiency (31%).

Final deprotection of the acetonide group in (787) using amberlite resin catalysis provided (–)-conduramine C-4 (–)-244 in nearly quantitative yield (Scheme 72).

Beyond chemoenzymatic approaches, alternative synthetic routes have also been developed for accessing conduramine derivatives and their epoxide analogues through azidoconduritol intermediates.

## 2.70. Synthesis of conduramine B-1 and conduramine F-1 epoxides *via* azidoconduritol intermediates

In 2007, Lysek *et al.* described the synthesis of conduramine F-1 epoxides starting from compound (±)-781.<sup>91</sup> Reduction of this starting material produced a 1 : 5.1 mixture of alcohols (±)-767 and (±)-768. Treatment of this mixture with DPPA (diphenylphosphoryl azide) and DEAD in toluene yielded a 1 : 2.5 mixture of azides (±)-788 and (±)-789, with an overall yield of about 67%.

Deprotection of the silyl ethers in azide (±)-789 afforded azidoconduritol F-1 (±)-790 in 84% yield. Subsequent


epoxidation using *m*-CPBA produced a mixture of epoxides (±)-791 (35%) and (±)-792 (16%). Palladium-catalyzed hydrogenation of these epoxides generated conduramine F-1 epoxides (±)-793 and (±)-794 in approximately 50% yield.

Reduction of azidoconduritol F-1 (±)-790 with triphenylphosphine followed by workup furnished conduramine F-1 (±)-183 in 78% yield. Similarly, deprotection of silyl ethers in (±)-788 gave azidoconduritol B-1 (±)-600 in 77% yield, which was reduced to conduramine B-1 (±)-772 in 73% yield.

Protection of the hydroxyl groups in epoxides (±)-791 and (±)-792 as silyl ethers yielded (±)-795 and (±)-796, both in 98% yield. Subsequent palladium-catalyzed reduction of the azides produced amines (±)-797 and (±)-798 in 81% and 74% yield, respectively. Finally, deprotection of the silyl ethers of these amines afforded conduramine F-1 epoxides (±)-793 and (±)-794 in 95% and 85% yields, respectively (Scheme 73).

Beyond the preparation of conduramine derivatives and their epoxide analogues, conduritol-derived intermediates have also been employed in the total synthesis of biologically important natural products.





Scheme 74 Convergent synthesis of (–)-narciclasine (–)-16 via Suzuki–Miyaura coupling of a conduritol-derived bromoconduramine and an aryl boronate.

### 2.71. Synthesis of (–)-narciclasine using conduritol-derived bromoconduramine and aryl boronate partners

In 2008, Matveenko *et al.* reported a convergent strategy for the total synthesis of (–)-narciclasine (–)-16, beginning from compound (799).<sup>13</sup> Nucleophilic substitution of (799) with sodium cyanide in the presence of manganese dioxide and diethylamine furnished diethylamide (800) in 58% yield. Directed metallation of (800) with *sec*-BuLi/TMEDA, followed by trapping with trimethyl borate and oxidative workup (H<sub>2</sub>O<sub>2</sub>/AcOH), afforded alcohol (801) in 90% yield. Protection of the hydroxyl group with TBSCl provided silyl ether (802) in 94% yield. Subsequent lithiation–iodination converted (802) into iodide (803) in 90% yield. Deprotection of the TBS ether furnished alcohol (804) in 62% yield, which was transformed into the corresponding MOM ether (805) in 99% yield. A Miyaura borylation step then delivered boronate (806), albeit in a modest 44% yield.

In a parallel sequence, *cis*-diol (74) was converted into acetal (807) using *p*-MBDMA and *p*-TsOH. Dihydroxylation of (807)


with OsO<sub>4</sub>/NMO gave diol (808) in 65% yield, which was fully protected as the MOM ether (809) in 75% yield. Reduction of (809) with DIBAL-H furnished bromoconduritol E derivative (810) in 84% yield. Conversion of the remaining free hydroxyl into a MOM ether gave (811) in 90% yield, and DDQ oxidation removed the PMB group to afford alcohol (812) in 95% yield. Formation of acetimidate (813) using trichloroacetonitrile/DBU, followed by microwave-assisted cyclization with K<sub>2</sub>CO<sub>3</sub>, generated amide (814) in 78% yield. DIBAL-H reduction of (814) provided bromoconduramine A (815) in 89% yield.

The key Suzuki–Miyaura cross-coupling between boronate (806) and bromoconduramine A (815) under microwave irradiation afforded biaryl intermediate (816) in 63% yield. Global deprotection of (816) then delivered the target natural product (–)-narciclasine (–)-16 in 48% yield (Scheme 74).

In addition to their application in natural product synthesis, conduritol-derived intermediates have also been employed for the stereocontrolled preparation of diverse conduramine analogues.







Scheme 76 Synthesis of tetraacetate derivatives of conduramine A-1, conduramine E.

Complementary to metathesis-based approaches, cycloaddition strategies have also been explored for the construction of aminocyclitol frameworks.

#### 2.74. Copper-catalyzed nitroso-Diels–Alder strategy for the synthesis of conduramine A-1 tetraacetate

In 2009, Jana *et al.* reported a synthesis of conduramine A-1 tetraacetate (**22**).<sup>94</sup> The process began with a nitroso-Diels–Alder reaction between compound (**56**) and 2-nitrosopyridine (**837**) using  $[\text{CuPF}_6(\text{MeCN})_4]$  and the Walphos- $\text{CF}_3$  ligand, yielding adduct (**838**) in nearly 99% yield. Reductive cleavage of the N–O bond with sodium borohydride in the presence of  $[\text{Mo}(\text{CO})_6]$ , followed by silyl protection of the hydroxyl group with TBSCl and imidazole, produced compound (**839**) in about 91% yield.

Subsequent reaction of (**839**) with methyl chloroformate and methyl magnesium chloride afforded compound (**840**) in approximately 96% yield. Deprotection of the pyridyl group and TBS ether yielded compound (**841**) with around 82% yield. Final cleavage of all protecting groups followed by acetylation furnished conduramine A-1 tetraacetate (**22**) in roughly 57% yield (Scheme 77).


In addition to cycloaddition-based approaches, chemoenzymatic strategies combined with selenium-mediated transformations have also been explored for the preparation of functionalized conduritol derivatives.

#### 2.75. Synthesis of deoxy-selenylconduritols and a partially protected conduritol C derivative


In 2009, Bellomo *et al.* developed a concise synthetic strategy for accessing deoxy-selenylconduritols and a partially protected conduritol C derivative.<sup>95</sup> The sequence commenced with the enzymatic dihydroxylation of bromobenzene (**308**) using *Pseudomonas putida* F39/D, affording *cis*-diol (**74**). Protection of the diol as its isopropylidene acetal proceeded in nearly quantitative yield ( $\sim 98\%$ ), and subsequent epoxidation with *m*-CPBA furnished epoxide (**27**) in 85% yield.

Radical debromination of epoxide (**27**) provided bromine-free intermediate (**164**) in  $\sim 70\%$  yield. Nucleophilic ring opening of (**164**) with diphenyl diselenide (DPDS) in the presence of  $\text{NaBH}_4$  afforded the selenylated intermediate (**842**) in  $\sim 72\%$  yield. Acidic resin-catalyzed hydrolysis of the acetonide protecting group in (**842**) gave 6-phenylselenylconduritol F derivatives (**843**) in 77% yield.





Scheme 77 Synthesis of conduramine A-1 tetraacetate (22) using copper-catalyzed nitroso-Diels–Alder strategy.



Scheme 78 Preparation of deoxy-selenylconduritol and conduritol C derivatives.

In an alternative transformation, compound (**842**) was subjected to oxidative rearrangement using  $\text{RuCl}_3\text{-NaIO}_4$ , generating partially protected conduritol C derivative (**844**) in  $\approx 30\%$  yield—an intermediate of utility for downstream syntheses of conduritol C. Moreover, direct treatment of epoxide (**27**) with DPDS/ $\text{NaBH}_4$  led to regioselective ring opening to give compound (**845**) in  $\approx 89\%$  yield, and deprotection of its acetonide group under acidic conditions delivered 4-bromo-6-phenylselenylconduritol F derivatives (**846**) in  $\approx 70\%$  yield (Scheme 78).

Halogenated conduritol derivatives have also attracted considerable interest because they serve as useful intermediates for further functionalization and biological investigations.

## 2.76. Divergent strategies for the synthesis of bromo-conduritol B and C

In 2009, Cantekin *et al.* reported efficient synthetic routes to both bromo-conduritol B and bromo-conduritol C.<sup>96</sup>

**2.76.1. Synthesis of bromo-conduritol B.** Hydroquinone (**847**) was brominated in ether to afford bromohydroquinone (**848**) in 87% yield. Oxidation of (**848**) with ceric ammonium nitrate (CAN) in acetonitrile furnished bromoquinone (**849**) in 85% yield, which upon further bromination in dichloromethane gave *anti*-dibromide (**850**) in 94% yield. Reduction of (**850**) with  $\text{NaBH}_4$  produced diol (**851**) in 82% yield, and

subsequent acetylation yielded diacetate (**852**) in 80% yield. Refluxing (**852**) with silver acetate in  $\text{AcOH}/\text{Ac}_2\text{O}$  delivered tetraacetate (**853**) in 74% yield. Final deacetylation with ammonia in methanol provided bromo-conduritol B (**854**) in 95% yield.


**2.76.2. Synthesis of bromo-conduritol C.** Photooxygenation of cyclohexadiene acetonide (**56**) with singlet oxygen in the presence of tetraphenylporphyrin gave *endo*-peroxide (**163**) in 95% yield. Bromination of (**163**) furnished dibromide (**855**) in 87% yield. Treatment of (**855**) with DMSO generated intermediate (**856**) in nearly quantitative yield, which underwent elimination to produce bromoenone (**857**). Reduction of (**857**) with  $\text{NaBH}_4$  provided a mixture of diols (**858**) and (**859**), which were acetylated to give diacetates (**860**) and (**861**) in 60% and 13% yield, respectively. Deacetylation of tetraacetate (**860**) subsequently afforded bromo-conduritol C (**862**) in 97% yield (Scheme 79).

Beyond halogenated conduritol derivatives, selective dihydroxylation strategies have also been explored for constructing key intermediates in conduramine synthesis.

## 2.77. Construction of a conduramine E precursor via selective dihydroxylation

In 2010, Chappell *et al.* developed an efficient route to a key precursor of conduramine E.<sup>97</sup> Initial bromination of






Scheme 79 Synthesis of bromo-conduritol B and bromo-conduritol C via photooxygenation and subsequent functional group transformations.

compound (**863**) using polymer-supported bromine ( $\text{Br}_3^-$ ) afforded intermediate (**864**). Sequential treatment of (**864**) with methanolic HCl and then triphosgene in the presence of pyridine generated urethane (**865**) in an overall 86% yield from (**863**).

Elimination of urethane (**865**) with DBU provided diene (**866**) in 90% yield. Dihydroxylation of (**866**) furnished diols (**867**) and (**868**). Use of AD-mix- $\beta$  in the presence of  $\text{MeSO}_2\text{NH}_2$  enabled

highly selective formation of diol (**867**) as the sole product (100 : 0 ratio) in 76% overall yield, whereas dihydroxylation with  $\text{K}_2\text{OsO}_4 \cdot 2\text{H}_2\text{O}$  delivered a 4 : 1 mixture of (**867**) and (**868**) in 55% yield.

Finally, refluxing diol (**867**) in trifluoroacetic acid provided compound (**869**) in 76% yield. This intermediate serves as a valuable building block for the synthesis of (–)-conduramine E (Scheme 80).



Scheme 80 Synthesis of precursor of conduramine E.





While chiral auxiliary-based approaches enable efficient access to several conduramine derivatives, carbohydrate-derived strategies have also been explored for the stereo-divergent synthesis of conduramine intermediates.

### 2.79. Divergent syntheses of precursors to (+)- and (-)-conduramine E

In 2012, Ghosal *et al.* reported stereodivergent strategies for preparing key intermediates en route to both enantiomers of conduramine E.<sup>99</sup>

**2.79.1. Precursor to (+)-conduramine E.** D-Galactose (D-887) was transformed into diacetone (888) in approximately 80% yield upon treatment with iodine in acetone. Conversion of (888) to iodide (889) using iodine and triphenylphosphine proceeded in 86% yield. Reductive deiodination of (889) with zinc dust, ammonium chloride, and vitamin B<sub>12</sub> afforded compound (890) in about 90% yield. Subsequent coupling of (890) with *trans*-2-phenylvinyl boronic acid in the presence of *tert*-butylamine generated compound (891), which after Boc protection furnished diene (892) in an overall yield of approximately 87% over the two steps. Ring-closing metathesis (RCM) using Grubbs' second-generation catalyst delivered cyclohexadiene derivative (893) in 51% yield. Final acetonide deprotection afforded diol (867) in 85% yield, a pivotal intermediate for the synthesis of (+)-conduramine E (+)-221.

**2.79.2. Precursor to (-)-conduramine E.** Beginning from D-mannose (D-894), diacetone (895) was obtained in ~80% yield. Wittig methylenation of (895) furnished alkene (896) in


approximately 85% yield. Protection of the free hydroxyl group with TBDPSCI yielded silyl ether (897) (87%), which upon treatment with 80% aqueous acetic acid generated diol (898) in 75% yield. Oxidative cleavage of (898) with NaIO<sub>4</sub> afforded aldehyde (899). Subsequent desilylation followed by coupling with *trans*-2-phenylvinyl boronic acid and *tert*-butylamine (*via* intermediate (900)) produced compound (901). Boc protection of (901) delivered diene (902) in an overall 21% yield from (898). RCM of (902) furnished cyclohexadiene derivative (903) in 48% yield. Final acetonide deprotection produced diol (868) in 91% yield, serving as the key intermediate for the synthesis of (-)-conduramine E (-)-221 (Scheme 82).

In addition to carbohydrate-derived metathesis strategies, alternative approaches employing boronate intermediates have also been developed for the synthesis of conduramine derivatives.

### 2.80. Divergent access to conduramine A-1 and C-4 using boronate intermediates


In 2012, Norsikian *et al.* reported efficient synthetic routes to conduramine A-1 (177) and conduramine C-4 (244), employing D-ribose derivatives as versatile chiral building blocks.<sup>100</sup>

**2.80.1. Synthesis of conduramine A-1 (177).** The sequence commenced with 2,3-*O*-isopropylidene-5-*O*-trityl-D-ribofuranose (904), which underwent a Demajoli olefination with dimethyl(1-diazo-2-oxopropyl)phosphonate (905) to afford alkyne (906) in ~87% yield. Protection of the free hydroxyl group as a silyl ether followed by trityl deprotection furnished intermediate (907) in



Scheme 82 Synthesis of precursors of both enantiomers of conduramine E (221).





Scheme 83 Synthesis of conduramine A-1 (177), conduramine C-4 (244).

~81% yield. Oxidation with Dess–Martin periodinane, followed by acetalization using trimethyl orthoformate and catalytic  $\text{H}_2\text{SO}_4$ , afforded acetal (909) in ~73% yield.

Bromination of (909) using NBS/AgNO<sub>3</sub>/AcOH produced bromide (910) (69%), while an alternative halogenation using NIS or HInCl<sub>2</sub>/Et<sub>3</sub>B/I<sub>2</sub> delivered iodide (911) in significantly higher yield (~95%). Cross-coupling of bromide (910) with bis(pinacolato)diboron under PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>/PPh<sub>3</sub> catalysis afforded a 3:7 mixture of *E/Z* boronic esters (912) in ~66% combined yield. Alternatively, borylation of iodide (911) *via* *t*-BuLi, trimethyl borate, and pinacol provided (912) in ~79% yield.

Oxidative cleavage of (912) with sodium metaperiodate generated aldehyde (913) (73%), which upon treatment with 6 N HCl afforded a mixture of hemiacetals (914a) and (914b). Cyclization with diallylamine (All)<sub>2</sub>NH yielded aminal (915), and final deallylation using Pd(PPh<sub>3</sub>)<sub>4</sub>/NDMBA furnished conduramine A-1 (177) in ~70% yield.

**2.80.2. Synthesis of conduramine C-4 (244).** Conduramine C-4 was accessed from 2,3-*O*-isopropylidene-β-D-ribofuranoside (916). Reaction with PPh<sub>3</sub> and CBr<sub>4</sub> generated bromide (917) in ~80% yield. Radical-mediated hydrogenolysis using Bu<sub>3</sub>SnH under Pd catalysis afforded a mixture of alkenes (*Z*-918) and (*E*-918) in an 89:11 ratio, with a combined yield of ~73%.

The major *Z*-isomer (*Z*-918) was treated sequentially with *t*-BuLi, trimethyl borate, pinacol, and sodium metaperiodate to

produce aldehyde (919) in approximately 70% yield. Cyclization of (919) in the presence of TFA and (All)<sub>2</sub>NH furnished aminal (920), which was finally converted into conduramine C-4 (244) through Pd(PPh<sub>3</sub>)<sub>4</sub>-catalyzed deallylation using NDMBA, delivering the target structure in ~78% yield (Scheme 83).


Beyond boronate-based approaches, alternative strategies involving diazide and diene intermediates have also been explored for the synthesis of diamino conduritol derivatives.

### 2.81. Construction of 2,3-diamino conduritol F *via* diazide and diene intermediates

In 2012, Ekmekci *et al.* reported a concise synthetic route to 2,3-diamino conduritol F (932), beginning from a simple anhydride precursor.<sup>101</sup> Initial methanolysis of the anhydride in the presence of HCl generated diester (921), which upon heating with hydrazine in methanol afforded hydrazide derivative (922) in ~59% yield. Conversion of (922) to diazide (923) was achieved *via* NaNO<sub>2</sub>/HCl treatment, delivering the desired intermediate in ~77% yield. Refluxing diazide (923) in benzene promoted rearrangement to diisocyanide (924), which upon heating with methanol furnished compound (925). Subsequent bromination of (925) using Br<sub>2</sub> in dichloromethane gave *anti*-dibromide (926) in ~87% yield.

Base-induced elimination of (926) using DBU provided diene (927) in ~34% yield. Photooxygenation of (927) under tetraphenylporphyrin sensitization afforded *endo*-peroxide (928) in





Scheme 84 Synthesis of 2,3-diamino conduritol F (932).

~82% yield. Reductive cleavage of the peroxide with thiourea generated diol (929), which was acetylated to yield diacetate (931) in ~63% yield. Final deacetylation of (931) using NaOH in methanol furnished 2,3-diamino conduritol F (932) in ~42% yield (Scheme 84).

Beyond diamino derivatives, conduritol frameworks have also been functionalized with heteroaromatic substituents to generate structurally diverse analogues with potential biological relevance.

### 2.82. Synthesis of *mono*- and *bis*-indole conduritol derivatives

In 2012, Çavdar *et al.* reported the synthesis of *mono*- and *bis*-indole conduritol derivatives.<sup>16</sup> The procedure began with *p*-benzoquinone (9), which was brominated (~70% yield), reduced with NaBH<sub>4</sub> (~84% yield), and subsequently acetylated (~75% yield) to give diacetate (368). Treatment of diacetate (368) with KOH induced acetate hydrolysis and an intramolecular substitution, producing *anti*-bisepoxide (370) in ~77% yield.

Reaction of *anti*-bisepoxide (370) with indoline, followed by acetylation, afforded compound (934) in ~72% yield. Oxidation of (934) with MnO<sub>2</sub> yielded the *mono*-indole conduritol B diacetate (935) in ~85% yield. Alternatively, reaction of *anti*-bisepoxide (370) with indoline in dichloromethane produced the *bis*-indolidine conduritol B (936) in ~80% yield. Subsequent


acetylation and MnO<sub>2</sub> oxidation of (936) furnished the *bis*-indole conduritol B diacetate (937) with an approximate yield of 74% (Scheme 85).

In addition to heteroaromatic functionalization of conduritol scaffolds, carbohydrate-derived strategies have also been developed for constructing conduramine frameworks.

### 2.83. Synthesis of conduramine C and D frameworks from ribofuranose


In 2013, Rajender *et al.* reported the synthesis of conduramine C and D derivatives.<sup>102</sup> The sequence began with ribofuranose (938), which was reacted with vinyl magnesium bromide to yield compound (939) in ~75% yield. Oxidation with NaIO<sub>4</sub> produced lactol (940) in ~80% yield. Treatment of (940) with benzylamine, followed by vinyl magnesium bromide, gave diene (941) in ~75% yield over the two steps. Protection of the amine in (941) using CbzCl and NaHCO<sub>3</sub> afforded diene (942) in ~90% yield.

Diene (942) underwent ring-closing metathesis (RCM) with Grubbs' 2nd-generation catalyst to yield cyclohexene (943) in ~80% yield. Subsequent treatment with sodium in liquid ammonia, followed by Boc protection, produced compound (944) in ~78% yield over two steps. Compound (944) was then converted into the protected conduramine C-1 derivative (945) *via* a Mitsunobu reaction with tetraphenylporphyrin, DEAD,




Scheme 85 Synthesis of mono and bis-indole conduritol derivatives.





Scheme 86 Synthesis of protected conduramine C-1 (945) and conduramine D-1 (284).



compound	R	compound	R	compound	R
166a		166g		166k	
166b		166h		166l	
166c		166i		166m	
166d		166j		166n	
166e					
166f					

Scheme 87 Synthesis of *N*-substituted (+)-conduramine F-4 (166a-n).

and *p*-nitrobenzoic acid, followed by hydrolysis, achieving ~80% yield over two steps.

In a parallel pathway, deprotection of the acetonide and Boc groups in (**944**) using trifluoroacetic acid, followed by acetylation, yielded conduramine D-1 tetraacetate (**284**) in ~90% yield over two steps. Both (**945**) and (**284**) serve as intermediates for the synthesis of conduramines and their derivatives (Scheme 86).

Beyond carbohydrate-derived approaches, alternative strategies have also been explored to prepare functionalized conduramine derivatives through epoxide intermediates.

#### 2.84. Construction of *N*-substituted conduramine F-4 analogues

In 2014, Kuno *et al.* reported the synthesis of *N*-substituted (+)-conduramine F-4 derivatives.<sup>103</sup> The sequence began with the protection of the hydroxyl groups of (+)-*proto*-quercitol (**946**) using 2,2-dimethoxypropane and *p*-TsOH, yielding compound (**947**) in ~90% yield. The remaining free hydroxyl group in (**947**) was then protected with MsCl in the presence of triethylamine, producing compound (**948**) in ~97% yield.

Treatment of (**948**) with DBU in toluene induced elimination, forming the cyclohexene derivative (**949**) in ~76% yield. Subsequent methanolysis with PPTS gave the *anti*-diol (**950**) in ~91% yield. Conversion of (**950**) into epoxide (**164**) using Martin sulfuran proceeded with ~69% yield. Finally, the epoxide (**164**) underwent ring opening with a primary amine (RNH<sub>2</sub>) in acetonitrile, followed by acetonide deprotection, furnishing the *N*-substituted (+)-conduramine F-4 derivatives (**166a-n**) in yields ranging from 64% to 100% (Scheme 87).

In addition to the synthesis of diversified *N*-substituted conduramine derivatives, stereodefined conduramine F-4 has also been prepared through ring-closing metathesis strategies.

#### 2.85. Synthesis of (–)-conduramine F-4 via RCM strategy

In 2016, Harit *et al.* reported a synthetic route to (–)-conduramine F-4 (–)-**166**.<sup>104</sup> The sequence began with the oxidation of diol (**951**) using DMSO and oxalyl chloride to form the corresponding aldehydes, yielding intermediate (**952**). This

intermediate was then subjected to a Wittig reaction, producing diene (**953**) with an overall yield of ~60% from (**951**).

Heating diene (**953**) in the presence of Grubbs' 2nd generation catalyst effected a ring-closing metathesis (RCM), furnishing cyclohexene derivative (**954**) in ~70% yield. Treatment of (**954**) with sodium amalgam yielded compound (**955**) in ~74% yield. Subsequent acetylation produced compound (**956**) in ~80% yield, and final deprotection of all protecting groups afforded (–)-conduramine F-4 (–)-**166** in ~52% yield (Scheme 88).

In addition to metathesis-based approaches starting from carbohydrate derivatives, amino acid-derived building blocks have also been employed for the synthesis of conduramine frameworks.


#### 2.86. Synthesis of (–)-conduramine A-1 from a *D*-serine-derived intermediate

In 2016, Myeong *et al.* reported an efficient synthetic route to (–)-conduramine A-1 (–)-**177**.<sup>105</sup> The sequence commenced with compound (**957**), derived from *D*-serine, which underwent ozonolysis followed by nucleophilic addition of vinyl magnesium bromide to furnish a mixture of adducts (**958**) and (**959**). The ratio of these products was influenced by the choice of Lewis acid, solvent, and reaction temperature.

Acetylation of the major isomer (**959**) provided acetate (**960**) in ~96% yield. Subsequent treatment with CbzCl and sodium bicarbonate generated the carbamate (**961**) in ~90% yield. Regioselective cleavage of the silyl ether in (**961**) using hydrofluoric acid afforded alcohol (**962**) in ~78% yield. Oxidation of (**962**) followed by a Wittig olefination delivered diene (**963**) in an overall yield of ~56%.


Exposure of diene (**963**) to Grubbs' 2nd generation catalyst induced a ring-closing metathesis (RCM), producing the cyclized intermediate (**964**) in ~62% yield. Final global deprotection under 6 M HCl furnished (–)-conduramine A-1 (–)-**177** in ~78% yield (Scheme 89).

Beyond the synthesis of simple conduramine frameworks, related strategies have also been employed to access *N*-substituted conduramine derivatives.



Scheme 88 Synthesis of (–)-conduramine F-4 (–)-**166**.





Scheme 89 Synthesis of (-)-conduramine A-1 (-)-177.

### 2.87. Synthesis of *N*-benzyl conduramine E-1 and F-1 via RCM


In 2017, Katakam *et al.* reported a stereodivergent strategy for the synthesis of *N*-benzyl conduramine E-1 and *N*-benzyl conduramine F-1.<sup>106</sup> The sequence commenced with NaIO<sub>4</sub>-mediated oxidative cleavage of compound (965), derived from *D*-mannitol, to afford aldehyde (966). Nucleophilic addition of vinyl magnesium bromide furnished a 1:1.3 mixture of diastereomers (967) and (968) in an overall yield of ~76% across two steps.



For the synthesis of *N*-benzyl conduramine F-1, selective deprotection of the primary acetone in (967), followed by oxidative cleavage with periodic acid, generated aldehyde (969). Condensation with benzylamine gave imine (970), which upon vinylmagnesium bromide addition furnished diene (971) in ~72% yield over three steps. Boc protection of (971) yielded

diene (972) in ~82% yield. Subsequent ring-closing metathesis (RCM) with Grubbs' 2nd generation catalyst produced cyclohexene derivative (973) in ~79% yield. Final deprotection of the acetone moiety using 6 N HCl afforded *N*-benzyl conduramine F-1 (974) in ~74% yield.

In the parallel pathway, intermediate (975) was obtained from compound (968) in ~70% yield across three steps. Boc protection furnished diene (976) in ~82% yield, which underwent RCM to generate cyclohexene derivative (977) in ~70% yield. Acetone cleavage under acidic conditions ultimately provided *N*-benzyl conduramine E-1 (978) in ~73% yield (Scheme 90).

Beyond RCM-based strategies employing carbohydrate-derived precursors, alternative approaches incorporating chiral auxiliaries and sulfinimine chemistry have also been explored for the synthesis of conduramine frameworks.

Scheme 90 Synthesis of *N*-benzyl conduramine E-1 (978) and *N*-benzyl conduramine F-1 (974).

Scheme 91 Synthesis of conduramine F-1 (**183**).Scheme 92 Synthesis of conduramine B-2 (**996**) and conduramine F-2 (**998**).

## 2.88. Synthesis of conduramine F-1 via sulfinimine addition and RCM

In 2018, Prasad *et al.* reported an efficient synthetic route to conduramine F-1 (**183**).<sup>107</sup> The sequence commenced with bis-Weinreb amide (**970**), derived from tartaric acid, which underwent nucleophilic addition of vinylmagnesium bromide to furnish the  $\alpha,\beta$ -unsaturated ketone (**980**) in ~74% yield. Luche reduction of (**980**) provided allylic alcohol (**981**) in ~88% yield, and subsequent protection of this alcohol as its TBDMS ether using TBDMSCl/imidazole afforded compound (**982**) in ~89% yield.

Reduction of (**982**) with DIBAL-H generated the corresponding aldehyde, which was transformed into sulfinimine (**983**) using (*S*)-*tert*-butanesulfinamide in the presence of  $\text{Ti}(\text{OEt})_4$  (~72% yield). Addition of vinylmagnesium bromide to sulfinimine (**983**) yielded sulfinamide (**984**) in ~89% yield. Deprotection of the silyl ether using TBAF provided diene (**985**) in ~94% yield.


Ring-closing metathesis (RCM) of (**985**) using Grubbs' 2nd generation catalyst delivered the cyclized intermediate (**986**) in ~86% yield. Final global deprotection furnished conduramine F-1 (**183**) in ~60% yield (Scheme 91).

Related strategies combining vinyl addition reactions with ring-closing metathesis have also been applied to the synthesis of other conduramine derivatives.

## 2.89. Synthesis of conduramine B-2 and F-2 via vinyl addition-RCM strategy

In 2019, Harit *et al.* described an efficient synthetic strategy for accessing conduramine B-2 (**996**) and conduramine F-2 (**998**) from a carbohydrate-derived precursor.<sup>108</sup> The sequence began with the reduction of 2-iodo-2-deoxy-1-sulfonamido- $\alpha$ -D-glucose (**987**) using sodium borohydride to yield compound (**988**) in ~95% yield. Acetylation of (**988**) in a  $\text{ZnCl}_2$ -catalyzed mixture of acetic anhydride and acetic acid (5 : 1) afforded acetate (**989**) in ~91% yield, which upon hydrolysis delivered alcohol (**990**) in ~93% yield.





Scheme 93 Synthesis of (-)-conduramine A-1 (-)-177, (-)-conduramine A-2 (-)-1012, and (-)-conduramine E-2 (-)-1013.


Conversion of alcohol (990) to iodide (991) using iodine, triphenylphosphine, and imidazole proceeded in ~92% yield. Sonochemical treatment of (991) with zinc induced dehydroiodination, furnishing alkene (992), which underwent nucleophilic addition of vinylmagnesium bromide to afford a mixture of dienes (993) and (994) in ~61% and 25% yields, respectively.

Ring-closing metathesis (RCM) of dienes (993) and (994) using Grubbs' 1st generation catalyst furnished the corresponding cyclohexene derivatives (995) and (997) in ~78% and 79% yields. Global deprotection of (995) and (997) provided conduramine B-2 (996) and conduramine F-2 (998) in ~76% and 77% yields, respectively (Scheme 92).

Alternative strategies based on stereoselective epoxide functionalization have also been explored for the synthesis of conduramine analogues.

## 2.90. Stereoselective construction of (-)-conduramine A and E analogues

In 2019, Pinto *et al.* reported an enantioselective strategy for synthesizing (-)-conduramine A-1 (-)-177, (-)-conduramine A-2 (-)-1012, and (-)-conduramine E-2 (-)-1013.<sup>109</sup> The sequence began with the epoxidation of cyclohexa-1,4-diene (999) using peracetic acid to afford epoxide (1000), which upon bromination in dichloromethane furnished anti-dibromide (1001) in ~88% yield. Base-induced elimination of (1001) with DBU in diethyl ether yielded alkene (1002), which underwent regio- and stereoselective epoxide opening upon treatment with enantiopure (*R*)- $\alpha$ -methyl-*p*-methoxybenzylamine (1003). This produced a separable mixture of amines (1004) and (1005), isolated in



Scheme 94 Synthesis of dimethyl derivatives of *chiro*-inositol (1018) and *scyllo*-inositol (1019).



$\approx 21\%$  and  $\approx 19\%$  yield, respectively, along with an additional mixed fraction ( $\sim 21\%$ ).

Further transformation of compound (**1005**) with 40% aqueous  $\text{HBF}_4$ , followed by oxidation with *m*-CPBA, generated a mixture of four derivatives—(**1008**), (**1009**), (**1010**), and (**1011**)—in a 17:37:32:14 ratio. These were separated by preparative TLC, affording isolated yields of  $\sim 8\%$ , 21%, 15%, and 5%, respectively.

Finally, global deprotection of the  $\alpha$ -methyl-*p*-methoxybenzyl (MPM) groups using  $\text{Et}_3\text{SiH/TFA}$  furnished the target natural products: (–)-conduramine A-1 (–)-**177**, (–)-conduramine A-2 (–)-**1012**, and (–)-conduramine E-2 (–)-**1013** in  $\sim 82\%$ , 79%, and 58% yields, respectively (Scheme 93).

Beyond the synthesis of conduramine analogues, conduritil-derived intermediates have also been employed for the preparation of structurally diverse inositol derivatives.

### 2.91. Synthesis of dimethylated inositol derivatives from conduritil B epoxide

In 2020, Aksu *et al.* reported an efficient synthetic route to various inositol derivatives using a conduritil B epoxide intermediate.<sup>110</sup> The sequence commenced with bromination of *p*-benzoquinone (**9**), affording *anti*-dibromide (**10**) in nearly 95% yield. Reduction of (**10**) with sodium borohydride provided diol (**369**) in approximately 85% yield. Subsequent treatment of diol (**369**) with sodium methoxide in methanol furnished 3,6-dimethoxy conduritil B (**255**) in 87% yield. Acetylation under acidic conditions using acetic anhydride generated the corresponding diacetate (**1014**) in nearly 89% yield.

Epoxidation of (**1014**) with *m*-CPBA afforded the protected conduritil B epoxide (**1015**) in about 70% yield. Ring opening of epoxide (**1015**) with acetic anhydride under acidic conditions produced a 9:1 mixture of acetoxyalcohols (**1016**) and (**1017**) in an overall yield of approximately 87%. Final deacetylation using potassium carbonate in methanol delivered two inositol derivatives: DL-2,5-di-*O*-methyl-*chiro*-inositol (**1018**) in 61% yield and DL-1,4-di-*O*-methyl-*scyllo*-inositol (**1019**) in 89% yield (Scheme 94).

## 3. Critical and comparative analysis of synthetic strategies toward conduritil derivatives

Beyond reporting individual synthetic routes, it is instructive to examine the broader trends that have shaped the development of conduritil chemistry. Comparative evaluation of these methodologies reveals recurring strategic themes, highlights their advantages and limitations, and provides insight into how different synthetic philosophies converge toward similar cyclitol frameworks. While advantages and limitations of individual methodologies are discussed, wherever possible, in the context of their respective synthetic approaches throughout the review, the following section provides a consolidated and comparative perspective to highlight overarching trends, strengths, and limitations across different strategies. In many cases, the original studies were developed in the context of

target-oriented synthesis, and therefore the breadth of substrate scope was not always systematically explored. Nevertheless, several methodologies demonstrate significant versatility through divergent transformations and adaptation to structurally distinct conduritil, conduramine, and inositol derivatives.

Taken together, the methodologies surveyed in this review highlight how the conduritil framework has evolved from a synthetic curiosity into a highly versatile chiral pool for accessing inositols, conduramines, aminocyclitols, and complex natural products. A clear trend over the last three decades is the progressive shift from linear, target-specific routes to divergent, platform-type strategies, where a single conduritil- or inositol-derived intermediate can be elaborated into families of polyols, amino derivatives, polyphosphates, and annulated analogues. Many of these transformations rely on well-established mechanistic principles, including stereospecific epoxide opening, osmium-mediated *syn*-dihydroxylation, and metathesis-driven ring formation, which collectively enable precise control over the stereochemical architecture of conduritil frameworks.

From the standpoint of starting material and chiral information, three broad philosophies emerge.

(i) Chemoenzymatic and microbial *cis*-dihydroxylation approaches (Hudlický, Banwell, Bellomo, Paul, Vitelio, Orsini, *etc.*) rely on arene oxidation (chlorobenzene, bromobenzene, *m*-dibromobenzene, naphthalenes) to introduce the initial *cis*-diol in a single step with excellent stereocontrol. These routes excel in step economy at the very beginning and often deliver densely functionalized cyclohexadienediols that can be channelled into conduritil A–F, inositols, and gabosine-type carbasugars. Their weaknesses are practical: dependence on whole-cell systems, oxygen transfer, fermentation-like conditions and sometimes modest substrate scope.

(ii) Carbohydrate-based strategies (Kornienko, Mehta, Patenburg, Saito, Andresen, Nadein, Ghosal, Rajender, Harit, Katakam, *etc.*) transform readily available sugars (*D*-glucose, *D*-mannose, *D*-galactose, *D*-xylose, *D*-ribose) into conduritil and inositol derivatives *via* olefination-RCM manifolds or carefully choreographed protecting-group patterns. These routes are attractive for chirality “for free” and scalability, but often suffer from heavy protecting-group load and multiple redox adjustments.

(iii) Small chiral pool and auxiliary-based routes (*L*-tartaric acid, proto-quercitol, *D*-serine, camphorsultam-derived auxiliaries, sulfinimines) provide flexible access to specific stereochemical arrays, particularly for conduramine A/F series, with high enantioselectivity, though at the cost of auxiliary installation/removal steps and sometimes lower overall atom economy.

A second major axis of comparison concerns the construction of the cyclohexene/cyclohexane core. Older approaches used pericyclic reactions such as Diels–Alder and nitroso-Diels–Alder reactions (Trost’s cyclophellitol and pancratistatin work, Elango’s narciclasine, Jana’s Cu-catalysed nitroso-DA to conduramine A-1), or photooxygenation of dienes derived from cyclooctatetraene or cyclohexadiene (Balci, Kelebekli, Cantekin, Ekmekci). These are powerful because they build complexity



rapidly and allow embedded peroxide or enone functionalities that can be leveraged for downstream dihydroxylation or fragmentation. However, they can be sensitive to scale, light, and oxygen and sometimes give mixtures of *endo/exo* or regioisomers that must be separated or equilibrated.

By contrast, ring-closing metathesis (RCM) has emerged as perhaps the single most general tactic for assembling the conduritol core from acyclic sugar- or tartaric-derived dienes (Gallos, Chang 1999 and 2009, Mehta, Saito, Ghosal, Myeong, Harit, Prasad, Nadein, Andresen). RCM offers excellent control over ring size and olefin geometry, tolerates multiple protecting groups, and is readily adapted to divergent programmes: the same diene manifold can be pushed toward conduritol E/F/B scaffolds and then onwards to inositols, valienamine, aminocyclitols or phosphates. The trade-offs are the cost and air-sensitivity of Ru catalysts and the need to manage *E/Z* mixtures in some cases; nonetheless, RCM strategies are arguably the most modular and “designable” across this landscape.

The installation and manipulation of heteroatom functionality (OH, N, X, Se, P) provides another clear point of comparison. For oxygenation, almost all families rely heavily on OsO<sub>4</sub>-based *syn*-dihydroxylation (either classical OsO<sub>4</sub>/NMO or ADMIX-β) and, to a lesser extent, RuO<sub>4</sub>/RuCl<sub>3</sub>-NaIO<sub>4</sub> oxidations for ring opening to inositols or oxidative rearrangements (*e.g.*, Podeschwa's *neo/allo/epi*-inositols, Banwell's L-ascorbic acid, Bellomo's deoxy-selenylconduritol). These steps are highly reliable and stereocontrolled but score poorly against green-chemistry metrics due to the toxicity and cost of Os and Ru. A positive development is the regioselective dihydroxylation control achieved in some systems (*e.g.*, Chappell's use of ADMIX-β/MeSO<sub>2</sub>NH<sub>2</sub> to select one diastereomer exclusively), which reduces separation overhead and waste. Future work could profitably target catalytic, less toxic alternatives while preserving the exquisite stereocontrol currently provided by late transition metals.

For nitrogen introduction, several conceptually distinct manifolds can be contrasted.

(a) Epoxide and cyclic sulfate aminolysis (Lee's conduramine F, Rinner's epoxyconduramine route to *epi*-7-deoxypancrastatin, Pandey's epoxidation/functionalization, Kuno's Martin sulfuran epoxide, Katakam's and Prasad's RCM-based routes) provide direct access to 1-amino or 1,4-diamino motifs with good regioselectivity, especially when combined with neighbouring protecting groups to steer attack.

(b) Mitsunobu and azide/mesylate inversion strategies (Prinzbach's (–)-conduramine E, Falshaw's conduritol B epoxides, Serrano's rich aminoinositol library, Lysek's conduramine B-1/F-1, Rajender's conduramine C/D derivatives) afford powerful control over relative configuration at multiple centres and are particularly useful for accessing *myo/scyllo/chiro* series from a single epoxide precursor. Their downside is reliance on stoichiometric DEAD/DIAD, PPh<sub>3</sub> and azides, which are environmentally problematic on scale.

(c) Chemoenzymatic and Pd-catalysed asymmetric approaches (Trost's allylic alkylations to conduramine C-4, Hygromycin A aminocyclitol, and pancratistatin; Lu's chiral auxiliary-mediated routes; Pinto's chiral amine-mediated

openings) achieve high enantioselectivity at the cost of more elaborate catalysts or auxiliaries. These asymmetric catalysis-based routes are particularly attractive when access to a single enantiomer is crucial, as for narciclasine, pancratistatin, cyclophellitol and halichondrin fragments.

Halogenation, selenylation and phosphorylation chemistry further expand the divergent potential of the conduritol core. Baran's haloconduritols (BCl<sub>3</sub>/BBr<sub>3</sub>-mediated halo-deacetalization) and Cantekin's bromo-conduritols B/C show that carefully orchestrated halogenation–elimination–acetate substitution sequences provide access to functional handles for cross-coupling or further oxidation. Bellomo's deoxy-selenylconduritols demonstrate that Se-based nucleophilic openings can be used not only to generate new C–Se and C–O patterns but also to trigger oxidative rearrangements to partially protected conduritol C. On the phosphorylation side, the work of Pattenburg, Podeschwa, Know, Saito and Andresen illustrates a robust “platform logic”: once a suitably protected inositol is in hand, phosphoramidite chemistry enables systematic construction of di-, tri-, tetra- and hexakisphosphate patterns, including azido- and amino-inositol phosphates of biological relevance. These late-stage, phosphorylation-based divergences are powerful but are inherently multistep and require extensive protecting-group choreography to control site selectivity.

Methodologically, several named reactions and motifs recur across otherwise different programmes: Ramberg–Bäcklund rearrangements from thiepane sulfones (Cerè, Arcelli, Vanda Cerè) as a general way to introduce cyclohexene unsaturation; photooxygenation of dienes to *endo*-peroxides followed by reductive cleavage (Balci, Kelebekli, Ekmekci) to deliver bis-homo-conduritols or diamino derivatives; Diels–Alder and nitroso-Diels–Alder cycloadditions as compact entries into highly functionalized cyclohexanes (Elango, Jana, Trost); and extensive use of RCM not just to give simple conduritol rings but also annulated systems (Mehta's cyclohexa- and cyclopenta-annulated inositols) and conformationally locked analogues. In general, Ramberg–Bäcklund and pericyclic/peroxide strategies are synthetically elegant but often less user-friendly than RCM in terms of operational simplicity and safety.

From an applications perspective, it is striking how often conduritols and conduramines are embedded in or serve as chiral building blocks for bioactive targets: (+)/(–)-cyclophellitol, pericosine B, (–)/(+)-gabosine A, (+)- and *epi*-7-deoxypancrastatin, pancratistatin, (–)- and (+)-narciclasine, halichondrin B fragments, Hygromycin A aminocyclitol, L-ascorbic acid, phosphatidylinositol analogues and inositol polyphosphates. Here, chemoenzymatic routes and RCM-enabled carbohydrate pathways clearly dominate because they combine reliable absolute stereocontrol with modular late-stage diversification (*e.g.*, conversion of conduritol B epoxide into a broad library of *scyllo*, *myo* and *chiro* aminoinositols by Serrano, or Saito/Know/Andresen's multiple polyphosphate topologies from one conduritol B precursor). In contrast, some of the more specialized haloconduritols, selenylconduritols, annulated and indole-functionalized derivatives (Baran, Bellomo, Çavdar, Mehta) are better viewed as methodology



demonstrations that enrich the structural diversity space rather than as immediately scalable routes to a single pharmacophore.

Finally, a few general advantages and limitations can be distilled.

- Strengths of the modern toolbox include: (a) extensive diastereo- and enantioselective control at each stage; (b) highly divergent use of common intermediates (epoxides, aziridines, partially benzylated or acetonide-protected conduritols); (c) compatibility with complex downstream targets and late-stage introduction of polar groups (phosphates, amines, amides); and (d) increasing use of catalytic processes (Pd, Cu, Ru-RCM, enzymatic lipases and dioxygenases).

- Weaknesses remain in the areas of step economy and sustainability: many sequences are long, rely on multiple protecting-group manipulations and redox toggling, and use toxic or precious reagents (OsO<sub>4</sub>, RuO<sub>4</sub>, Bu<sub>3</sub>SnH, DEAD, DPPA, Pb/Se chemistry, peracids). Chemoenzymatic methods, though stereochemically superb, may pose scale-up and reproducibility challenges outside of specialized laboratories.

Looking ahead, the body of work summarized here suggests that future progress will likely come from integrating the best features of these strategies: using biocatalytic or chiral-pool inputs for initial stereocontrol, employing RCM or other catalytic annulations to build the ring with minimal protecting-group overhead, and then applying site-selective C–H or C–O functionalization, milder aminating agents, and greener oxidation methods to install the desired nitrogen, phosphorus and halogen functions. Such developments would not only streamline access to classical conduritol/conduramine targets, but also enable rapid exploration of new, densely functionalized cyclitol space for medicinal chemistry and chemical biology.

From a practical standpoint, several factors influence the broader applicability of the synthetic strategies discussed in this review. While many routes provide excellent stereochemical control and access to structurally diverse conduritol derivatives, aspects such as reaction scalability, cost of reagents, and environmental considerations remain important limitations. For instance, several widely used transformations including osmium-mediated dihydroxylation, peracid epoxidation, Mitsunobu reactions, and tributyltin hydride reductions rely on reagents that may present challenges in terms of toxicity, cost, or waste generation when considered for large-scale synthesis. Moreover, detailed impurity profiles, robustness studies, and large-scale reaction data are often not reported in the primary literature, which makes systematic comparison difficult. Consequently, while many of the reported methodologies are highly effective at the laboratory scale, further optimization and development of greener, scalable alternatives will be essential for translating these strategies into practical synthetic platforms.

## 4. Medicinal relevance of conduritol-derived aminocyclitols

Conduritol and conduramine frameworks have also attracted significant attention in medicinal chemistry because closely related aminocyclitol structures form the core of several clinically important glycosidase inhibitors. These compounds mimic carbohydrate substrates and inhibit carbohydrate-processing enzymes, thereby modulating glucose metabolism. Several approved antidiabetic drugs, including acarbose, miglitol, and voglibose, contain highly functionalized cyclitol or aminocyclitol motifs related to conduritol-derived scaffolds. These agents act as  $\alpha$ -glucosidase inhibitors, delaying carbohydrate digestion in the intestine and reducing post-prandial hyperglycemia. The inhibitory potency of these molecules varies depending on the enzyme source and assay conditions, but reported IC<sub>50</sub> values typically fall within the micromolar to sub-millimolar range. The development and clinical success of these drugs highlight the broader pharmaceutical importance of densely functionalized cyclitols and underscore the value of synthetic strategies that enable efficient access to conduritol and conduramine derivatives (Table 1).<sup>111–114</sup>

## 5. Future perspectives

Looking ahead, several promising directions can be envisaged for the continued development of conduritol- and conduramine-based chemistry.

### 5.1. Greener and more step-economic oxidation and amination methods

Replacing Os-, Ru- and peracid-based protocols with milder, more sustainable catalytic systems such as organocatalytic, electrochemical, enzymatic, or earth-abundant metal-mediated oxidations will be crucial for translating many of these routes to larger scale. Similarly, safer, catalytic alternatives to azide- and Mitsunobu-based nitrogen introduction would significantly improve the environmental and safety profiles of aminocyclitol syntheses.

### 5.2. Refined divergent platforms and late-stage functionalization

The concept of using a single conduritol or conduramine scaffold as a branching point to multiple inositol, aminoinositol and polyphosphate derivatives is already well established. Future work can focus on designing “minimal protection” or “protection-free” platforms that combine site-selective C–H or C–O functionalization, orthogonal protecting groups, and programmable phosphorylation. Such approaches would

Table 1 Selected clinically used aminocyclitol-based  $\alpha$ -glucosidase inhibitors related to conduritol frameworks

Drug	Core scaffold	Therapeutic use	Target enzyme	Approximate IC <sub>50</sub>
Acarbose	Valienamine-derived aminocyclitol	Type-2 diabetes	$\alpha$ -glucosidase/ $\alpha$ -amylase	~0.78 mM
Miglitol	Iminosugar (aminocyclitol)	Type-2 diabetes	$\alpha$ -glucosidase	~10–20 $\mu$ M
Voglibose	Valiolamine-derived aminocyclitol	Type-2 diabetes	$\alpha$ -glucosidase	~0.1–1 $\mu$ M



facilitate rapid assembly of focused libraries of cyclitol-based probes, inhibitors, and mimetics.

### 5.3. Integration of biocatalysis with modern catalysis and flow chemistry

Microbial and enzymatic *cis*-dihydroxylation provides unparalleled stereocontrol at an early stage. Coupling these transformations with RCM, cross-coupling, and catalytic functionalizations in telescoped or continuous-flow sequences could dramatically reduce purification steps and improve overall efficiency. Engineered dioxygenases, epoxide hydrolases, and transaminases tailored to polyfunctional cyclohexene substrates may further expand the accessible structural space.

Microbial and enzymatic *cis*-dihydroxylation provides unparalleled stereocontrol at an early stage. Coupling these transformations with RCM, cross-coupling, and catalytic functionalizations in telescoped or continuous-flow sequences could dramatically reduce purification steps and improve overall efficiency. Engineered dioxygenases, epoxide hydrolases, and transaminases tailored to polyfunctional cyclohexene substrates may further expand the accessible structural space.

It is worth noting, however, that several key transformations in conduritol chemistry—including heterogeneous catalytic reactions (*e.g.*, Pd/C hydrogenations), enzymatic oxidations, and reactions involving insoluble reagents, pose practical challenges for direct translation into continuous-flow systems. Nevertheless, recent advances in flow chemistry, such as packed-bed reactors, immobilized catalysts and enzymes, slurry-based flow systems, and segmented (gas–liquid or liquid–liquid) flow technologies, have demonstrated that heterogeneous processes can be effectively adapted to flow conditions. These developments suggest that, with appropriate reactor design, even traditionally heterogeneous transformations relevant to conduritol and conduramine synthesis could be rendered compatible with continuous processing.

### 5.4. Rational design of bioactive analogues and structure–activity studies

The successful syntheses of pancratistatin, narciclasine, cyclophellitol, halichondrin fragments, gabosines, and inositol polyphosphates highlight the pharmacological relevance of conduritol and conduramine cores. Moving forward, the emphasis is likely to shift from “can we make it?” to “how do we systematically vary it?”. Efficient, divergent routes will be invaluable for generating analogues with subtle changes in stereochemistry, substitution pattern, or phosphorylation state to probe enzyme inhibition, receptor binding, signalling modulation, and transport properties.

### 5.5. Expansion into materials, supramolecular, and glycobiology applications

The dense, polyhydroxylated nature of these frameworks makes them attractive not only as enzyme inhibitors but also as building blocks for multivalent ligands, chiral ionophores, molecular recognition motifs, and functional materials (*e.g.*, in self-assembly or metal coordination). Polyhydroxylated cyclitol

scaffolds can participate in highly organized supramolecular interactions through hydrogen bonding, metal coordination, and host–guest recognition processes, which are central to the design of molecular recognition systems and functional supramolecular assemblies. Recent studies have highlighted how such polyfunctional motifs can be incorporated into modern supramolecular and materials architectures where precise spatial arrangement of functional groups governs molecular recognition and self-assembly processes.<sup>115</sup> Future research may exploit conduritol- and inositol-based scaffolds in polymer chemistry, nanoscience, and glycobiology, where the precise spatial arrangement of hydroxyl and amino groups is often critical. Polyhydroxylated cyclitol motifs have recently attracted attention as functional building blocks for advanced polymeric and supramolecular materials, including responsive polymer networks, dynamic covalent systems, and carbohydrate-inspired nanostructures. Such systems demonstrate how reversible covalent interactions and densely functionalized cyclitol frameworks can be integrated into modern materials design and polymer architectures.<sup>116–119</sup>

In summary, the synthetic methodologies reviewed here have established conduritols, conduramines, and their inositol derivatives as exceptionally rich and flexible platforms at the interface of synthetic methodology, medicinal chemistry, and chemical biology. Continued progress in catalytic, chemo-enzymatic, and diversity-oriented synthesis, guided by sustainability considerations and biological questions, can be expected to further unlock the potential of these compact yet information-dense scaffolds in both fundamental research and applied science.

## 6. Conclusion

Over the past few decades, conduritols and conduramines have evolved from structurally intriguing cyclitols into central scaffolds for the construction of inositols, aminocyclitols, and complex bioactive natural products. The synthetic studies summarized in this review clearly demonstrate that these frameworks are not merely end points, but highly versatile platform intermediates that can be divergently elaborated into a wide spectrum of molecular architectures.

Collectively, the available methodologies span chemo-enzymatic *cis*-dihydroxylation of simple arenes, carbohydrate-derived strategies, small chiral pool approaches, auxiliary- and catalyst-controlled asymmetric routes, and pericyclic or metathesis-based ring constructions. Among these, ring-closing metathesis (RCM) of sugar- or tartaric acid-derived dienes and microbial or enzymatic arene *cis*-dihydroxylation have emerged as particularly powerful tactics for assembling densely functionalized cyclohexene or cyclohexane cores with precise stereochemical control. Subsequent use of epoxidation, aziridination, Ramberg–Bäcklund rearrangements, selective dihydroxylation, and Mitsunobu or azide/mesyate inversions allows for fine-tuning of the oxygen and nitrogen substitution patterns required for conduritol, conduramine, and inositol derivatives.



A notable theme is the progressive shift from linear, target-specific syntheses toward modular, divergent strategies. Conduritol B and E derivatives, in particular, have served as nodal intermediates, enabling access to *myo*, *scyllo*, *chiro*, *allo*, *neo*, and *epi* inositols, as well as to polyphosphate, azido-, amino-, halo-, and selenyl-functionalized analogues. This platform concept has been exploited in the synthesis of structurally and biologically important compounds such as pancratistatin and its analogues, cyclophellitol, pericosine B, narciclasine, halichondrin fragments, hygromycin A aminocyclitol units, L-ascorbic acid, inositol polyphosphates, and phosphatidylinositol mimetics.

Although most reported syntheses of conduritols and conduramines have been developed within academic laboratories, these frameworks possess significant relevance in medicinal chemistry. Aminocyclitol structures derived from conduritols serve as key scaffolds in the design of glycosidase inhibitors, antiviral agents, and other bioactive molecules. Several natural products and drug candidates, including valienamine-based  $\alpha$ -glucosidase inhibitors such as acarbose and voglibose, contain closely related aminocyclitol motifs. Consequently, synthetic methodologies developed for conduritols and conduramines provide valuable strategies for constructing highly functionalized cyclohexene and aminocyclitol architectures relevant to pharmaceutical research and lead optimization. Furthermore, scalable synthetic approaches and chemoenzymatic methods reported for conduritols offer potential pathways for future process-chemistry development.

Despite this impressive toolbox, certain limitations remain. Many routes are still relatively long and protecting-group intensive, often relying on toxic or environmentally problematic reagents such as OsO<sub>4</sub>, RuO<sub>4</sub>/RuCl<sub>3</sub>-NaIO<sub>4</sub>, tributyltin hydride, stoichiometric Mitsunobu reagents, and organoselenium or azide chemistry. Chemoenzymatic processes, while highly stereoselective, may pose challenges in terms of operational simplicity and scalability. Nevertheless, the breadth of strategies now available provides a solid foundation for more sustainable and streamlined approaches to these densely functionalized cyclitols.

From a translational and medicinal chemistry perspective, it is important to recognize that several practical challenges remain in advancing conduritols- and conduramine-based compounds toward therapeutic applications. Detailed pharmacokinetic (DMPK) and toxicity data for these scaffolds are still relatively limited. Owing to their highly polar and polyhydroxylated nature, such compounds typically exhibit high aqueous solubility but may suffer from low membrane permeability and limited oral bioavailability, a trend commonly observed for glycosidase inhibitors and related aminocyclitols. While many members of this class have demonstrated low intrinsic toxicity in biological assays, systematic investigations addressing absorption, distribution, metabolism, and long-term safety remain underexplored.

In addition, the widespread use of transition-metal catalysts (*e.g.*, Ru in RCM, Pd in cross-coupling, Os in dihydroxylation) necessitates careful consideration of residual metal content in the final active pharmaceutical ingredient (API), in accordance

with ICH Q3D guidelines. Although most methodologies discussed herein are developed at laboratory scale, established process-chemistry strategies—such as the use of metal scavengers (*e.g.*, silica-supported thiols, amines, or phosphines), crystallization-based purification, aqueous workups, and chromatographic techniques—are effective in reducing residual metal levels to acceptable limits. Furthermore, the development of immobilized catalysts, recyclable catalytic systems, and low-metal-loading protocols provides promising avenues for minimizing metal contamination at the source.

More broadly, this review aims to provide a unified and critically connected perspective on the synthesis of conduritols, conduramines, and their related cyclitol frameworks, which have often been treated in a fragmented manner across the literature. By systematically compiling chemoenzymatic, carbohydrate-derived, chiral pool, and catalytic strategies within a single framework, this work highlights underlying design principles, recurring mechanistic motifs, and points of convergence between seemingly distinct synthetic approaches. In contrast to earlier reviews that have primarily focused on specific subclasses of cyclitols or individual synthetic methodologies, the present review emphasizes a comparative and integrative analysis, enabling clearer identification of strengths, limitations, and opportunities across the field. It is anticipated that this consolidated perspective will not only assist synthetic chemists in selecting appropriate strategies but also help bridge existing gaps between methodology development, scalability, and medicinal chemistry applications, thereby guiding future research toward more efficient, sustainable, and application-oriented cyclitol synthesis.

Taken together, these considerations highlight that, alongside synthetic innovation, future progress in this field will also depend on improving pharmacokinetic properties, ensuring regulatory compliance, and developing scalable, environmentally responsible processes. Consequently, the continued development of efficient, scalable, and sustainable synthetic strategies for conduritols and their derivatives is expected to play a pivotal role in advancing glycosidase inhibitor research, natural product synthesis, and the discovery of new cyclitol-based therapeutic agents.

## Author contributions

SM initially prepared the draft following the suggestions of AKM. AKM later modified and rewrote the manuscript according to the standard of the journal.

## Conflicts of interest

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

## Data availability

No new data were created or analyzed in this study. Data sharing is not applicable to this article.



## Acknowledgements


The authors would like to acknowledge Prof. Ashutosh Ghosh, Vice-Chancellor of Rani Rashmoni Green University, for his guidance and encouragement throughout the process of preparing this manuscript. SM would also like to acknowledge the invaluable support of his parents.

## References

- 1 J. Duchek, D. R. Adams and T. Hudlicky, *Chem. Rev.*, 2011, **111**, 4223–4258.
- 2 M. Balci, Y. Sütbeyaz and H. Secen, *Tetrahedron*, 1990, **46**, 3715–3742.
- 3 M. S. Gultekin, M. Celik and M. Balci, *Curr. Org. Chem.*, 2004, **8**, 1159–1186.
- 4 K. Kubler, *Arch. Pharm.*, 1908, **246**, 620–660.
- 5 G. Dangschat and H. O. L. Fischer, *Naturwissenschaften*, 1939, **27**, 756–757.
- 6 S. Malik and A. K. Mitra, *Tetrahedron*, 2025, **178**, 134605.
- 7 (a) N. Verma, S. Arora, A. K. Singh and A. Kumar, *Targets*, 2025, **3**, 32; (b) N. Verma, S. Arora, A. K. Singh and J. Ahmed, *RSC Pharm.*, 2025, **2**, 1201.
- 8 D. C. Billington, F. Perron-Sierra, I. Picard, S. Beaubras, J. Duhault, J. Espinal and S. Challal, *Bioorg. Med. Chem. Lett.*, 1994, **4**, 2307–2312.
- 9 N. Şimşek Kuş, *Chem. Biodiversity*, 2024, **21**, e202301064.
- 10 T. Hudlicky, F. Rulin, T. Tsunoda, H. Luna, C. Andersen and J. D. Price, *Isr. J. Chem.*, 1991, **31**, 229–238.
- 11 D. Gonzalez, T. Martinot and T. Hudlicky, *Tetrahedron Lett.*, 1999, **40**, 3077–3080.
- 12 S. Elango and T.-H. Yan, *J. Org. Chem.*, 2002, **67**, 6954–6959.
- 13 M. Matveenko, M. G. Banwell and A. C. Willis, *Tetrahedron*, 2008, **64**, 4817–4826.
- 14 S. Arora and C. Mao, *Nucleosides, Nucleotides Nucleic Acids*, 2024, **43**, 316–339.
- 15 Y.-U. Kwon, C. Lee and S.-K. Chung, *J. Org. Chem.*, 2002, **67**, 3327–3338.
- 16 H. Çavdar, O. Talaz and D. Ekinici, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 7499–7503.
- 17 G. Legler, *Hoppe-Seyler's Z. Physiol. Chem.*, 1966, **345**, 197–214.
- 18 G. Legler, in *Methods in Enzymology*, Academic Press, 1977, vol. 46, pp. 368–381.
- 19 K. J. Lee, S. A. Boyd and N. S. Radin, *Carbohydr. Res.*, 1985, **144**, 148–154.
- 20 A. E. Gal and J. P. Voorstad, *J. Labelled Compd. Radiopharm.*, 1987, **24**, 397–407.
- 21 O. Werbitzky, K. Klier and H. Felber, *Liebigs Ann. Chem.*, 1990, **1990**, 267–270.
- 22 S. Arora, J. Liang, S. K. Fullerton-Shirey and J. E. Laaser, *ACS Mater. Lett.*, 2020, **2**, 331–335.
- 23 T. Hudlicky, J. D. Price, F. Rulin and T. Tsunoda, *J. Am. Chem. Soc.*, 1990, **112**, 9439–9440.
- 24 H. A. J. Carless and K. Busia, *Tetrahedron Lett.*, 1990, **31**, 3449–3452.
- 25 M. C. McIntosh and S. M. Weinreb, *J. Org. Chem.*, 1991, **56**, 5010–5012.
- 26 K. Schürle, B. Beier and W. Piepersberg, *J. Chem. Soc., Perkin Trans. 1*, 1991, 2407–2412.
- 27 T. Hudlicky, H. Luna, H. F. Olivo, C. Andersen, T. Nugent and J. D. Price, *J. Chem. Soc., Perkin Trans. 1*, 1991, 2907–2917.
- 28 H. A. J. Carless and O. Z. Oak, *Tetrahedron Lett.*, 1991, **32**, 1671–1674.
- 29 T. Hudlicky and H. F. Olivo, *J. Am. Chem. Soc.*, 1992, **114**, 9694–9696.
- 30 C. R. Johnson, P. A. Plé, L. Su, M. J. Heeg and J. P. Adams, *Synlett*, 1992, **1992**, 388–390.
- 31 F. Chretien, R. Wolf and Y. Chapleur, *Nat. Prod. Lett.*, 1993, **2**, 69–75.
- 32 M. Mandel and T. Hudlicky, *J. Chem. Soc., Perkin Trans. 1*, 1993, 741–743.
- 33 (a) L. Pingli and M. Vandewalle, *Tetrahedron*, 1994, **50**, 7061–7074; (b) Y. Siitbeyaz, H. Seçen and M. Balci, *J. Chem. Soc., Chem. Commun.*, 1988, 1330.
- 34 (a) C. R. P. Johnson, A. Patrick, S. Lin, H. Mary Jane and P. Adams Joseph, *Synlett*, 1992, **1992**, 388–390; (b) H. Paulsen, W. Roben and F. R. Heiker, *Chem. Ber.*, 1981, **114**, 3242.
- 35 S. Allemann and P. Vogel, *Helv. Chim. Acta*, 1994, **77**, 1–9.
- 36 (a) H. Seçen, S. Gültekin, Y. Sütbeyaz and M. Balci, *Synth. Commun.*, 1994, **24**, 2103–2108; (b) M. Nakajima, A. Hasegawa and N. Kurihara, *Chem. Ber.*, 1962, **95**, 2709.
- 37 R. Leung-Toung, Y. Liu, J. M. Muchowski and Y.-L. Wu, *Tetrahedron Lett.*, 1994, **35**, 1639–1642.
- 38 Y. Kara, M. Balci, S. A. Bourne and W. H. Watson, *Tetrahedron Lett.*, 1994, **35**, 3349–3352.
- 39 B. M. Trost and S. R. Pulley, *J. Am. Chem. Soc.*, 1995, **117**, 10143–10144.
- 40 O. Arjona, A. de Dios, J. Plumet and B. Saez, *Tetrahedron Lett.*, 1995, **36**, 1319–1320.
- 41 B. M. Trost and S. R. Pulley, *Tetrahedron Lett.*, 1995, **36**, 8737–8740.
- 42 J. L. Chiara and N. Valle, *Tetrahedron:Asymmetry*, 1995, **6**, 1895–1898.
- 43 D. A. Entwistle and T. Hudlicky, *Tetrahedron Lett.*, 1995, **36**, 2591–2594.
- 44 A. Patti, C. Sanfilippo, M. Piattelli and G. Nicolosi, *Tetrahedron:Asymmetry*, 1996, **7**, 2665–2670.
- 45 R. Angelaud, Y. Landais and K. Schenk, *Tetrahedron Lett.*, 1997, **38**, 1407–1410.
- 46 C. Sanfilippo, A. Patti, M. Piattelli and G. Nicolosi, *Tetrahedron:Asymmetry*, 1997, **8**, 2083–2084.
- 47 V. Cerè, F. Peri and S. Pollicino, *Tetrahedron Lett.*, 1997, **38**, 7797–7800.
- 48 M.-C. Lallemand, M. Desjardins, S. Freeman and T. Hudlicky, *Tetrahedron Lett.*, 1997, **38**, 7693–7696.
- 49 V. Cerè, F. Peri, S. Pollicino and A. Ricci, *Synlett*, 1998, **1998**, 1197–1198.
- 50 M. Banwell, S. Blakey, G. Harfoot and R. Longmore, *J. Chem. Soc., Perkin Trans. 1*, 1998, 3141–3142.



- 51 R. Leung-Toung, Y. Liu, J. M. Muchowski and Y.-L. Wu, *J. Org. Chem.*, 1998, **63**, 3235–3250.
- 52 T. J. Donohoe, K. Blades, M. Helliwell, M. J. Waring and N. J. Newcombe, *Tetrahedron Lett.*, 1998, **39**, 8755–8758.
- 53 W.-W. Lee and S. Chang, *Tetrahedron:Asymmetry*, 1999, **10**, 4473–4475.
- 54 T. Hudlicky, N. Restrepo-Sánchez, P. D. Kary and L. M. Jaramillo-Gómez, *Carbohydr. Res.*, 2000, **324**, 200–203.
- 55 J. K. Gallos, T. V. Koftis, V. C. Sarli and K. E. Litinas, *J. Chem. Soc., Perkin Trans. 1*, 1999, 3075–3077.
- 56 H. Ovaa, J. D. C. Codée, B. Lastdrager, H. S. Overkleeft, G. A. van der Marel and J. H. van Boom, *Tetrahedron Lett.*, 1999, **40**, 5063–5066.
- 57 B. M. Trost and E. J. Hembre, *Tetrahedron Lett.*, 1999, **40**, 219–222.
- 58 A. Kornienko and M. d'Alarcao, *Tetrahedron:Asymmetry*, 1999, **10**, 827–829.
- 59 G. Mehta and S. Lakshminath, *Tetrahedron Lett.*, 2000, **41**, 3509–3512.
- 60 O. Plettenburg, S. Adelt, G. Vogel and H.-J. Altenbach, *Tetrahedron:Asymmetry*, 2000, **11**, 1057–1061.
- 61 D. Spielvogel, J. Kammerer, M. Keller and H. Prinzbach, *Tetrahedron Lett.*, 2000, **41**, 7863–7867.
- 62 A. Falshaw, J. B. Hart and P. C. Tyler, *Carbohydr. Res.*, 2000, **329**, 301–308.
- 63 G. Mehta and S. S. Ramesh, *Chem. Commun.*, 2000, 2429–2430.
- 64 S. H. Lee and C. S. Cheong, *Bull. Korean Chem. Soc.*, 2000, **21**, 1061–1062.
- 65 M. G. Banwell, A. M. Bray and D. J. Wong, *New J. Chem.*, 2001, **25**, 1351–1354.
- 66 B. M. Trost, D. E. Patterson and E. J. Hembre, *Chem.–Eur. J.*, 2001, **7**, 3768–3775.
- 67 B. M. Trost Jr, D. Joseph and E. J. Hembre, *Chem.–Eur. J.*, 2001, **7**, 1619–1629.
- 68 S. E. de Sousa, P. O'Brien and C. D. Pilgram, *Tetrahedron Lett.*, 2001, **42**, 8081–8083.
- 69 B. J. M. Paul, A. Theodore, W. Jerremey and H. Tomas, *Synthesis*, 2001, **2001**, 952–956.
- 70 A. Arcelli, V. Cerè, F. Peri, S. Pollicino and A. Ricci, *Tetrahedron*, 2001, **57**, 3439–3444.
- 71 U. Rinner, P. Siengalewicz and T. Hudlicky, *Org. Lett.*, 2002, **4**, 115–117.
- 72 W. T. Lambert and S. D. Burke, *Org. Lett.*, 2003, **5**, 515–518.
- 73 G. Mehta, R. S. Senaiar and M. K. Bera, *Chem.–Eur. J.*, 2003, **9**, 2264–2272.
- 74 G. Mehta and S. S. Ramesh, *Tetrahedron Lett.*, 2003, **44**, 3105–3108.
- 75 A. Baran, C. Kazaz, H. Seçen and Y. Sütbeyaz, *Tetrahedron*, 2003, **59**, 3643–3648.
- 76 M. Podeschwa, O. Plettenburg, J. vom Brocke, O. Block, S. Adelt and H.-J. Altenbach, *Eur. J. Org. Chem.*, 2003, **2003**, 1958–1972.
- 77 M. A. L. Podeschwa, O. Plettenburg and H.-J. Altenbach, *Org. Biomol. Chem.*, 2003, **1**, 1919–1929.
- 78 Y.-U. Kwon, J. Im, G. Choi, Y.-S. Kim, K. Yong Choi and S.-K. Chung, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 2981–2984.
- 79 O. N. Nadein and A. Kornienko, *Org. Lett.*, 2004, **6**, 831–834.
- 80 C. Vitelio, A. Bellomo, M. Brovotto, G. Seoane and D. Gonzalez, *Carbohydr. Res.*, 2004, **339**, 1773–1778.
- 81 F. Orsini, G. Sello, S. Bernasconi and G. Fallacara, *Tetrahedron Lett.*, 2004, **45**, 9253–9255.
- 82 S. Saito, R. Shimazawa and R. Shirai, *Chem. Pharm. Bull.*, 2004, **52**, 727–732.
- 83 S. Freeman and T. Hudlicky, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 1209–1212.
- 84 T. L. Andresen, D. M. Skytte and R. Madsen, *Org. Biomol. Chem.*, 2004, **2**, 2951–2957.
- 85 V. Cerè, M. Minzoni, S. Pollicino, A. Ricci, F. Gasparrini, A. Ciogli and I. D'Acquarica, *J. Comb. Chem.*, 2006, **8**, 74–78.
- 86 P. Serrano, A. Llebaria and A. Delgado, *J. Org. Chem.*, 2005, **70**, 7829–7840.
- 87 R. Lysek, C. Schütz and P. Vogel, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 3071–3075.
- 88 L. Kelebekli, M. Çelik, E. Şahin, Y. Kara and M. Balci, *Tetrahedron Lett.*, 2006, **47**, 7031–7035.
- 89 R. Lysek, C. Schütz, S. Favre, A. C. O'Sullivan, C. Pillonel, T. Krülle, P. M. J. Jung, I. Clotet-Codina, J. A. Esté and P. Vogel, *Bioorg. Med. Chem.*, 2006, **14**, 6255–6282.
- 90 A. Bellomo, C. Giacomini, B. Brena, G. Seoane and D. Gonzalez, *Synth. Commun.*, 2007, **37**, 3509–3518.
- 91 R. Lysek, S. Favre and P. Vogel, *Tetrahedron*, 2007, **63**, 6558–6572.
- 92 G. Pandey, K. N. Tiwari and V. G. Puranik, *Org. Lett.*, 2008, **10**, 3611–3614.
- 93 Y.-K. Chang, H.-J. Lo and T.-H. Yan, *Org. Lett.*, 2009, **11**, 4278–4281.
- 94 C. K. Jana, S. Grimme and A. Studer, *Chem.–Eur. J.*, 2009, **15**, 9078–9084.
- 95 A. Bellomo, A. Bertucci, H. Stefani, Á. Vázquez and D. Gonzalez, *Tetrahedron:Asymmetry*, 2009, **20**, 2673–2676.
- 96 S. Cantekin, A. Baran, R. Çalişkan and M. Balci, *Carbohydr. Res.*, 2009, **344**, 426–431.
- 97 D. D. Chappell, G. B. Michael, S. Gibson, L. M. Harwood and A. T. Russell, *Synlett*, 2010, **2010**, 517–520.
- 98 P.-H. Lu, C.-S. Yang, B. Devendar and C.-C. Liao, *Org. Lett.*, 2010, **12**, 2642–2645.
- 99 P. Ghosal and A. K. Shaw, *J. Org. Chem.*, 2012, **77**, 7627–7632.
- 100 S. Norsikian, J.-F. Soulé, A. Cannillo, R. Guillot, M.-E. Tran Huu Dau and J.-M. Beau, *Org. Lett.*, 2012, **14**, 544–547.
- 101 Z. Ekmekci and M. Balci, *Eur. J. Org. Chem.*, 2012, **2012**, 4988–4995.
- 102 A. Rajender and B. V. Rao, *Tetrahedron Lett.*, 2013, **54**, 2329–2331.
- 103 S. Kuno, K. Higaki, A. Takahashi, E. Nanba and S. Ogawa, *Medchemcomm*, 2015, **6**, 306–310.
- 104 V. K. Harit and N. G. Ramesh, *J. Org. Chem.*, 2016, **81**, 11574–11586.
- 105 I.-S. Myeong, J.-S. Kim, Y.-T. Lee, J.-C. Kang, S.-H. Park, C. Jung and W.-H. Ham, *Tetrahedron:Asymmetry*, 2016, **27**, 823–828.
- 106 R. Katakam, R. Anugula, L. Macha and V. R. Batchu, *Tetrahedron Lett.*, 2017, **58**, 559–562.



## Review

- 107 K. R. Prasad and V. A. Rangari, *Tetrahedron*, 2018, **74**, 6689–6693.
- 108 V. K. Harit and N. G. Ramesh, *Org. Biomol. Chem.*, 2019, **17**, 5951–5961.
- 109 S. Da Silva Pinto, S. G. Davies, A. M. Fletcher, P. M. Roberts and J. E. Thomson, *Org. Lett.*, 2019, **21**, 7933–7937.
- 110 K. Aksu, H. Akincioglu, I. Gulcin and L. Kelebekli, *Arch. Pharm.*, 2021, **354**, 2000254.
- 111 F. Laar, *Vasc. Health Risk Manage.*, 2008, **4**, 1189–1195.
- 112 N. Asano, *Glycobiology*, 2003, **13**, 93R–104R.
- 113 H. E. Lebovitz, *Endocrinol. Metab. Clin. North Am.*, 1997, **26**, 539–551.
- 114 E. Truscheit, W. Frommer, B. Junge, L. Müller, D. D. Schmidt and W. Wingender, *Angew Chem. Int. Ed. Engl.*, 1981, **20**, 744–761.
- 115 S. Arora and N. Verma, *ChemistrySelect*, 2026, **11**, e02016.
- 116 S. Arora and N. Verma, *RSC Appl. Polym.*, 2024, **2**, 317–355.
- 117 S. Arora, J. Rozon and J. E. Laaser, *Macromolecules*, 2021, **54**, 6466–6476.
- 118 Z. Huo, S. Arora, V. A. Kong, B. J. Myrga, A. Statt and J. E. Laaser, *Macromolecules*, 2023, **56**, 1845–1854.
- 119 J. Liang, K. Xu, S. Arora, J. E. Laaser and S. K. Fullerton-Shirey, *Materials*, 2020, **13**, 1089.

